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ABSTRACT
HAROLD LEWIS HAUN. Role of Dynorphin/Kappa Opioid Receptor Activity Within
the Extended Amygdala in Binge Alcohol Drinking (Under the direction of
HOWARD C. BECKER).
Alcohol Use Disorder (AUD) is a significant national and global public health
problem. Of concern, binge drinking is the most common pattern of excessive
alcohol consumption and serves as a risk factor for the development of AUD.
Recent studies have implicated the dynorphin/kappa opioid receptor (DYN/KOR)
neuropeptide system in this pattern of drinking but the precise circuitry mediating
these effects are poorly understood. The central amygdala (CeA) and bed nucleus
of the stria terminalis (BNST) are two interconnected structures within the
extended amygdala macrostructure that are rich in DYN/KOR and thought to
contribute to binge drinking behavior. In the present studies, we demonstrate that
KOR in the BNST contribute to excessive drinking by showing that site-specific
delivery of a KOR antagonist decreased, while an agonist increased, binge-like
alcohol consumption. Furthermore, we show that high levels of drinking induced
by systemic administration of a KOR agonist were reversed by selective KOR
blockade within the BNST. These findings suggest that KOR in the BNST promote
binge drinking behavior, however, the endogenous dynorphinergic circuitry
underlying this effect remains unknown. The CeA is a likely candidate in that it is
involved in excessive drinking and sends dense dynorphinergic projections to the
BNST (CeA-BNSTDYN). In support of this hypothesis, we demonstrate that
neuronal activity is increased within the CeA during a binge drinking session and
that chemogenetic inhibition of the CeA-BNSTDYN pathway selectively decreased
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binge-like alcohol consumption. Collectively, these studies suggest that the CeABNSTDYN circuit contributes to binge-like alcohol consumption and KORs in the
BNST likely mediate this effect. These studies provide valuable insight into
neuronal circuitry underlying a key aspect of AUD and point to the DYN/KOR
system as a potential therapeutic target for the treatment of excessive drinking.
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CHAPTER 1: Background and Significance
INTRODUCTION
Alcohol Use Disorder
The earliest reported consumption of alcohol by humans dates to 7000 BC
and alcohol use continues to be a stable fixture in most societies across the globe
(McGovern et al., 2004; WHO, 2018). In fact, Roughly 55% of the global adult
population has consumed alcohol and 20% of adults have engaged in heavy
episodic drinking placing alcohol as the most widely used drug of abuse next to
tobacco (GBD, 2018; Peacock et al., 2018; SAMHSA, 2018). In the United States,
however, the vast majority (86%) of the population has reported drinking alcohol
within their lifetime and 26% of adults have reported heavy drinking (SAMHSA,
2018). Alcohol drinking to excess presents a multitude of adverse societal and
health effects creating a significant socioeconomic burden (WHO, 2018). Further,
excessive drinking is associated with 88,000 deaths per year in the U.S. and 3.3
million deaths worldwide, propelling alcohol abuse into the spotlight as a serious
epidemiological concern (Rehm and Imtiaz, 2016; Rehm et al., 2003; WHO, 2018).
While alcohol abuse is a broad term, the Diagnostic and Statistical Manual of
Mental Disorders, 5th Edition (DSM-V) systematically defines a diagnosis of
Alcohol Use Disorder (AUD) based on 11 criteria that encompasses both alcohol
dependence and abuse (Dawson et al., 2005; Grant et al., 2015; Hasin, 2012).
AUD is characterized as behavior consisting of compulsive, uncontrolled bouts of
heavy episodic drinking accompanied by a negative emotional state and craving
during periods of abstinence, which contributes to chronic relapse (Grant et al.,
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2015; Hasin, 2012). A diagnosis of AUD is not uncommon given a 30% life-time
prevalence in the U.S. (Grant et al., 2015). Given the adverse health effects of
alcohol abuse and high occurrence of AUD, it is not surprising that alcohol drinking
is a significant contributor to the global burden of disease. In fact, alcohol-related
disease is the third leading cause of preventable death behind tobacco use and
poor diet and exercise, and alcohol-related mortality has doubled in the last 20
years (Mokdad et al., 2004; SAMHSA, 2018; White et al., 2020). Alcohol abuse
taxes the US economy a staggering $250 billion annually generated largely by a
loss of workplace productivity, healthcare expenses associated with treating
alcohol-related injury and disease, and criminal justice expenses (Sacks et al.,
2015; SAMHSA, 2016; WHO, 2018). Therefore, better understanding of the
mechanisms that contribute to and promote heavy alcohol consumption is of the
utmost importance to develop treatment strategies aimed at attenuating harmful
alcohol drinking.
The exact cause of uncontrolled drinking and relapse in patients diagnosed
with an AUD arises from the diverse and complex interaction between genetic,
epigenetic, and environmental factors that influence the neurobiological basis of
behavior (Koob and Volkow, 2010, 2016). Presently, viable treatment strategies
for patients suffering from an AUD include behavioral interventions and
pharmacotherapies, which are modestly effective given the 60% relapse rates in
treatment-seeking individuals within the first year (Dawson et al., 2005; Grant et
al., 2015; SAMHSA, 2016). Brief interventions, cognitive behavioral therapy, and
motivational-enhancement therapy are the most common forms of psychosocial
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treatments for AUD (Miller and Wilbourne, 2002). These include behavioral and
cognitive interventions aimed at addressing the maladaptive behavioral patterns
that promote compulsive alcohol consumption and contribute to relapse (Coates
et al., 2018; McHugh et al., 2010; Miller and Wilbourne, 2002). Because chronic
alcohol consumption promotes maladaptive changes within the brain that drive
uncontrolled drinking and amplify negative affect during withdrawal, it is not
surprising that treatment outcomes are greatly improved when psychosocial
interventions are combined with pharmacotherapy (Anton et al., 2006; Koob, 2013;
Koob and Volkow, 2010). Presently, pharmacological treatment is limited to three
clinically approved drugs by the U.S. Food and Drug Administration (Heilig and
Egli, 2006; Swift and Aston, 2015). These include naltrexone, disulfiram, and
acamprosate yet the efficacy of these drugs alone is modest and clinical utilization
low (Akbar et al., 2018; Heilig and Egli, 2006). This is, in part, due to each
compound having specific clinical utility based on distinct neurochemical and
peripheral systems involved in alcohol’s effects. For example, naltrexone is an
opioid antagonist that attenuates the reinforcing properties of alcohol thereby
reducing the drive to drink (Anton et al., 2004). On the other hand, disulfiram
decreases alcohol consumption by amplifying the negative reinforcing properties
of alcohol by blocking the metabolism of acetaldehyde, a metabolite of alcohol,
that is toxic and causes nausea, tachycardia, and flushing (Banys, 1988; Brewer,
1984; Lester et al., 1952). Acamprosate, albeit a biologically inactive molecule, has
anti-relapse properties through the actions of calcium salt acting as a calcium
therapy (Heilig, 2014; Spanagel et al., 2014). While medication-assisted therapy is
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an effective treatment strategy, less than 15% of individuals meeting the criteria
for AUD actually receive formal treatment due to the high cost of healthcare
services and fear of social exclusion (SAMHSA, 2018). Social exclusion and
stigma are due, in part, to a lack of lay knowledge concerning the neuroadaptations
that occur in patients with AUD and dependence that justify a diagnosable medical
disorder (Glass et al., 2014; Schomerus et al., 2011; Weine et al., 2016). Thus, a
major component of the NIAAA is to disseminate scientific findings to the public in
regards to the neuroadaptive changes that accompany chronic alcohol
consumption. More specifically, recent attention has focused on binge drinking as
a particularly risky behavior that is associated with the development of AUD
(Llerena et al., 2015; McCarty et al., 2004)

BINGE DRINKING
Habitual heavy drinking is a behavioral pattern acquired over time and is
accompanied by neuroadaptations that further promote uncontrolled drinking
behavior despite negative consequences. A behavioral pattern consisting of
repeated bouts of heavy episodic drinking is a hallmark of AUD and defined as 5
or more instances of binge drinking within a month. The NIAAA further defines
binge drinking as 5 or more units of alcohol consumed within a 2-hour period for
men, or 4 units within a 2-hour period for women (Alcoholism, 2004; SAMHSA,
2018). Binge drinking is a common occurrence within the U.S. population in that 1
in 6 persons displays this pattern of drinking within a 30-day period and, among
individuals with a history of excessive drinking, roughly 90% report patterns of
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binge drinking (Kanny et al., 2013). Furthermore, this pattern of excessive drinking
has the greatest potential for harm because of the cognitive impairments and organ
damage caused by high levels of alcohol circulating the body (Centers for Disease
and Prevention, 2012; Jennison, 2004). Rapid consumption of alcohol in this
fashion results in a blood alcohol concentration (BAC) in excess of the 0.08 g/dL
(80 mg/dL) legal limit of intoxication (Alcoholism, 2004; Courtney and Polich, 2009;
Kanny et al., 2013). Total alcohol metabolism under basal conditions is roughly
0.015 g per hour per 100 mL, or the equivalent of 1 standard drink per hour
(Cederbaum, 2012; Holford, 1987). Alcohol is metabolized at a steady state and
the rapid consumption occurring during a binge quickly overwhelms metabolic
processes leading to exponential increases in BACs (Holford, 1987). Generally, 23 unit doses of alcohol consumed in an hour result in a BAC below 0.08 g/dL and
is accompanied by a feeling relaxation and well-being (Hughes et. al., 2001).
Consumption of 4-5 standard drinks, however, elevates BACs into a binge range
between 0.08-0.09 g/dL. This level of intoxication is accompanied by reduced
judgement, impairments in memory and reasoning, and impairments in motor
coordination and reflex time. As alcohol consumption continues, BACs ranging
from 0.10-0.25 g/dL result in gross impairments in motor coordination, slurring of
speech, blurred vision, dysphoria, and nausea. Symptoms of alcohol poisoning
begin to present when BACs in excess of 0.25 mg/dL are reached, which include
confusion, severe nausea, vomiting, seizures, hypothermia, irregular breathing,
and loss of consciousness. In cases of severe acute intoxication, coma and
respiratory arrest can lead to death when BACs supersede 0.40 g/dL. The rapid
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elevation of BAC achieved during a binge is potentially harmful because alcohol is
a central nervous system (CNS) depressant and the subjective effects of alcohol
are not felt until roughly 10-30 minutes after ingestion (Holford, 1987; Tagawa et
al., 2000). Thus, a high volume of alcohol consumed during a 10-30 minute period
can lead to an elevation in BAC to a damaging and potentially lethal level before
an individual experiences negative feedback and slows subsequent drinking.

Risk for Injury
The high BAC achieved during a binge is associated with cognitive
impairments that negatively affect decision making and increase the users risk for
self-harm and harm to others (Jennison, 2004). For example, BACs superseding
0.08 g/dL are associated with deficits in motor coordination, reduced ability to
visually track moving objects, and impaired decision-making that collectively
increase the risk of harm to the individual and others (Balodis et al., 2009; Courtney
and Polich, 2009; Kanny et al., 2013). Acute intoxication results in deficits in motor
coordination that are highly correlated with accidental injury and 42% of
hospitalizations involve intoxication or alcohol-related disease (Gerke et al., 1997;
Tagawa et al., 2000). In fact, binge drinking increases the risk for accidental injury
and the level of alcohol intoxication is associated with emergency room visit
severity in a dose-dependent manner (Borges et al., 1998; Cherpitel et al., 2004;
Gmel et al., 2007). Injury most often presents as a fracture, abrasion, or
concussion resulting from falls (Charalambous, 2002). Binge drinking is thought to
result in injury in moderate drinkers because the high level of intoxication achieved
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during an isolated binge is a foreign experience (Gruenewald and Nephew, 1994;
Treno et al., 1997). However, habitual heavy episodic drinking is associated with
repeated injury resulting in chronic hospitalization or emergency room visits
(D'Onofrio and Degutis, 2002; Ponzer et al., 1999). Repeated episodes of binge
drinking and injury are also associated with a diagnosis of AUD (Gmel et al., 2007;
Mancino et al., 1996). Thus, it is likely that the high BAC achieved during a binge
is predictive of a generalized increased risk for accidental injury.
Accidental injuries are common in individuals with BACs above 0.08 g/dL
due to the cumulative effect of deficits in psychomotor coordination and impaired
decision making (Grant et al., 2000). Acute alcohol intoxication decreases an
individuals perceived probability of negative outcomes and consequences of their
actions (Fromme et al., 1997). Furthermore, alcohol is often referred to as a social
lubricant because it decreases inhibition and increases self-confidence that can
lead to an overestimation of one’s own abilities (Tiplady et al., 2004). Alcohol also
increases impulsive behaviors in a dose-related manner and increased impulsivity
is associated with increased propensity for risk taking (Kovacs et al., 2017; Lyvers
et al., 2015; Upton et al., 2011). It is therefore not surprising that individuals are
more likely to engage in dangerous behaviors that they would otherwise not take
part in whilst sober. For example, individuals are more likely to engage in risky
sexual behavior while intoxicated that increases the risk for spread of sexually
transmitted disease, unwanted pregnancy, and/or sexual abuse (Hines and
Straus, 2007; Naimi et al., 2003). Because intoxication during a binge drinking
episode results in reduced cognitive control over emotional reactivity, incidences
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of domestic violence and violent crime are also higher among binge drinkers
(Brewer and Swahn, 2005; Llerena et al., 2015). Finally, because acute alcohol
intoxication negatively affects the ability to track moving objects, impairs cognitive
processes, and delays motor responsiveness, it is of no surprise that high BAC
achieved during a binge negatively affects an individual’s ability to operate a motor
vehicle (Brumback et al., 2007; Christoforou et al., 2013). Cognitive impairments
associated with intoxication significantly contribute to mortality rates in intoxicated
drivers (Marczinski and Fillmore, 2009; Wundersitz and Raftery, 2017). In fact,
28% of all traffic related deaths involve alcohol-impaired drivers and, of self-reports
within the US, there are roughly 115 million instances of alcohol-impaired driving
annually (Mancino et al., 1996; National Highway Traffic Safety, 2010; Wundersitz
and Raftery, 2017). The collective ensemble of cognitive processes affected by
binge drinking contributes to but one of multiple facets of the negative effects of
alcohol.

Alcohol Toxicity
The rapid consumption of alcohol during a binge exerts an extreme stress
on metabolic pathways that work to process the large bolus of alcohol entering the
system (Cederbaum, 1980; Llerena et al., 2015). The liver is of particular
importance because it is the principal site of first pass metabolism and the most
susceptible to life threatening complications due to excessive drinking (Badawy,
1978; Zakhari, 2006). Prolonged stress on this metabolic pathway leads to high
levels of alcohol circulating in the bloodstream as well as metabolites that are toxic
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to organs and tissue (Holford, 1987). After oral consumption, alcohol enters the
body and is readily absorbed in the intestines and passes through the portal vein
to the liver (Badawy, 1978). Primary hepatic alcohol metabolism involves alcohol
dehydrogenase (ADH) that converts alcohol to acetaldehyde through oxidative
metabolism (Edenberg, 2007). Acetaldehyde is highly toxic and buildup produces
nausea, headache, and vomiting. Acetaldehyde is metabolized through oxidation
by mitochondrial aldehyde dehydrogenase 2 (ALDH2) into acetate in an
irreversible reaction (Cederbaum, 2012; Holford, 1987). Acetate is then further
metabolized in the liver or excreted to the periphery and metabolized. This occurs
as mitochondrial acetyl-CoA synthetase (acetyl-CoA synthetase 2 in cytosol)
reduces acetate to acetyl-CoA, an essential molecule in the tricarboxylic acid
(TCA) cycle. This primary process of alcohol metabolism accounts for roughly 90%
of alcohol metabolism, but when high concentrations of alcohol enter the system,
the remaining 10% of alcohol is metabolized through microsomal oxidation
(Cederbaum, 2012; Zakhari, 2006). This also occurs in the liver and involves
CYP2E1, a cytochrome P450 enzyme that converts alcohol to acetaldehyde
(Zakhari, 2006). An important byproduct of this reaction is the generation of
reactive oxygen species (ROS) that can cause damage to DNA and mitochondria
at high levels (Zakhari, 2006). The majority of acetaldehyde is converted by ALDH
into acetate, but it can also be converted by CYP2E1 into acetate generating ROS
in the process (Yun et al., 2014). The rapid consumption of alcohol during a binge
exerts a taxing force on the liver because of the zero-order kinetics of alcohol
metabolism. The prolonged stress on these metabolic pathways leads to high
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levels of alcohol circulating in the bloodstream as well as acetaldehyde, acetate,
NADH, acetyl-CoA, and ROS (Zakhari, 2006). Heavy drinkers have higher levels
of acetaldehyde within the liver that promotes oxidative stress and lipid
peroxidation (Barry, 1988; Setshedi et al., 2010). Increased NADH and acetylCoA production causes dysregulation of metabolic pathways including glycolysis,
TCA cycle, and gluconeogenesis (Badawy, 1978; Cederbaum, 1980; Zakhari,
2006). Dysregulation of these pathways directly contributes to alcoholic liver
disease. For example, fatty acid oxidation is suppressed in the liver during alcohol
metabolism and, as a result of prolonged heavy episodic drinking, contributes to
fatty liver disease (Lieber, 1975; Rasineni and Casey, 2012). Acetaldehyde and
ROS generated during chronic heavy drinking directly damage the liver as well
(Barry, 1988; Setshedi et al., 2010). Alcohol-induced damage to the liver most
commonly presents as fatty liver disease and cirrhosis of the liver, and together
are the leading causes of death in heavy drinkers (Lieber, 1975; Llerena et al.,
2015; SAMHSA, 2018).
Apart from direct effects on tissues involved in metabolism, the large bolus
of alcohol entering the body during a binge can cause damage to multiple tissues
and organs, especially with chronic use. For example alcohol causes a
proinflammatory response in the tongue and gums, and chronic inflammation is a
common risk factor for oral cancer (Ogden, 2005). After oral intake, alcohol travels
down the esophagus damaging the esophageal mucosa that precipitates and
exacerbates the symptoms of gastroesophageal reflux disease (Pan et al., 2019).
Once reaching the gastrointestinal (GI) tract, alcohol suppresses prostaglandin
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function further promoting inflammation and erosion of the lining within the large
intestine (Punchard et al., 1994). Furthermore, alcohol decreases digestive
enzyme levels within the small intestine resulting in poor nutrient extraction from
food, which creates a metabolic imbalance and disrupts general health (Bode and
Bode, 1997). Damage to the gut, however, is not limited to direct tissue damage.
The gut microbiome balance shifts toward dysbiosis with heavy alcohol
consumption that is associated with a number of different pathologies including
obesity, diabetes, irritable bowel syndrome, and celiac disease (Purohit et al.,
2008). Finally, excessive alcohol consumption has long been associated with
pancreatitis and chronic binge drinking is a risk factor for pancreatic cancer (Gupta
et al., 2010; Juliusson et al., 2018). In fact, heavy episodic drinking is associated
with 70% of cases of chronic pancreatitis (Dufour and Adamson, 2003). Therefore,
alcohol drinking disrupts various systems within the body that negatively affect
general health and binge drinking significantly contributes to mortality associated
with alcohol-induced disease.

Risk Factor for AUD
Social drinking is common worldwide and individuals at risk for developing
AUD are more likely to binge drink in social situations than those at low risk (Gowin
et al., 2017; Peacock et al., 2018). This is of importance because binge drinking is
the most common pattern of excessive alcohol consumption regardless of age and
sex (Kanny et al., 2013). In fact, roughly 50% of individuals that consumed alcohol
in the past year did so in a binge fashion and instances of binge drinking continue
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to rise within the US, as do corresponding emergency room visits, alcohol-related
mortality, and diagnoses of AUD (Castle et al., 2016; Hingson et al., 2017; White
et al., 2020). Even more, the intensity and duration of binge drinking serves as a
strong predictor for the development of AUD (Gowin et al., 2017). Furthermore, the
subjective response to alcohol is predictive of AUD in that binge drinkers report
increased stimulation and craving for alcohol after a single beverage whereas non
drinkers report a sedative effect (Holdstock et al., 2000). The predictive nature of
the response to alcohol and patterns of binge drinking has been documented in
humans, non-human primates, and rodents suggesting an evolutionarily
conserved mechanism of addiction pathology (Baker et al., 2017; Hingson et al.,
2017; Zhou et al., 2017). Engagement in binge drinking may predispose an
individual to AUD because BACs in excess of 0.08 g/dL are associated with a host
of genetic and neuroadaptive changes that promote excessive drinking (Ferguson
et al., 2019; Mulligan et al., 2011). Thus, study of the neurobiological mechanisms
underlying binge drinking is critical to understanding the trajectory of AUD.

NEUROBIOLOGICAL BASIS OF AUD AND BINGE DRINKING
Alcohol is consumed, in part, because of the feelings of relaxation and
euphoria experienced during intoxication that contributes to a positive affective
state and gives the drug reinforcing properties. At the most basic level, alcohol
influences mood and behavior through a pharmacological interaction with
neurotransmitter systems that modulate inhibition and excitation within the brain.
Alcohol is a nonspecific drug that is considered to be a CNS depressant because

12

it potentiates neural inhibition and attenuates excitatory processes. For example,
the GABAA receptor is a ligand-gated ion channel that is activated by gammaaminobutyric acid (GABA), the major inhibitory neurotransmitter system in the CNS
(Allan et al., 1987). Activation of GABAA receptors results in inward chloride ion
flux that has a net effect of hyperpolarization of the cell (Mihic and Harris, 1997).
Alcohol and other sedatives such as benzodiazepines and barbiturates are
considered negative allosteric modulators because they have a synergistic effect
with endogenous GABA interactions at the receptor that facilitate, and potentiate,
GABAA-mediated neuronal inhibition (Mihic et al., 1997). Alcohol suppresses
excitatory activity in the CNS through its action as an antagonist at the N-methyl
D-aspartate (NMDA) receptor (Lovinger et al., 1989). NMDA receptors are ligandgated ion channels that modulate inward flux of sodium and calcium and outward
flux of potassium, thereby resulting in depolarization of a neuron (Loftis and
Janowsky, 2003; Yamakura and Shimoji, 1999). Activation of NMDA receptors
occurs after binding of both glutamate, the major excitatory neurotransmitter, and
glycine. In fact, alcohol inhibits synaptic functions of both ionotropic NMDA and
AMPA glutamate receptors, which is somewhat unique in the adult brain (Gonzales
and Jaworski, 1997; Lovinger et al., 1990; White et al., 1990). Thus, modulation of
ionotropic glutamate and GABA receptors by alcohol functions to directly affect
intracellular ionic balance and subsequent neuronal activity. However, alcohol also
exerts its effects on the CNS through interactive effects of neuromodulatory
monoamine systems. Briefly, alcohol increases dopamine, norepinephrine, and
serotonin release that promotes the rewarding properties of the drug, enhances
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arousal, and affects mood (Lovinger, 1997; Zahr and Pfefferbaum, 2017). Lastly,
alcohol interacts with a number of different neuropeptide systems that similarly
contribute to the reinforcing properties of alcohol and promote alcohol
consumption, which will be discussed in detail later. Because the acute effects of
alcohol enhance inhibition and blunt excitation through GABA and glutamate
respectively, compensatory neuroadaptations occur after chronic alcohol abuse
that result in rebound excitation during periods absence of drug that contribute to
withdrawal syndrome. For example, internalization of GABAA and upregulation of
NMDA receptors results in decreased inhibitory tone and hyperexcitability within
brainstem structures that contributes to generalized seizure activity (Banerjee,
2014; Rogawski, 2005).
Human neuroimaging of patients with AUD and animal studies that
approximate AUD have revealed that discrete neurocircuitry contributes to
behaviors involved in the cycle of addiction, which are more precisely defined as
1) binge consumption and intoxication, 2) withdrawal and negative affect, and 3)
preoccupation and craving (Koob and Volkow, 2010). Different neuroanatomical
substrates are involved in the behaviors observed in each stage of this cycle that
collectively contribute to the manifestation of AUD. Preclinical models of excessive
alcohol drinking and dependence have provided further insight into brain regions
and neurochemical systems that are affected by chronic alcohol intake/exposure.
For example, alcohol consumption to excess during a bout of binge drinking
involves signaling within the mesolimbic dopamine system that reinforces the
rewarding properties of alcohol and neuroadaptations within the dorsal striatum
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promotes habitual binge drinking (Di Chiara, 1997; Nutt et al., 2015; Wang et al.,
2015). The negative affective state experienced during withdrawal involves activity
within the extended amygdala and hypothalamus that promotes an internal stress
response (Koob, 2009; Stephens and Wand, 2012). Finally, craving and
preoccupation with alcohol consumption during periods of abstinence is
associated with activity within the prefrontal cortex and hippocampus that
contribute to relapse (Sinha and O'Malley, 1999). The dominant theory of the
neurobiology of addiction proposes that a homeostatic balance is necessary within
the brain for normal processing (Koob and Volkow, 2010). Alcohol disrupts this
process by driving a positive affective state whilst intoxicated. But, with every
action there is an equal and opposite reaction. Therefore, a negative affective state
is experienced during withdrawal consistent with the opponent process theory. As
a result of chronic binge drinking, the homeostatic balance skews towards a net
negative state that presents during withdrawal as the emergence of persistent
negative affect, drives craving, and promotes chronic relapse. Thus, engagement
in repeated binge drinking is an effort to restore baseline homeostatic balance and
regain an allosteric set-point. The discrete neurocircuitry underlying the stages of
the addiction cycle as they relate to this shift in allostasis are described in greater
detail below.
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Binge Drinking and Reward
As we have previously described, binge drinking is a destructive pattern of
behavior that involves the rapid consumption of alcohol over a short amount of
time. Binge drinking and intoxication is a key component of the conceptual
framework underlying the neurobiological basis for AUD (Koob and Volkow, 2010).
Alcohol, like all drugs of abuse, is consumed because it has positive reinforcing
properties that promote excessive alcohol drinking. Operant conditioning
paradigms are used to study reward-driven behavior in rodents and early
experiments revealed that animals will lever press for intracranial self-stimulation
(ICSS) of the medial forebrain bundle. Mice and rats will establish lever press
behavior to receive ICSS, natural rewards, or drugs of abuse, which suggests a
common neuronal mechanism involved in reward. In fact, responding for ICSS is
decreased when subjects are pretreated with alcohol, demonstrating the innate
rewarding properties of the drug (Negus and Miller, 2014). The medial forebrain
bundle encompasses fibers of passage that originate in the ventral tegmental area
(VTA) and terminate in the basal forebrain. The VTA is a midbrain structure
involved in reward-related behaviors and is comprised of largely GABAergic
neurons that express the neuromodulator, dopamine (DA). Systemic challenge or
microinjection of alcohol directly into the VTA increases firing of DA neurons
through an excitatory mechanism (Brodie et al., 1999; Gessa et al., 1985).
Activation of neurons within the VTA results in release of DA in downstream
structures in the ventral striatum involved in reward, such as the nucleus
accumbens (NAc) (Kohl et al., 1998; Yim et al., 1998). Alcohol also facilitates
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endogenous opioid release within the VTA resulting in activation of Mu-opioid
receptor (MOR) locally on GABAergic terminals arising from the rostromedial
tegmental nucleus (RMTg) (Font et al., 2013; Jhou et al., 2009; Matsui and
Williams, 2011). Activation MOR on these terminals results in disinhibition of VTA
projections to the NAc and increased phasic DA release that contributes to reward
salience (Jhou et al., 2009). In fact, alcohol and all drugs of abuse increase
extracellular DA release in the NAc and suggests a common mechanism involved
in the reinforcing properties of these substances (Di Chiara, 1997; Di Chiara and
Imperato, 1988).
The mesolimbic DA system is not only responsive to the pharmacological
effects of alcohol, but also drives alcohol drinking and seeking behavior. For
example, alcohol consumption and anticipation of access to alcohol results in DA
release within the NAc and blockade of DA receptors therein decreases voluntary
intake (Hodge et al., 1997; Rassnick et al., 1992; Weiss et al., 1993). Furthermore,
cues associated with alcohol are sufficient to induce activation of the VTA and NAc.
Selective optogenetic activation of the VTA-NAc circuit promotes reinstatement of
alcohol seeking, an effect that is dependent upon DA signaling in the NAc (Bass
et al., 2013; Budygin et al., 2020; Juarez et al., 2017). Thus, projections from the
VTA to the NAc play a prominent role in reward salience that promotes goal driven
behavior, such as alcohol seeking and binge drinking. The NAc is further
subdivided into the NAc core and NAc shell. Both the core and shell receive DA
input from the VTA but each play a nuanced role in motivated behaviors. More
specifically, the NAc core is involved in general reward processes such as alcohol
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drinking and seeking behavior in response to discrete cues (Chaudhri et al., 2010).
The NAc shell plays a more prominent role in the balance of stimulus-outcome and
response-outcome processing (Corbit et al., 2001). Finally, D1- and D2-expressing
neurons in the NAc core project to the ventral pallidum (VP) via the direct “go” and
indirect “no-go” pathways, respectively, that are involved in various reward
behaviors, such as drug seeking and contribute to the reinforcing properties of
alcohol (Heinsbroek et al., 2020; Kupchik and Kalivas, 2013; Melendez et al.,
2004). D2-expressing neurons in the striatum are of interest because patients with
AUD show decreased D2 availability compared to controls (Volkow et al., 2002).
Furthermore, individuals with high levels of D2 expression are less likely to develop
an AUD even if they are predisposed through familial alcoholism (Volkow et al.,
2006). Therefore, DA signaling within VTA-NAc-VP circuitry plays an important role
in the rewarding properties of alcohol that promote drinking behavior. Interestingly,
pharmacological inactivation of the VTA or NAc blocks the expression of
conditioned place preference (CPP) for alcohol but lesion of DA terminals in the
NAc does not affect voluntary alcohol consumption (Bechtholt and Cunningham,
2005; Rassnick et al., 1993), suggesting that the mesolimbic DA systems works in
concert with other regions and systems to provide the cumulative rewarding
properties of alcohol that promote binge drinking.
Habitual alcohol consumption is a key component to the addiction cycle and
AUD. The dorsal striatum (DS) is of relevance because it plays a prominent role in
assigning reward value to a behavior, and compulsive, habitual drug-seeking
(Belin and Everitt, 2008; Malvaez and Wassum, 2018). Generally speaking the DS
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is a part of the basal ganglia that is involved in the initiation and control of motor
behaviors. The DS can be subdivided into the dorsal medial striatum (DMS) and
the dorsal lateral striatum (DLS), which are analogues of the human caudate and
putamen, respectively. The DMS is involved in goal-directed behavior and
inactivation of the DMS disrupts lever-press responding for alcohol only when
responding is sensitive to outcome value, indicative of action/outcome
associations (Corbit et al., 2012; Fanelli et al., 2013). Devaluation studies revealed
that selective inactivation of the DLS only decreased inflexible lever-press
responding for alcohol, suggesting that the DLS is more so associated with habitlike behavior (Corbit et al., 2012; Fanelli et al., 2013). This DMS/DLS dichotomy in
responding for alcohol is in agreement with the general theory that behavioral
acquisition and skill learning is mediated by associative corticostriatal activity
involving the DMS. As behaviors are repeated and actions refined, behavioral
responses become habitual, driven by a shift involving engagement of
sensorimotor circuitry involving the DLS (Kupferschmidt et al., 2017). Indeed, the
DS is a key component of the basal ganglia and DA signaling therein is involved
in the initiation and continuation of motor behavior involved in alcohol seeking and
consumption (Everitt and Robbins, 2013). Unlike the NAc, dopaminergic signaling
in the DS arises from projections originating in the substantia nigra pars compacts
(SNc), a midbrain DA-containing structure that innervates both the DMS and DLS.
SNc inputs to the DS are classically associated with the direct and indirect
pathways that drive thalamic inputs to the motor cortex through respective D1- and
D2-expressing striatal neurons. Acute alcohol treatment increases extracellular DA
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release within the striatum that has important consequences for behaviors that
involve the DS (Gonzales et al., 2004; Sulzer, 2011). For example, D1 antagonist
microinjection into the DMS decreases alcohol drinking and D2 antagonist in DLS
decreases habitual responding for alcohol (Corbit et al., 2012; Wang et al., 2015).
Interestingly, nonspecific D1/D2 antagonist into DLS decreases PR-breakpoint for
alcohol suggesting a role for DA signaling in the DLS in the motivation to work for
alcohol (Spoelder et al., 2017). Thus, the DMS is likely recruited after the
engagement of mesolimbic reward circuity to promote and facilitate drug seeking
behavior and, over time, the DLS is promotes more habitual patterns of drinking
that contribute to compulsive alcohol consumption (Barker and Taylor, 2014).
The amygdala is a structure located within the rostral pole of the temporal
lobe that is classically associated with emotional behavior. Recent studies,
however, suggest that subregions of the amygdala contribute to the reinforcing
properties of alcohol that promote binge drinking. For example, lesion of the
amygdala blocks the acquisition and expression of alcohol-induced CPP (Gremel
and Cunningham, 2008). Further studies revealed that selective lesion of the
central amygdala (CeA) attenuates voluntary alcohol consumption (Moller et al.,
1997). The CeA receives direct dopaminergic input from the VTA and SNc and,
similar to the striatum, extracellular DA is increased within the CeA after acute
alcohol challenge (Hasue and Shammah-Lagnado, 2002; Yoshimoto et al., 2000).
Furthermore, blockade of D1 receptors in the CeA attenuates alcohol drinking and
seeking behavior (Yoshimoto et al., 2000). Interestingly, activation of D2
expressing neurons in the CeA promotes impulsive behavior that is involved in
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chronic binge drinking (Kim et al., 2018). The CeA sends monosynaptic projections
to the VTA and SNc and this circuitry is involved in appetitive learning (Lee et al.,
2010). Within the CeA, bath application of alcohol decreases glutamate release
through inhibition of N-type calcium channels and in-vivo, nonselective blockade
of NMDA/AMPA receptors in the CeA blocks the expression of CPP (Zhu et al.,
2007). Finally, the CeA is also the most sensitive site of GABAA antagonists’ effects
on alcohol consumption and a history of chronic intermittent ethanol (CIE)
exposure increases GABAergic tone and responsiveness to alcohol in the CeA
(Gilpin et al., 2015; Hyytia and Koob, 1995; Roberto et al., 2012). Together, these
studies suggest involvement of the CeA in the rewarding properties of alcohol and
processes involved in the motivation to drink excessively.
Therefore, alcohol is consumed because of the rewarding properties of the
drug that arise from the collective activity of VTA-NAc-VP circuitry in addition to
activity in the CeA. Neuroadaptations within the aforementioned brain regions as
well as the DLS occur over time and contribute to the transition to habitual,
compulsive, uncontrolled bouts of binge drinking that are a hallmark of AUD.

Withdrawal and Negative Affect
Chronic excessive drinking leads to neuroadaptations that promote
withdrawal symptomology in the absence of alcohol. This is not to be confused
with what is commonly referred to as a “hangover” that manifests as nausea,
vomiting, and headache due to dehydration that is experienced after acute binge
intoxication (Swift and Davidson, 1998). In fact, this acute negative experience has
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strong aversive properties that are associated with stimuli related to alcohol and
act as a positive punishment, which decreases the likelihood of further drinking.
Alcohol consumption, however, can alleviate this symptomology and promote
further drinking through negative reinforcement (Koob, 2013). Over time, repeated
instances of binge drinking can result in neuroadaptations that contribute to
withdrawal syndrome, which is characterized by physical symptomology, such as
increased heart rate, sweating, tremor, seizure activity, and increased pain
sensitivity combined with a negative emotional state that is experienced when
access to alcohol is prevented (Becker and Hale, 1993; Jesse et al., 2017; Koob
and Le Moal, 2008).
Chronic binge drinking results in neuroadaptive changes that promote
tolerance, dependence, and the manifestation of withdrawal syndrome that is
associated with an imbalance of excitatory and inhibitory neurotransmitter
systems. More specifically, alcohol is a GABAA PAM and NMDA antagonist, and
chronic alcohol exposure results in a rebound effect of decreased inhibition due to
GABAA hypofunction and NMDA-mediated hyperexcitability during withdrawal
(Davies, 2003; Gonzales and Jaworski, 1997). Cessation of alcohol after chronic
consumption results in CNS autonomic hyperexcitability that contributes to
generalized tonic-clonic seizure activity (Becker and Hale, 1993; Rogawski, 2005).
More specifically, withdrawal-related seizure activity occurs most commonly within
48 hours of alcohol cessation and is related to a decrease in seizure threshold
(Brathen et al., 1999; Victor and Brausch, 1967). Seizure activity originates in the
brainstem during withdrawal due to decreased GABAA-mediated gating of
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neuronal activity (Rogawski, 2005). Thus, drugs that restore activity of the GABAA
receptor, such as benzodiazepines and alcohol, act as anticonvulsants and
normalize seizure threshold during withdrawal (Mayo-Smith, 1997). Glutamatergic
hyperexcitability also occurs that contributes to seizure activity through an
upregulation of NMDA receptors and NMDA antagonists block withdrawal-related
seizures (Grant et al., 1990; Kalluri et al., 1998). Cognitive processes are also
greatly affected during acute withdrawal, and in the most severe cases, symptoms
of alcohol withdrawal delirium, or Delirium Tremens (DTs) present as extreme
confusion, hallucinations, autonomic hyperactivity, and cardiovascular arrhythmia
(Grover and Ghosh, 2018; Schuckit, 2014). Dysregulation of monoamine systems
contribute to confusion, hallucinations, and extreme shifts in mood. DA in particular
plays an important role in major alcohol withdrawal whole body tremor. For
example, heavy episodic drinking decreases DA signaling in basal ganglia and
promotes cerebellar degeneration that presents as resting tremor during
withdrawal (Deik et al., 2012; Yokota et al., 2006).
As previously discussed, alcohol increases DA release within reward
circuitry and promotes the positive reinforcing effects of the drug. Chronic alcohol
consumption, however, drives a maladaptive shift towards a hypodopaminergic
state within the NAc that contributes to a reward-deficit (Edwards and Koob, 2010;
Karkhanis et al., 2015). For example, under basal conditions acute alcohol
increases endogenous opioid and DA release that is associated with positive affect
(Yim et al., 1998). As drinking escalates over time, MOR-related signaling and
subsequent DA release in response to alcohol is attenuated, necessitating greater
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levels of alcohol consumption to achieve a positive state (Koob and Volkow, 2016).
This rationale is supported by imaging studies that show reduced methylphenidateinduced DA release within the striatum of patients with AUD (Volkow et al., 2013).
Furthermore, chronic alcohol treatment increases ICSS reward threshold during
withdrawal suggesting an increased hedonic drive to drink during withdrawal
(Chester et al., 2006; Schulteis et al., 1995). Thus, heavy episodic drinking
emerges as a maladaptive behavioral process to relieve the reward-deficit. The
homeostatic set point shifts towards a net negative as signaling of the pro-affective
MOR decreases and signaling in systems involved in dysphoria, aversion, and
stress are increased.
Withdrawal is generally accepted to be a stressful state and is associated
with increased circulation of stress-responsive hormones and neuropeptides. The
heightened stress/anxiety state resulting from repeated activation of the reward
system contributes to negative hedonic value that has been conceptualized as an
anti-reward system (Koob, 2013; Koob and Le Moal, 2008). For example, the
hypothalamic-pituitary-adrenal (HPA) axis regulates the endogenous stress
response and is severely impacted by chronic alcohol consumption (Blaine et al.,
2016). The paraventricular nucleus of the hypothalamus (PVN) produces
corticotrophin release factor (CRF) that is secreted in response to input from
structures that detect and are responsive to stress-associated stimuli (Turnbull and
Rivier, 1997). CRF-expressing neurons within the PVN project to various
structures within the CNS and also send axonal projections through the
infundibular stalk that release CRF into the median eminence. CRF travels through
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the hypophyseal portal system and drives the release of adrenocorticotrophic
hormone (ACTH) from the anterior pituitary gland. ACTH then moves freely
through the body and stimulates the secretion of cortisol/corticosterone (CORT)
and glucocorticoids from the adrenal cortex. Feedback from CRF, ACTH, and
CORT regulates the stress response and disrupted in patients with AUD (Stephens
and Wand, 2012). Indeed, a moderate dose of alcohol reflecting BACs below 0.08
g/dL blunt HPA axis responsiveness to experimenter-delivered CORT, supporting
the anxiolytic properties of alcohol (Waltman et al., 1993). However, higher BACs
achieved during a binge increase CRF, ACTH, and CORT release, as well as
norepinephrine, and promotes positive feedback at the level of the PVN (Borg et
al., 1981; Wright, 1978). Chronic alcohol consumption further disrupts HPA axis
function by dynamically altering the response to alcohol, abstinence, and stress.
For example, HPA axis activity is increased during chronic consumption and
withdrawal, but is suppressed in response to stressors (Adinoff et al., 1998;
Becker, 2012). Increased circulating stress hormone levels during withdrawal
contribute to the shift toward negative allostasis that is relieved by binge drinking,
consistent with the tension-reduction hypothesis (Becker, 2012; Cappell and
Herman, 1972; Koob, 2013). However, repeated instances of binge drinking to
alleviate withdrawal symptoms facilitate neuroadaptations that exacerbate the
dysregulation of HPA axis reactivity and the stress response that perpetuates the
addiction cycle.
The extended amygdala macrostructure is considered to be a key node in
the interface of stress and arousal systems with limbic drivers of hedonic behavior
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affected during withdrawal (Koob and Le Moal, 2008). The extended amygdala is
comprised of the CeA, bed nucleus of the stria terminalis (BNST), substantia
innominata, and NAc shell (Alheid and Heimer, 1988). The CeA and BNST in
particular modulate the stress response through projections to the PVN and lesion
of either structure disrupts HPA axis activation (Crestani et al., 2013; Xu et al.,
1999). C-Fos immunoreactivity is increased within these structures during acute
withdrawal and this heightened neuronal activity is thought to promote stress and
anxiety-like behavior (Kimbrough et al., 2020; Smith et al., 2019). Interestingly,
activity and connectivity between the CeA and BNST is observed during
withdrawal that may contribute to negative affective states (Hu et al., 2018;
Pedersen et al., 2020). In fact, inhibition of a select populations of projections
between the CeA and BNST decreased alcohol intake and attenuated anxiety-like
behavior in alcohol-dependent rats (de Guglielmo et al., 2019). Further, the CeA
and BNST are rich in CRF and glucocorticoid receptors that are activated during
withdrawal and contribute to excessive drinking (Kash et al., 2015; Pomrenze et
al., 2019a; Silberman and Winder, 2013). Indeed, CRF and glucocorticoid
antagonists have shown promise in attenuating excessive drinking and withdrawalrelated stress and anxiety in preclinical models of AUD (Funk et al., 2007; Shaham
and de Wit, 2016; Stephens and Wand, 2012). More specifically, microinjection of
a CRF1 antagonist into the CeA decreased dependent-like escalation in alcohol
intake and reduced anxiety-like behavior during protracted withdrawal (Baldwin et
al., 1991; Funk et al., 2006). CRF-expressing neurons within the BNST are also
affected by chronic alcohol exposure and modulate activity in the VTA through
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CRF1 receptors therein (Rinker et al., 2017; Silberman et al., 2013). Within the
BNST, dysregulation of excitatory/inhibitory balance by alcohol-induced alteration
of monoamine and peptide release mediate withdrawal-induced anxiety and are
thought to also promote excessive drinking (Kash, 2012; Kash et al., 2015; Pleil et
al., 2016).
Koob et al., have described the negative affective state experienced during
withdrawal that drives negative reinforcement and promotes alcohol drinking as
the “dark side of addiction”, embodied by dysphoria, anxiety, and irritability (Koob,
2013; Schulteis and Koob, 1994). The dark side emerges over time as functioning
of anti-reward systems increase concurrent with frequent bouts of heavy episodic
drinking. Thus, the chronic relapsing nature of AUD is evident as individuals seek
to restore a homeostatic set point through alcohol consumption to alleviate
withdrawal symptomology and persistent negative affect. However, since reward
systems are desensitized over time, alcohol drinking to excess in repeated/chronic
binges emerge as an effort to offset the negative allosteric load experienced during
the reward deficit.

Opponent Process Theory and Craving
Individuals diagnosed with AUD report that craving, and an inability to
regulate the behavioral response to craving, significantly contributes to relapse that
perpetuates the chronic relapsing nature of the disorder (Breese et al., 2011; Fox
et al., 2007). Therefore, understanding the neurobiological mechanisms that drive
craving is essential to break the cycle of addiction and prevent relapse. Craving
presents as an intense, urgent, and abnormal desire to consume alcohol that
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arises from the complex interplay between neuroadaptations that occur as a result
of prolonged alcohol abuse and environmental influences that trigger craving and
relapse (Seo and Sinha, 2014; Sinha, 2013). As previously described, chronic
excessive alcohol consumption results in neuroadaptations that create a
maladaptive imbalance in positive and negative affect. The resulting increase in
allosteric load leaves individuals with AUD susceptible to relapse because of
increased reward salience, persistent negative affect, and deficits in the top-down
control of impulsive behavior and emotional processing (Koob, 2013). It is not
surprising that neurocircuitry involved in reward (striatum), behavioral inhibition
(PFC), and emotional control (limbic system/amygdala) are affected by chronic
alcohol abuse and drive craving (Koob and Volkow, 2016). Thus, allosteric
pressure and resultant dysregulation of cortico-striatal-limbic circuitry is a likely
culprit contributing to craving in patients with AUD.
We have previously discussed the role of the NAc within the context of
reward and provided evidence demonstrating that alcohol dependence drives a
hypodopaminergic state during withdrawal. Concurrent neuroadaptations within
reward circuitry shift during the transition to dependence to assign greater salience
to alcohol and alcohol-related stimuli compared to natural rewards. Robinson and
Berridge describe this process as incentive sensitization that is consistently
observed across drugs of abuse (Robinson and Berridge, 1993). Therefore,
craving for alcohol emerges in place of natural rewards as reward circuits are
sensitized over time resulting in a homeostatic shift toward compulsive drinking.
This is particularly evident in the sensitized response to cues associated with
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alcohol. For example, increased activity is observed in the ventral and dorsal
striatum in response to alcohol-related cues in subjects diagnosed with AUD and
activity within these regions is predictive of the likelihood of relapse (Seo et al.,
2011). Preclinical models have shown that inactivation of the NAc attenuated
reinstatement of alcohol-seeking behavior suggesting a causal role for this
structure in what is considered the rodent approximation of craving and relapse
(Chaudhri et al., 2010).
Beyond mesolimbic DA, alcohol-predictive cues trigger the intense urge to
seek alcohol and this craving is related to altered glutamatergic tone in the NAc.
In fact, increased glutamate within the NAc of humans is observed during
withdrawal and strongly predicts the intensity of craving (Bauer et al., 2013). In
rodents, extracellular glutamate is increased within the NAc of alcohol-dependent
mice and pharmacological attenuation of glutamatergic tone normalized alcohol
intake to a moderate level (Griffin et al., 2014). Similarly, glutamate is released
within the NAc in response to alcohol-associated cues and triggers reinstatement
of alcohol-seeking in a mGlur2-dependent manner (Gass et al., 2011; Meinhardt
et al., 2013). Thus, glutamate overflow within the NAc resulting from chronic
alcohol consumption is thought to promote craving, preoccupation, and obsessive
thoughts that drive relapse (Kalivas, 2009).
The mPFC is classically associated with cognitive processing and top-down
control over limbic structures, such as the NAc and amygdala, that drive hedonic
behavior (Kouneiher et al., 2009). Neuroimaging studies have revealed that
chronic alcohol abuse is associated with decreased gray matter volume within the
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mPFC that manifests as deficits in higher order functioning such as decision
making, impulse control, and emotional regulation (Bechara, 2005; Goldstein and
Volkow, 2011; Yang et al., 2016). Even though there is decreased volume within
the medial PFC (mPFC) and subdivisions therein, increased activity within these
structures as a function of AUD have been associated with craving (Sinha, 2013).
The orbitofrontal cortex (OFC) and insular cortex (IC) in particular are associated
with incentive motivation and behavioral inhibition (Arana et al., 2003; Naqvi et al.,
2014). Activity within the OFC is increased in response to alcohol-associated cues
and correlates with craving (Myrick et al., 2004). In fact, heightened OFC activity
predicts the likelihood of relapse during protracted abstinence (Reinhard et al.,
2015). Similarly, alcohol-associated cues result in increased activity within the IC
and this increase is more pronounced in alcohol-dependent individuals (Schacht
et al., 2013). The heightened responsiveness of the IC is also predictive of the
severity of AUD symptomology (Claus et al., 2011). Another region of the PFC, the
dorsolateral prefrontal cortex (dlPFC), has been extensively studied in the context
of craving and alcohol seeking behavior. The dlPFC is highly reactive to cues
associated with alcohol and this activity is strongly correlated with craving (Park et
al., 2007). Furthermore, modulation of neuroplasticity within the dlPFC using
noninvasive techniques such as repeated transmagnetic stimulation (rTMS) has
shown promise in reducing craving and relapse in treatment-seeking patients with
AUD (Zhang et al., 2019). In rodents, the dlPFC is analogous to the prelimbic
cortex (PL). The PL exerts excitatory control over the VTA through a glutamatergic
projection involved in incentive salience (Carr and Sesack, 2000). The PL also
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sends a direct monosynaptic projection to the NAc core and promotes drug
seeking behavior (McGlinchey et al., 2016). Indeed, cues associated with alcohol
increase c-Fos expression within the PL and selective inhibition or ablation of the
PL-NAc core pathways is sufficient to block cue-induced reinstatement of alcohol
seeking (Keistler et al., 2015; Keistler et al., 2017).
During early withdrawal, uncontrolled craving is associated with
dysregulation of the HPA axis that presents as a negative emotional state and
promotes compulsive drinking (Koob, 2013). An inability to control emotional
behavior in response to stress is associated with relapse and increased drinking
(Claus et al., 2011). The ventromedial prefrontal cortex (vmPFC) has been
implicated in the top-down control over emotional reactivity and dysregulated
activity has been observed in abstinent patients with AUD (Seo et al., 2013). More
specifically, basal activity is increased within the vmPFC and the level of resting
state activity is positively correlated with craving scores and predicts relapse (Seo
et al., 2013). In healthy subjects, vmPFC activity is increased in response to a
stressor but this effect is not observed after chronic alcohol abuse suggesting a
blunting in stress-responsivity. The vmPFC projects to the amygdala and
decreased coupling of these structures is associated with negative affect (Urry et
al., 2006). As a function of chronic alcohol consumption or a familial history of
alcoholism, amygdala volume is decreased and the reduced size predicts craving
and relapse (Hill et al., 2013; Wrase et al., 2008; Zhang et al., 2013). However,
cues associated with alcohol illicit a robust increase in activity within the amygdala
that is associated with relapse (Schact et al., 2013). Further study of PFC-
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amygdala connectivity in rodent models of AUD and relapse support these
observations, although the neuroanatomical terminology for these structures
differs slightly. For example, the human vmPFC is analogous to the rodents
infralimbic cortex (IL) and sends glutamatergic projections to the BLA. Studies of
conditioned fear and extinction learning have demonstrated that activity of IL-BLA
projections is necessary for extinction learning and the expression of extinction
behavior, which is sensitive to alcohol abuse (Bloodgood et al., 2018; Do-Monte et
al., 2015; Holmes et al., 2012). Indeed, CIE exposure reduces activity within the IL
and impairs extinction learning, reflective of a dysregulation in the top-down control
of emotional behavior (Scarlata et al., 2019). The BLA, however, is not only
involved in the regulation/expression of fear, but is highly reactive to cues
associated with alcohol and a key node in reinstatement circuitry (Gass et al.,
2011; Sinclair et al., 2012). In fact, ablation of BLA projections to the NAc
attenuates cue-induced reinstatement of alcohol-seeking (Keistler et al., 2017).
The BLA also sends projections to the hippocampus, which is involved in
contextual associations with alcohol that trigger relapse, and inhibition of BLA
projections to the ventral hippocampus decreases excessive drinking (Ewin et al.,
2019). Thus, cortico-striatal-limbic circuity drives craving in response to cues
associated with alcohol.
Dysregulation of the HPA axis and the endogenous response to stress is a
major component of craving and not only facilitates excessive drinking but
sensitizes the response to cues associated with alcohol that drive relapse (Koob,
2013; Koob and Le Moal, 2008). We have previously described that CRF, ACTH,
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and CORT levels are elevated at rest as a function of dependence that contributes
to craving and further drinking to alleviate the hyper aroused state, consistent with
the tension reduction hypothesis (Sinha, 2001). Stress reactivity, however, is also
altered as a function of dependence that drives craving. Rodent models have been
useful in demonstrating this relationship in that rats show increased response to a
mild stressor during withdrawal that promotes alcohol-seeking behavior (Zorilla et
al., 2001; Breese et al., 2005; Le at al., 1998). Repeated cycles of CIE exposure
results in increased voluntary alcohol consumption in mice, and the addition of
chronic FSS further elevates drinking beyond that of CIE alone (Anderson et al.,
2016; Lopez et al., 2016a). This suggests that a history of dependence sensitizes
stress-related circuitry that selectively promotes excessive alcohol consumption,
an effect not seen in non-dependent subjects. Furthermore, a history of alcohol
dependence blunts the HPA axis response to stress that may present behaviorally
as a maladaptive coping response (Adinoff et al., 1998; Becker, 2012). The
extended amygdala and specifically the CeA and BNST are highly enriched in
CRF-expressing neurons and adaptations within these structures has been
suggested to play a role in the altered stress response that contributes to craving
(Merlo Pich et al., 1995; Olive et al., 2002).
In summary, the loss of control over craving is associated with compulsive
alcohol drinking, especially when individuals are faced with situations, cues, or
environments associated with alcohol, and in the face of stressful events. Indeed,
circuits that are involved in emotional responses and cognitive control over
behavior become dysregulated and contribute to craving and relapse. Thus,
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cortico-striatal-limbic circuitry is a likely culprit driving craving and relapse because
these regions are involved in regulation of behavioral control, reward, and emotion.
Koob

and

Volkow

propose

a

framework

underlying

craving

where

neuroadaptations within the NAc occur first that promote incentive salience. This
is followed by alterations within the PFC resulting in a lack of top-down control of
behavior. Finally, a gain of function in limbic structures, specifically the extended
amygdala that modulate stress, push the system to promote alcohol drinking over
natural rewards.

Summary
The development of AUD and dependence arises from the complex
interplay between neuroadaptations within multiple brain regions that occur as a
result of repeated binge intoxication. Intoxication achieved during a binge activates
reward circuitry and reinforces further alcohol consumption. As binge drinking
continues, reward pathways are sensitized in response to stimuli associated with
alcohol and drinking behavior that dysregulates reward circuitry. Furthermore, with
repeated instances of binge drinking, withdrawal sequalae emerge from a gain of
function in stress-related systems that presents as a persistent negative emotional
state. Thus, chronic binge drinking and subsequent withdrawal create an allosteric
load that shifts the act of alcohol consumption from positive to negative
reinforcement. During abstinence, the negative emotional state experienced
during withdrawal creates a strong drive to consume alcohol. Relapse presents as
an effort to relive this state and Koob et al, 2013 suggested classifying AUD as a
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stress surfeit disorder for this reason. The extended amygdala structure is a shared
neuroanatomic substrate of binge drinking, withdrawal, and craving and the CeA
and BNST in particular have garnered much interest as a druggable target for the
treatment of AUD. More specifically, the CeA and BNST are home to a plethora of
neuropeptides that are involved in the addiction cycle and pharmaceutical
compounds targeting these systems have shown promise in decreasing drinking
behavior, relieving withdrawal-related negative affect, and curbing craving/relapse.
Of particular interest is the kappa opioid receptor, which is expressed within the
extended amygdala and implicated in each stage of the addiction cycle. We will
expand upon the function of this receptor and its endogenous ligand in relation to
AUD in the following section.

DYNORPHIN/KAPPA OPIOID RECEPTOR SYSTEM
Neuropeptide systems play a critical role in the modulation of binge drinking
behavior, withdrawal, and craving that comprise the addiction cycle. Dynorphin
(DYN) is one such neuropeptide that is involved in the various aspects of the
addiction cycle and has emerged as a potential therapeutic target for the treatment
of AUD. Dynorphins (DYN) are a class of endogenous opioid peptides classically
associated with stress, dysphoria, pain, and aversion and are the primary ligand
to the kappa opioid receptor (KOR) (Bruchas et al., 2010; Chavkin et al., 1982;
Mucha et al., 1985; Pfeiffer et al., 1986). DYN arises from a single precursor
protein, preprodynorphin, which is enzymatically processed within the soma by
proprotein convertase-2 into prodynorphin (PDYN) and further processed to
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functionally active DYN peptides A and B (together referred to as “Big Dynorphin”)
and neo-endorphin (Chavkin et al., 1982; Massotte and Kieffer, 1998). Like other
opioid peptides, DYN is stored in dense-core vesicles where it is released from
axon terminals or dendritic processes. The rate of DYN metabolism varies by brain
region but occurs through proteolysis resulting in leu-enkephalin production
(Sandin et al., 1997). Leu-enkephalin is an active metabolite with high affinity at
the delta-opioid receptor, moderate affinity at the mu-opioid receptor, and very low
affinity for KOR (Sandin et al., 1997). Upon release, DYNs cross the synaptic cleft
and bind to KORs that are expressed primarily on presynaptic terminals. The KOR
is a seven transmembrane G-protein coupled receptor encoded by the OPRK1
gene (Chavkin, 2013). KORs exert a largely inhibitory effect on neuronal activity
through Gi/o intracellular signaling. For example, upon DYN binding to KOR, GDP
is displaced allowing for GTP association with the Gi/o subunit. GTP-bound Gi/o
and beta/gamma subunits then dissociate from the c-terminus of KOR and have
distinct signaling pathways. The Gi/o complex acts to inhibit adenylyl cyclase
activity that, in turn, decreases cAMP production (Law et al., 2000). The GTPbound Gi/o subunits further exerts a hyperpolarizing effect on tonic neuronal
activity by facilitating G-protein gated inward rectifying potassium channels (Kir3)
(Henry et al, 1995). Finally, the beta-gamma subunit promotes hyperpolarization
by blocking N-type voltage-gated calcium channels (Tallent et al., 1994). After Gprotein dissociation, the c-terminus is phosphorylated by G-protein receptor kinase
2 (GRK2) at serine 369 that acts to functionally desensitize the receptor
(McLaughlin et al., 2003b). Interestingly, KOR can be desensitized after ligand
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binding and GRK2 phosphorylation at Ser-369, yet remain in the membrane
without internalization (McLaughlin et al., 2004; McLaughlin et al., 2003b).
Prolonged agonist activity at the receptor, however, results in internalization via
beta-arrestin recruitment at the sites of phosphorylation (McLaughlin et al., 2004).
Dephosphorylation occurs via protein phosphatase 1 and 2a allowing for receptor
recycling to the membrane (Appleyard et al., 1997).

Location and Function
KORs are widely expressed throughout both the peripheral nervous system
(PNS) and central nervous system (CNS). Within the PNS, KOR are expressed on
primary sensory afferent neurons, within the gastrointestinal tract, and heart, and
compounds with selective KOR agonist properties have been considered as
potential treatment strategies for maladies of these regions (Galligan and Sternini,
2017; Snyder et al., 2018; Sobanski et al., 2014). For example, KORs are
expressed throughout primary afferent neurons on the cell body, dorsal root
ganglion, and terminals within the spinal cord and, like mu- and delta-opioid
receptors, activation of KOR within peripheral nerves has analgesic properties (Ji
et al., 1995; Snyder et al., 2018). In fact, peripherally restricted KOR agonists
attenuate the behavioral response to thermal allodynia, sciatic nerve injury, and
hind-paw inflammation suggesting involvement of KOR in various pain models
(Berg et al., 2011; Jamshidi et al., 2015). KOR agonists have spinal anesthetic
properties and modulate the peripheral response to pain through reduced
excitatory neurotransmission from sensory input to the CNS. Opioid receptors are
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widely expressed in the gastrointestinal tract and morphine, through agonist action
at the mu-opioid receptor, has strong analgesic properties, but reduces intragastric contractions that cause constipation (Pasternak and Pan, 2013). KOR are
also expressed within the gastrointestinal tract and modulate acetylcholine release
at the neuromuscular junction within the colon (Chamouard et al., 1993; Riviere,
2004). The use of KOR agonists to treat chronic pain is viable alternative to classic
opiates because they do not cause gastrointestinal distress and there is little
concern for dependence or abuse (Riviere, 2004). Of concern for drug
development, KOR are expressed on myocardial cells within the heart and have
anti- and pro- arrhythmic effects depending on dosage (Coles et al., 2003; Mousa
et al., 2010). However, KOR agonists reduce the size of myocardial infarction and
show promise for the prevention of tissue damage caused by heart attack (Peart
et al., 2004). Finally, KOR agonists have also been considered for drug
development given the anti-pruritic, anti-inflammatory, and anti-emetic properties
of peripheral KOR activation (Phan et al., 2012; Liang, 2016; Porreca et al., 2009).
Within the CNS, KOR are expressed in brain regions implicated in the
experience of consciousness, mood/affect, and motivational behavior, such as the
claustrum, frontal cortex, mesolimbic dopamine system, substantia nigra,
hypothalamus, and the extended amygdala network (Bruchas et al., 2010;
Chavkin, 2013; DePaoli et al., 1994; Simonin et al., 1995). Interestingly, KOR
agonists have a profound effect on human consciousness and use of plants
containing naturally occurring compounds with KOR agonist properties, such as
Salvia divinorum, have been used in religious ceremonies or for medicinal
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purposes by shamans in South America and Mexico for many years (Valdes et al.,
1983). More specifically, salvinorin A is a selective KOR agonist found within the
leaves of the Salvia divinorum (salvia) plant and is considered to be one of the
most potent naturally occurring hallucinogenic drugs (Chavkin et al., 2004; Roth et
al., 2002). Inhalation of vapor derived from extracts of dried salvia leaves or
ingestion of plant material has extreme hallucinogenic and dissociative properties
(Valdes, 1994). Individuals report profound changes in all sensory modalities, out
of body experiences, and psychotomimetic effects during clinical experimentation
with salvinorin A (Pfeiffer et al., 1986; Siebert, 1994; Valdes, 1994). In support of
DYN/KOR-mediated psychotomimetic effects, DYN levels are increased in the
CSF of patients with schizophrenia and KOR antagonists attenuate hallucinations
in these subjects (Gunne et al., 1977; Heikkila et al., 1990). Interestingly,
documentation of experiences with salvinorin A have played an important role in
unraveling one of the greatest unanswered questions in neuroscience, the
“problem of consciousness”. In the last article written before his death, Francis
Crick postulated that the claustrum, a structure rich in KOR and located between
the insular cortex and striatum, may act as a “grand conductor of consciousness”
(Crick and Koch, 2003). The claustrum is highly interconnected with cortical
structures and is involved in the integration of sensory modalities and the
experience of “self”. Thus, it is not surprising that activation of KOR by salvinorin
A results in vivid hallucinations, disrupted perception of self and, what many refer
to as ego death or ego dissolution (Stiefel et al., 2014). Even though the
psychotropic effects of acute salvia intoxication resemble that of psychedelic
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compounds such as psilocybin, lysergic acid diethylamide, or dimethyltryptamine,
salvia is not classified as a psychedelic because it does not have agonist
properties at the 5-HT2A receptor (Roth et al., 2002). Even more interesting,
salvinorin A decreases release of DA in the NAc setting this recreational drug apart
from drugs of abuse (Zhang et al., 2005). Indeed, the use of salvia has gained
popularity but the pattern of usage does not reflect abuse potential due to the
dysphoric properties of the drug (SAHMSA, 2012). These unique properties have
led many to be interested in the development of KOR agonists for various
treatments due to the lack of abuse potential.

Aversion, Stress, and Anxiety
Within the CNS, however, KOR antagonists are more commonly
investigated as treatment strategies for psychiatric disorders involving negative
affective states, such as those of anxiety, depression, and addiction. This is
because KOR agonists, while novel in their analgesic properties, promote
dysphoric states in humans and rodents (Pfeiffer et al., 1986; Roth et al., 2002).
More specifically, rodents display a variety of behaviors associated with dysphoria
in response to KOR agonists such as aversion, a stress response, and anxiety-like
behavior, all of which are critical components of alcohol withdrawal (Bals-Kubik et
al., 1993; Lalanne et al., 2014; Shippenberg et al., 2001). For example, early
studies revealed that repeated treatment with a KOR agonist produced conditioned
place aversion (CPA) to a drug-paired environment, suggesting that KOR
activation has aversive properties (Shippenberg and Herz, 1986). Further studies
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revealed a dynamic relationship between DYN/KOR and DA signaling in the NAc
that mediate aversion (Di Chiara and Imperato, 1988; Maisonneuve et al., 1994).
KOR are found on presynaptic terminals of NAc-projecting dopaminergic neurons
within the VTA (Margolis et al., 2003; Svingos et al., 1999). During reward-related
behavior or exposure to drugs of abuse, DA is released from these VTA terminals
in the NAc. Upon release, DA binds D1 receptors on medium spiny neurons
(MSNs) that express DYN. D1 MSNs within the medial shell send long range
projections to the VTA and release GABA and DYN onto dopaminergic cells
therein and inhibit downstream release (Yang et al., 2018). More prominently, Gsmediated intracellular signaling after D1 MSN activation drives local release of
DYN that activates KOR on VTA terminals and decreases DA release in the NAc
(Al-hassani). DYN and KOR agonists alike decrease extracellular DA release
within the NAc through Gi-mediated signaling on presynaptic VTA terminals
(Margolis et al., 2003; Spanagel et al., 1992). Intracellular KOR signaling also
enhances activity of the DA transporter (DAT) that increases clearance of DA from
the extracellular space (Thompson et al., 2000). Thus, DYN/KOR activation in the
NAc acts as a negative feedback mechanism gating mesolimbic DA activity. In the
context of aversion, selective delivery of a KOR agonist into the NAc decreases
local DA release and is sufficient to drive CPA (Bals-Kubik et al., 1993; Donzanti
et al., 1992). A series of elegant studies from the Bruchas lab revealed that
photostimulation of DYN-containing neurons within the ventral NAc shell results in
the display of real-time place aversion and decreased responding for a natural
reward, both of which are reversed by KOR antagonist challenge (Al-Hasani et al.,
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2015). Furthermore, genetic deletion of KOR from VTA-DA terminals in the NAc
blocks CPA learning and can be restored by selective KOR knock-in (Chefer et al.,
2013). These data suggest that DYN-containing neurons within the NAc contribute
to aversive-like behavior in a KOR-dependent fashion, likely though the modulation
of local DA release. However, KOR in the NAc also modulate CPP and, more
specifically, photoactivation of dorsal NAc shell DYN-containing neurons has
rewarding properties suggesting that topographical organization of KOR
expression may differentially regulate opposing behaviors (Al-Hasani et al., 2015;
Castro and Berridge, 2014).
It is also important to note that aversive behavior is also observed after
microinjection of a KOR agonist into the PFC and VTA, and there is strong
evidence suggesting that the aversive properties of KOR activation in the VTA is
due to disrupted DA release within the PFC (Chavkin, 2013; Knoll and Carlezon,
2010; Tejeda et al., 2013). In fact, KOR agonist microinjection into the VTA induces
CPA by decreasing activity in projections to the PFC, but projections to the NAc
are not affected (Bals-Kubrick et al., 1993). This finding was bolstered by the
Shippenberg lab who demonstrated that KOR agonists decrease DA overflow
within the PFC and this effect can be blocked by genetic deletion of KOR on DATexpressing neurons, suggesting KOR regulation of DA release within the PFC
(Tejeda et al., 2013). Furthermore, systemic KOR agonist challenge resulted in
CPA, as expected, but was blocked by selective KOR antagonist microinjection in
the PFC. Decreased DA tone within the PFC and NAc have important clinical
implications because positive valence disorders, such as depression, addiction,
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some aspects of schizophrenia, and ADHD involve disruption to DA signaling in
the PFC and NAc that mediates cognitive symptomology and reward deficits
(Braver et al., 1999; Brennan and Arnsten, 2008; Ford et al., 2006).
We have thus far described involvement of the DYN/KOR system in
cognition and the balance of reward/aversion. Activity of DYN/KOR is also involved
in the dynamic processes that mediate the physiological response to stress as well
as behaviors involved in the stress response. Preclinical models of stress, such as
the forced swim stress (FSS) task or fear conditioning have revealed an
endogenous release of DYN in response to stress exposure (Land et al., 2008;
McLaughlin et al., 2003a; Nabeshima et al., 1992). Release of DYN within the CNS
has a number of effects that promote an internal stress response, which is not
surprising given the expression pattern of DYN/KOR within the hypothalamus.
Most notably, endogenous KOR activity in the hypothalamus triggers activation of
the HPA axis and release of CRF, ACTH, and corticosterone (Drolet et al., 2001;
Nikolarakis et al., 1987). Similarly, systemic administration of a KOR agonist
increases c-Fos expression within the PVN and is accompanied by increased
serum corticosterone levels indicative of pharmacological activation of the HPA
axis (Buckingham and Cooper, 1986; Pechnick, 1993). Although these studies are
correlative in nature, they suggest involvement of KOR in the physiological
response to acute stress. More causal studies have been conducted in relation to
DYN/KOR involvement in the behavioral response to repeated stress exposure.
For example, KOR antagonists or global Pdyn-knockout blocks the emergence of
pro-depressive behavior as a result of repeated foot-shock stress (Land et al.,
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2008). Furthermore, associative aversive learning involving an odor or context
paired with a foot-shock is blocked by systemic KOR antagonist challenge or Pdynknockout (Land et al., 2008). Similarly, repeated exposure to FSS results in
increased immobility indicative of a pro-depressive state and is blocked by
systemic KOR antagonist treatment (Mague et al., 2003; McGlaughlin et al., 2003).
Increased immobility resulting from chronic FSS can be recapitulated in naïve
animals when challenged with a KOR agonist (McGlaughlin et al., 2006).
Involvement of KOR in response to the other ethologically relevant stressors, such
social defeat stress, has also been demonstrated (Donahue et al., 2015). As with
foot-shock or FSS, treatment with a KOR antagonist or Pdyn-knockout decreased
the display of submissive posture, heightened nociception, and analgesia
observed after social defeat stress (McGlaughlin et al., 2003).
Foot-shock, FSS, and social defeat stress provoke DYN release and
indicate activity of KOR in the behavioral response to stress (Knoll et al., 2010).
CRF is also released in response to these stressors and it appears that CRF can
stimulate release of DYN in the hypothalamus, suggesting a dynamic interaction
between the DYN and CRF systems involved in the stress response (Almeida et
al., 1986). For example, systemic challenge with CRF increases KOR
phosphorylation, indicative of CRF activity provoking DYN release and KOR
activation (Land et al, 2008; Bruchas et al., 2010). From a behavioral perspective,
administration of CRF (ICV) promotes aversive learning and the expression of CPA
is blocked by pharmacological blockade of KOR or Pdyn-knockout (Land et al.,
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2008). These data suggest a reciprocal interaction between the CRF and
DYN/KOR systems as both a cause and causality involved in the stress response.
The DYN/KOR system has also been strongly implicated in anxiety-like
behavior but a clear role has been difficult to ascertain due to similar behavioral
outcomes in response to KOR agonists and antagonist. This discrepancy arises
from studies demonstrating that acute systemic treatment with a KOR agonist or
antagonist both promote an anxiolytic phenotype (Knoll et al., 2007; Kuzmin et al.,
2006; Narita et al., 2006). Further studies have revealed a more prominent role for
DYN/KOR activation in promoting anxiety-like behavior. For example, global Pdynknockout attenuates the startle response and presents as an anxiolytic phenotype
within the open field, elevated plus maze, and light/dark box tests (Bilkei-Gorzo et
al., 2008; Wittmann et al., 2009). Anxiogenic behavior is restored within knockout
mice, and potentiated in wild-type mice, by systemic challenge with a KOR agonist,
suggesting that endogenous DYN/KOR activity promotes the expression of
anxiety-like behavior (Wittmann et al., 2009).

Furthermore, KOR antagonists

increase open arm entries in the elevated plus maze and decrease the fearpotentiated startle response indicative of anxiolytic properties of the drug (Knoll et
al., 2007).
The extended amygdala is rich in DYN/KOR and recent studies suggest that
connectivity between the CeA the BNST is involved in the expression of anxietylike behavior (Alheid, 2003; Fallon and Leslie, 1986; Mansour et al., 1994;
Marchant et al., 2007; Poulin et al., 2009; Sim-Selley et al., 1999). For example,
projection neurons in the CeA express and co-express various neuropeptides,
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such as DYN, somatostatin (SST), and CRF. Optogenetic stimulation of CeA
projections to the BNST (CeA-BNST) produces an anxiogenic phenotype in an
open field task (Ahrens et al., 2018). Neurons within this circuit largely express
Pdyn mRNA (along with SST) and the anxiogenic response resulting from circuitlevel activation can be blocked by KOR antagonist administration into the BNST.
Interestingly, microinjection of the long-lasting KOR antagonist nor-BNI into the
BNST alone does not affect anxiety-like behavior in the open field task suggesting
that strong stimuli that provoke DYN release within the BNST are involved in the
expression of anxiety, opposed to tonic dynorphinergic tone. In contrast, DYNcontaining neurons within the BNST release DYN locally and may promote anxiety
(Crowley et al., 2016). The mechanism by which KOR in the BNST modulates
anxiety is not completely clear, but it is likely through affecting excitatory/inhibitory
balance through the regulation of glutamate/GABA release in select circuits. For
example, activation of KOR in the BNST decreases presynaptic release of GABA
through an ERK-dependent signaling mechanism from projections originating in
the CeA (Li et al., 2012). This is in stark contrast to p38-MAPK signaling that
mediates the dysphoric component of KOR activation in other structures (Bruchas
et al., 2007). Interestingly, activation of BLA projections to the BNST results in
anxiolytic behavior presumably through glutamate release downstream in the
BNST, and optogenetic stimulation of DYN-containing neurons within the BNST
decreases glutamate release by activation of KOR on BLA terminals (Crowley et
al., 2016). The behavioral consequence of KOR modulation of glutamatergic and
GABAergic terminals may depend on the topographical input to sub-compartments
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in the BNST that modulate anxiety. More specifically, the oval, anterodorsal, and
ventral BNST are involved in anxiety and direct GABAergic input onto these
population may be anxiolytic (Jennings et al., 2013; Kash and Winder, 2006; Kim
et al., 2013; Lebow and Chen, 2016; Lovinger and Kash, 2015). However, there
are numerous GABAergic interneurons within the BNST and KOR antagonists may
restore glutamate release onto these subpopulations driving feed-forward
inhibition of anxiogenic populations. Thus, KOR antagonists may promote
anxiolytic behavior directly, or indirectly through local circuits, by inhibition of
anxiogenic hotspots in the BNST.
Given the complex interplay with CRF and DYN in the stress response, it is
not surprising that both are synergistically involved in anxiety. This interaction was
clearly demonstrated by the Chavkin lab who showed that central administration
of CRF provokes an anxiogenic phenotype in the elevated plus maze that is
blocked by nor-BNI treatment within the BLA (Bruchas et al., 2009). Because KOR
agonists decrease LTP and glutamate release in the BLA, it is tempting to
speculate that intra-BLA nor-BNI disinhibits the BLA-BNST circuit thereby
promoting anxiolytic behavior, but this has not been directly tested to the best of
our knowledge (Huge et al., 2009; Crowley et al., 2016). CRF and DYN largely colocalize within the nearby CeA and compensatory mechanisms have been
observed in CRF expression after genetic alteration of DYN (Pomrenze et al.,
2015; Wittmann et al., 2009). For example, global Pdyn-knockout or nor-BNI
treatment decreased Crf mRNA expression in the CeA (and PVN), which is
associated with decreased expression of anxiety-like behavior (Wittmann et al.,
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2009). This is interesting because it demonstrates an influence of DYN/KOR
activity on CRF expression, whereas CRF1 activation also promotes DYN release
in other regions (Bruchas et al., 2009). Finally, direct infusion of CRF into the CeA
is anxiogenic and enhances excitability of CeA neurons that project to the BNST
(Asok et al., 2018). Indeed, anxiogenic neurons within the CeA-BNST circuit are
known to express DYN and CRF, and expression of anxiety-like behavior is
dependent upon KOR and the CRF1 receptor activity in the BNST (Ahrens et al.,
2018; Pomrenze et al., 2019). Thus, DYN and CRF play complimentary roles within
the extended amygdala that contribute to anxiety-like behavior.

DYN/KOR IN AUD AND DEPENDENCE
Clinical Perspective
Given the role of DYN/KOR in aversion, stress, and anxiety, it is not
surprising that this system has gained much attention as a druggable target for the
treatment of indices of negative effect in individuals with AUD. Indeed, examination
of polymorphisms in the genes coding for DYN and KOR have revealed a strong
association with AUD and dependence. More specifically, a single nucleotide
polymorphism (SNP) in the PDYN gene has been identified in patients with AUD
and is associated with drinking severity (Preuss et al., 2013; Williams et al., 2007;
Xuei et al., 2006). In fact, PDYN SNPs are associated with negative craving and
predict the likelihood of drinking severity in response to stress (Karpyak et al.,
2013; Preuss et al., 2013). SNPs in the Oprk1 gene coding for KOR are similarly
found in individuals with AUD and are predictive of the severity of symptoms
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assessed by AUDIT (Edenberg et al., 2008; Park et al., 2020). Furthermore,
polymorphisms in PDYN and Oprk1 are associated with increased impulsivity,
anxiety, and negative craving that predicts drinking severity (Edenberg et al., 2008;
Park et al., 2020; Votinov et al., 2014; Xuei et al., 2006; Xuei et al., 2007). A more
casual role for KOR in AUD has been identified in clinical studies through the use
of the non-selective opioid antagonist naltrexone. Naltrexone is primarily thought
to reduce alcohol intake with greater efficacy in individuals with a select
polymorphism in the gene coding for the mu-opioid receptor (MOR), although there
is some evidence suggesting this effect may be mediated by the KOR (Anton,
2008; Oroszi et al., 2009). For example, alcohol-dependent individuals show less
KOR bioavailability in the amygdala, insular cortex, frontal cortex, and striatum, all
regions implicated in excessive drinking, withdrawal, and craving (Vijay et al.,
2018). Furthermore, naltrexone was found to decrease craving and alcohol intake
in nontreatment-seeking heavy drinkers and this response was associated with
KOR availability prior to treatment (de Laat et al., 2019). Similarly, nalmefene is a
MOR antagonist and partial KOR agonist that has been shown to reduce the
frequency and intensity of drinking in alcohol-dependent subjects (Mann et al.,
2013; van den Brink et al., 2013). Therefore, the development and application of
selective KOR antagonists for the treatment of AUD has shown promise, and
preclinical studies have been successful in demonstration the underlying
processes that mediate these effects.
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Preclinical Models of AUD
For roughly 30 years, the relationship between DYN/KOR activity and
alcohol consumption has been studied in preclinical models of AUD. Because KOR
are located within brain regions that are involved in reward and aversion, much
work has been done to determine the contribution of KOR to alcohol-induced CPP
and CPA. However, a clear role for KOR within these behaviors has been difficult
to ascertain due to mixed results. For example, systemic administration of the KOR
agonist, U50,488, 10-min before alcohol conditioning blocks CPP learning in
DBA/2 mice (Logrip et al., 2009). However, U50,488 treatment 90-min before
alcohol pairings potentiates CPP in C57BL/6J mice, suggesting that the anxiolytic
properties of alcohol relieved the aversive state driven by U50,488 (Sperling et al.,
2010). However, a provocateur of KOR signaling, be it endogenous DYN release
in response to stress or exogenous administration of a KOR agonist, may be
necessary to uncover KOR involvement in CPP. For example, FSS drives
endogenous release of DYN and repeated FSS prior to conditioning potentiates
CPP expression, an effect that is blocked by nor-BNI (McLaughlin et al., 2003a;
Sperling et al., 2010). Interestingly, nor-BNI alone has no effect on CPP learning
or expression, but does potentiate state-dependent CPP expression (Nguyen et
al., 2012). These data are indicative of a facilitation of reward-pathway signaling
during alcohol challenge, stress, or KOR antagonist administration that potentiates
the rewarding properties of alcohol. Few studies, however, have explored the
relationship between CTA and the DYN/KOR system. Nor-BNI does not affect
alcohol-induced CTA during conditioning or testing but does attenuate CTA in
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stressed rats suggesting potentiation of the aversive properties of alcohol by stress
in a KOR-dependent manner (Anderson et al., 2013; Roma et al., 2008). Thus,
further studies are necessary to determine a clear role for KOR in mediating
reward/aversion related to alcohol.
In the context of voluntary home-cage alcohol drinking, systemic
administration of a KOR antagonist generally reduces intake that has been
observed across multiple limited-access drinking paradigms ranging from 30-min
to 24-hours of access (Anderson and Becker, 2017; Karkhanis et al., 2017). More
specifically, nor-BNI reduced alcohol drinking during a 3-hour 2-bottle choice
session in Rhesus monkeys and produced a reduction of intake in male C57BL/6J
mice during 18- and 24-hour access to alcohol (Logrip et al., 2008; Williams and
Woods, 1998; Zhou et al., 2017). However, the effect of a KOR antagonist on
home-cage drinking is not consistent given that, under similar experimental
conditions, either no effect or an increase in drinking has been observed. For
example, nor-BNI reduced alcohol intake in female Long Evans rats during a 30min drinking session but increased drinking in males, suggesting possible sex
differences in responsiveness to KOR antagonists (Morales et al., 2014). Nor-BNI
also increased drinking in a subset of male Lewis rats that were high drinkers, but
had no effect in females (Lindholm et al., 2001; Mitchell et al., 2005). Effects of
KOR agonists on voluntary consumption have also been inconsistent across
species and drinking paradigms. More specifically, chronic administration of
enadoline increased alcohol intake in Wistar rats as does U50,488 treatment in
C57BL/6J mice during continuous access drinking (Holter et al., 2000; Sperling et
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al., 2010). Similarly, U50,488 increased alcohol intake during 1- and 2-hour limited
access drinking sessions in C57BL/J5 mice (Anderson et al., 2016; Rose et al.,
2016). However, others have shown that U50,488 decreased intake in rats in both
2- and 24-hour access drinking paradigms (Lindholm et al., 2001; Sandi et al.,
1990). Thus, differences in species, strain, time-course of drug delivery, and
experimental design likely account for the inconsistency of the results in these
studies.
Although results have been mixed in the context of home cage drinking, a
clear role for KOR has been demonstrated in models of operant self-administration
in rats. Systemic administration of a KOR antagonist decreased operant selfadministration, blocked spontaneous recovery, and lowered progressive ratio
breakpoints in Wistar and P-rats, respectively (Deehan et al., 2012; Rorick-Kehn
et al., 2014; Schank et al., 2012; Walker et al., 2011). Furthermore, KOR
antagonists block alcohol-seeking behavior in response to cues associated with
alcohol or a pharmacological stressor, such as yohimbine (Schank et al., 2012;
Funk et al., 2014). In fact, systemic challenge with U50,488 acts like a
pharmacological stressor and is sufficient to induce reinstatement behavior in rats
under extinction conditions, and this effect is blocked by nor-BNI (Funk et al., 2014;
Hayes and Stewart, 1985). Studies involving mice, however, are mainly conducted
in the context of home-cage drinking whereas the vast majority of studies involving
reinstatement involve rats. This is particularly true in the context of models of
alcohol dependence where rats typically self-administer alcohol opposed to mice

52

that are commonly presented alcohol in limited-access home cage drinking
paradigms.
Recently, focus has shifted toward probing DYN/KOR involvement
dependence and negative affect associated with withdrawal that drives excessive
drinking, aka the “dark side of addiction” (Koob, 2013; Schulteis and Koob, 1994).
Rodent models of alcohol dependence, such as the chronic intermittent ethanol
(CIE) exposure paradigm, produce a phenotypic escalation of voluntary alcohol
consumption, withdrawal-related sequalae, and genetic adaptions that are seen in
humans thus serving as a robust platform for the study of AUD (Becker and Lopez,
2004; Lopez and Becker, 2005; Melendez et al., 2012; Osterndorff-Kahanek et al.,
2015). The CIE model involves repeated cycles of alcohol vapor exposure and
withdrawal that mimics repeated bouts of binge drinking and withdrawal observed
in humans. In a groundbreaking study, Walker and Koob compared the effects of
naltrexone, nalmefene, and the selective KOR antagonist nor-BNI on alcohol selfadministration in CIE-exposed Wistar rats (Walker and Koob, 2008). Interestingly,
naltrexone and nalmefene had a general effect on decreasing responding for
alcohol, but nor-BNI selectively decreased self-administration in dependent rats
without affecting moderate responding and intake in non-dependent subjects
(Walker and Koob, 2008). These data suggest that the DYN/KOR system in
particular is sensitive to a history of dependence/CIE exposure and further studies
have supported this notion. For example, systemic challenge with nor-BNI
decreased high levels of alcohol intake and attenuated anxiety-like behavior during
withdrawal from CIE exposure (Walker et al., 2011). The anxiolytic properties of
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KOR antagonists have been demonstrated in measures of withdrawal-induced
anxiety, such as marble burying, elevated plus maze, and ultrasonic vocalizations
(Rose et al., 2016; Berger et al., 2013; Schank et al., 2012). The extended
amygdala is a likely culprit in mediating these effects because this macrostructure
is rich in DYN/KOR and involved in excessive alcohol consumption (Al-Hasani et
al., 2015; Bloodgood et al., 2020; Marchant et al., 2007). In fact, site-specific
delivery of nor-BNI into the NAc, CeA, or BNST attenuates dependent-like drinking
in CIE-exposed subjects without affecting drinking in non-dependent controls
(Erikson et al., 2018; Kissler et al., 2014; Nealey et al., 2011). We will describe the
role of KOR within the NAc, CeA, and BNST below in further detail.
We have previously described the role of DA within the NAc in relation to
the motivation to drink excessively and it is theorized that KOR antagonists may
be effective in restoring dopaminergic homeostasis in the NAc under extreme
conditions such as alcohol dependence. For example, a history of alcohol
dependence achieved through CIE exposure results in increased expression of
Pdyn mRNA within the NAc and selective microinjection of nor-BNI decreased
dependent-like drinking (Karkhanis et al., 2015; Nealey et al., 2011). Alcohol is
known to increase extracellular DA in the NAC but this response is inverted in CIEexposed mice in that DA levels decrease in response to acute alcohol challenge
(Karkhanis et al., 2016). Furthermore, DA release within the NAc is decreased in
dependent mice through enhanced functionality of KOR on VTA terminals
(Karkhanis et al., 2015). The hypodopaminergic state observed during withdrawal
is specific to alcohol-dependent mice and reflective of increased sensitivity of KOR
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to agonists. The functional consequence of the so-called CIE-induced “supersensitivity” to KOR agonists is a hypodopaminergic state that promotes dysphoria,
anxiety, and drug-seeking, which can be blocked by nor-BNI (Rose et al., 2016).
This effect has been observed in rodent models as well as in non-human primates
suggesting a conserved mechanism across species in the development of AUDlike phenotypes (Siciliano et al., 2015; Siciliano et al., 2016). In support of the
hypothesis that KOR-mediated suppression of DA activity drives negative affective
states, microinjection of a KOR agonist into the NAc promotes anhedonia-like
behavior that is blocked by a KOR antagonist (Muschamp et al., 2011). It is
reasonable to suspect then that KOR antagonists would, in theory, block KOR
activity on VTA terminals and disinhibit DA release in the NAc, reflecting rewarding
properties and a potential for abuse. Indeed, KOR antagonists increased
extracellular DA and KOR knockout potentiated evoked-DA release in the NAc, but
ICSS reward threshold is not affected (Karkhanis et al., 2016; Todtenkopf et al.,
2004; Zapata and Shippenberg, 2006). Thus, it is theorized that DYN/KOR
modulation of phasic DA release in the NAc is activity dependent and that KOR
antagonists may be effective in restoring homeostasis under extreme conditions,
such as alcohol dependence. It is also important to note that increased Pdyn
mRNA has been observed within the NAc shell of seizure-prone mice during
withdrawal from chronic alcohol (Beadles-Bohling and Wiren, 2005). Nor-BNI
increased seizure activity in these mice during early withdrawal, although
administration was via systemic injection and not localized to the NAc (BeadlesBohling and Wiren, 2006). Furthermore, systemic U50,488 increased seizure
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threshold suggesting opposing KOR involvement in seizure activity and withdrawal
related-negative affect. Future studies with targeted treatment will be of
importance.
Less is known about DYN/KOR function within the CeA and BNST in the
context of alcohol dependence but the existing data support a similar role in
excessive drinking and withdrawal-related negative affect. For example, Pdyn
expression and DYN-A immunoreactivity are increased within the CeA after
chronic alcohol treatment and KOR therein display increased GTPyS signaling
indicative of super-sensitivity, similar to the that observed in the NAc (D'Addario et
al., 2013; Kissler and Walker, 2016). Kissler and collogues further demonstrated
that microinjection of nor-BNI into the CeA selectively decreased drinking in
dependent rats suggesting that the increase in KOR sensitivity contributes to
excessive drinking (Kissler et al., 2014). However, physical signs of withdrawal
were not affected by nor-BNI thus KOR within the CeA appear to play a
predominant role in drinking behavior that is dissociable from negative affect. The
exact mechanism driving the decrease in drinking is not entirely clearly, but could
be through modulation of GABA release onto select populations within the CeA.
For example, output neurons of the centromedial amygdala (CeM) are known to
promote alcohol drinking and seeking behavior (Gilpin et al., 2015; Roberto et al.,
2012). Acute alcohol increases GABA release within the CeM and CIE exposure
not only increases basal extracellular GABA, but potentates GABA release in
response to alcohol (Roberto et al., 2003; Roberto et al., 2004). Interestingly, KOR
regulate tonic inhibition within the CeM through modulation of GABA release from
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presynaptic terminals (Kang-Park et al., 2013). The KOR agonist, U69593 reduces
IPSCs indicative of KOR regulation of tonic GABAergic tone. Acute alcohol
increases evoked IPSCs within the CeM from nearby KOR-expressing neurons
within the centrolateral amygdala (CeL) and this effect is potentiated by nor-BNI or
by genetic deletion of KOR (Kang-Park et al., 2013). GABA within the CeA is also
associated with the reinforcing properties of alcohol as both GABA A antagonists
and nor-BNI decrease self-administration (Hyytia and Koob, 1995; Kissler and
Walker, 2016). The discrepancy between increased GABAergic tone resulting from
CIE-induced dependence and increased GABA release in response to KOR
antagonists is not fully understood, but may be reflective of topography of KORexpressing populations within the CeA. For example, KOR-expressing neurons
within the CeL may functionally gate output neurons of the CeM such that nor-BNI
restores tonic inhibitory control over this output population resulting in decreased
drinking. Thus, future studies mapping expression patterns of KOR within the CeA
in relation to output neurons that are known to promote excessive drinking will be
of importance.
Much like the CeA, the BNST is highly enriched in DYN/KOR and sensitive
to the effects of chronic alcohol. For example, a history of CIE exposure increased
alcohol self-administration and upregulated Oprk1 expression within the BNST
(Erikson et al., 2018). Interestingly, Pdyn expression was not affected by moderate
alcohol self-administration nor CIE exposure. This observed increase in Oprk1
contributes to excessive drinking because site-specific microinjection of nor-BNI
into the BNST decreased alcohol self-administration in dependent rats without
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affecting moderate responding in non-dependent control groups (Erikson et al.,
2018). In contrast to the CeA, KOR blockade in the BNST decreased ultrasonic
vocalizations during withdrawal suggesting a reduction in negative affect (Erikson
et al., 2018; Kissler et al., 2014). Thus, KOR within the BNST likely modulate
maladaptive excessive drinking behavior by relieving withdrawal-related sequala
in the negative affective domain, but the endogenous source of DYN mediating
this effect is unknown.

Extended Amygdala and Binge Drinking
We have thus far discussed DYN/KOR involvement within the extended
amygdala in relation to excessive drinking as a function of alcohol dependence.
Binge drinking, however, is unique in that drinking is excessive yet infrequent, and
occurs prior to development of dependence or AUD. Therefore, neuroadaptive
processes involved in early binge drinking likely change over time during the
transition to dependence that promote frequent, uncontrolled binge drinking. The
amygdala has been implicated in binge drinking because it is a critical hub in
reward circuitry involved in emotional reactivity and appetitive behavior (Gilpin et
al., 2015; Koob, 2003; Roberto et al., 2012; Stephens and Duka, 2008). A history
of binge drinking produces alterations in amygdala activity that present as poor
mood states, heightened anxiety, altered stress-responsiveness, and increased
impulsivity (Stephens and Duka, 2008; Stephens et al., 2005; Townshend and
Duka, 2005). Furthermore, human functional magnetic resonance imaging (fMRI)
studies show that increased activity at rest in the amygdala is associated with
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heightened anxiety and impulsive decision-making in binge drinkers (Xiao et al.,
2013). Anxiety and impulsivity have a positive relationship with binge drinking and
are associated with aberrant connectivity between the amygdala and the prefrontal
cortex (PFC), which reflects deficits in networks mediating top-down control of
excessive drinking (Balodis et al., 2009; Stautz and Cooper, 2013). In fact,
decreased coupling of amygdala and PFC connectivity predicts long-term alcohol
intake as a function of drinking during adolescence, suggesting neuroadaptations
within amygdala-circuitry that contribute to the trajectory of AUD (Peters et al.,
2017). In contrast, acute alcohol intoxication to binge levels is anxiolytic and
dampens

amygdala

activity,

blunting

emotional

processing

and

threat

responsiveness (Gilman et al., 2008; Gorka et al., 2013). Risky decision-making is
a hallmark of binge intoxication and is associated with a dysregulation of emotional
processing and decreased inhibitory control over behavior. Therefore, the
amygdala plays a critical role in the motivation to consume alcohol excessively and
is affected by a history of binge drinking. Given the role of DYN/KOR within the
amygdala in preclinical models of AUD, it is likely that this system is recruited to
promote binge drinking behavior as well. However, examination of DYN/KOR
within the amygdala and projection sites in humans is currently not possible given
the limitations of current imaging technology.
An animal models that approximate binge drinking, the Drinking in the Dark
(DID) paradigm, has been widely used in the field and proven to be an effective
platform for pharmacological and circuit-level interrogation of brain systems that
drive binge drinking (Crabbe et al., 2017; Rhodes et al., 2005; Sprow and Thiele,
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2012). An important aspect of the DID model is that it captures excessive drinking
behavior prior to the development of dependence when neuroadaptations are likely
to occur that promote the progression to compulsive, inflexible drinking (Ferguson
et al., 2019). The DID model capitalizes on natural rhythms in rodent behavior such
that alcohol bottles are present 3 hours into the dark cycle, coinciding with a period
of high alcohol consumption. Thus, mice drink more alcohol during this time period
when presented with a single bottle of 20% alcohol (vol/vol) compared to any other
period in the circadian cycle (Rhodes et al., 2005). Furthermore, BACs achieved
after 2 or 4 hours of drinking exceed the 0.08 g/dL legal limit of intoxication and
effectively models binge drinking behavior in humans. Indeed, a history of binge
drinking results in lasting neuroadaptations that are associated with increased
intake over time in mice, rats, non-human primates, and humans suggesting a
conserved mechanism across species (Baker et al., 2017; Hingson et al., 2017;
Zhou et al., 2017). Further, a growing body of literature has demonstrated
involvement of the extended amygdala and neuropeptide systems therein in
excessive alcohol drinking in the DID model (Anderson et al., 2014; King et al.,
2017; Pleil et al., 2015; Rinker et al., 2017).
There has been considerable interest in the contribution of the DYN/KOR
system to excessive drinking and negative affect produced by alcohol
dependence, but recent studies suggest a general role in the regulation of binge
drinking. For example, we have shown that systemic administration of the KOR
agonist U50,488 increased binge-like alcohol consumption in male mice
(Anderson et al., 2018). In contrast, systemic administration of the short acting
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KOR antagonist LY2459989 decreased binge drinking. These findings compliment
those that demonstrate efficacy of KOR antagonists to decrease dependent-like
drinking, and are reflective of a general reduction of excessive drinking
independent of a history of dependence. Furthermore, these findings are
consistent with others that have shown that KOR agonists and antagonists
bidirectionally modulate voluntary alcohol consumption, and the extended
amygdala is a likely candidate in mediating these effects. The CeA is enriched in
dynorphinergic neurons that may promote binge drinking behavior through
activation of KOR locally or in downstream structures, such as the BNST
(Marchant et al., 2007; Bloodgood et al., 2020). Indeed, a history of binge drinking
increased excitability in DYN-containing neurons within the CeA of male mice
suggesting a neuroadaptation in endogenous dynorphinergic circuitry underlying
excessive drinking (Bloodgood et al., 2020). This rationale is supported by studies
demonstrating that chemogenetic inhibition of DYN-containing neurons within the
CeA, or genetic deletion of DYN in the CeA, decreased binge-like drinking in male
and female mice (Anderson et al., 2018; Bloodgood et al., 2020). These studies
demonstrate a clear role for DYN within the extended amygdala, but the
downstream KORs mediating these effects are not known. Local release of DYN
within the CeA is a possible explanation in that microinjection of nor-BNI or genetic
deletion of KOR therein attenuated binge drinking in male mice (Anderson et al.,
2018; Bloodgood et al., 2020). However, KOR knockout in the CeA of female mice
does not affect binge-like alcohol consumption alluding to possible KOR activity in
a downstream structure (Bloodgood et al., 2020). Interestingly, systemic U50,488
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increased c-Fos immunoreactivity within the CeA and the BNST, but expression in
the BNST strongly correlated with reinstatement of alcohol-seeking (Le et al.,
2018). Therefore, KOR in the BNST may more directly contribute to binge drinking.
Indeed, the CeA sends dense dynorphinergic projections to the BNST (CeABNSTDYN) and the observed increase in c-Fos immunoreactivity within the CeA
and BNST during bouts of binge drinking may be reflective of circuit level activation
(Anderson et al., 2018; Ahrens et al., 2018; Le et al., 2018). A considerable gap
exists in the literature in relation to KOR activity in the BNST and CeA-BNST
connectivity in the context of binge drinking. Studies addressing this open question
are critical to understanding the mechanisms that promote binge drinking prior to
the development of dependence.

Summary
Binge drinking is the most common form of excessive drinking and presents
a multitude of adverse effects on health and behavior, propelling binge patterns of
drinking into the spotlight as a serious epidemiological concern (Sacks et al., 2015;
SAMHSA, 2018; WHO, 2018). This pattern of intake is associated with increased
engagement in risky behavior, poor health, and increased risk of developing
alcohol dependence and/or an AUD (Centers for Disease and Prevention, 2012;
Jennison, 2004). Binge drinking is a critical component in the cycle of addiction
and understanding the mechanisms that promote binge drinking is important to
understanding the trajectory of neuroadaptations that contribute to the
development of an AUD. Among several neurochemical and neuropeptide
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systems implicated in binge drinking, recent findings suggest a prominent role for
the DYN/KOR system. This present dissertation uses a multifaceted approach
involving pharmacology, immunohistological assessment of neuronal activity, and
chemogenetics to interrogate the DYN/KOR neuropeptide system within extended
amygdala circuity as it relates to excessive binge-like alcohol consumption in male
and female mice. More specifically, we aim to determine the effect of KOR
agonist/antagonist microinjection in the BNST on binge drinking behavior. We then
examine endogenous activity of CeA projections to the BNST during drinking and
functionally probe the role of the CeA-BNSTDYN circuit as it relates to binge-like
alcohol consumption. Results from these studies provide important information
regarding this neuropeptide system as a potential target for the development of
therapeutics in treating individuals that engage in dangerous, excessive levels of
alcohol drinking and provide valuable insight into the trajectory of AUD.
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CHAPTER 2: Kappa Opioid Receptors in the Bed Nucleus of the Stria
Terminalis Regulate Binge-Like Alcohol Consumption in Male and Female
Mice.
INTRODUCTION
As described in Chapter 1, a growing body of literature has focused on the
dynorphin/kappa opioid receptor (DYN/KOR) system in mediating excessive
drinking (Anderson and Becker, 2017; Koob and Le Moal, 2008; Walker and Koob,
2008). Activation of the DYN/KOR system following chronic alcohol exposure has
been associated with behaviors reflective of a negative affective state experienced
during alcohol withdrawal, and this has been suggested to increase relapse
vulnerability as well as promote excessive levels of drinking (Karkhanis et al.,
2017; Sirohi et al., 2012). In fact, KOR antagonists have garnered much interest
as a potential therapeutic intervention for the treatment of AUD (Karkhanis et al.,
2017). In support of this idea, studies have shown that systemic administration of
the KOR antagonist, nor-BNI, attenuates dependence-related escalation of alcohol
consumption and alleviates withdrawal symptomology in rats (Walker et al., 2011).
These effects appear to be mediated by blockade of KORs in the extended
amygdala as direct injection of nor-BNI into the central nucleus of the amygdala
(CeA), bed nucleus of the stria terminalis (BNST), or nucleus accumbens shell
(NAc shell) reduced elevated drinking and anxiety-like behavior in alcohol
dependent animals (Erikson et al., 2018; Kissler et al., 2014; Rose et al., 2016).
While these findings strongly implicate a role for the DYN/KOR system
within the extended amygdala in alcohol dependence, recent findings suggest a
more general role for KORs in the regulation of alcohol consumption in non-
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dependent animals. For example, mice lacking prodynorphin or KORs show
decreased alcohol drinking and preference (Blednov et al., 2006; Kovacs et al.,
2005; Van't Veer et al., 2016). However, few studies have probed the role of KORs
within the context of binge drinking. The Drinking-in-the-Dark (DID) paradigm
models binge drinking in rodents by producing high levels of alcohol consumption
within a relatively short period of time such that subjects reliably achieve BACs
above the 80 mg/dL threshold of intoxication (Rhodes et al., 2005; Thiele et al.,
2014; Thiele and Navarro, 2014). We previously demonstrated that systemic
administration of a KOR agonist increased, while a KOR antagonist decreased,
binge-like alcohol consumption in male C57BL/6J mice (Anderson et al., 2018a).
Since the BNST is rich in KORs and sensitive to alcohol (Burnham and Thiele,
2017; Poulin et al., 2009), the present study examined whether manipulation of
KORs in the BNST influence binge-like alcohol consumption using the DID model.

MATERIALS AND METHODS
Subjects
Male and female C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME)
ranging from 10-12 weeks old were singly housed and tested in a temperature and
humidity controlled AAALAC approved facility on a reverse 12-hr light/dark cycle
with food and water continuously available. For all experiments, mice were treated
in accordance with both the NIH Guide for the Care and Use of Laboratory Animals
(National Research Council, 2011) and the Institutional Animal Care and Use
Committee at MUSC.
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Surgical Procedures
Mice were anaesthetized with isoflurane and bilateral guide cannula
(Plastics One, Inc.) were positioned above the BNST (AP: +0.8, ML: +/- 0.75, DV:
-3.6) and secured to the skull with a light-cured resin system (Haun et al., 2018).
Once inserted, microinjector tips extended 1 mm beyond the guide to target the
BNST for microinjection. After surgery, all mice were given 2 weeks to recover prior
to the start of experiments.
Alcohol Binge Drinking Procedure
After recovery from surgery, mice were habituated to the microinjection
procedure by removing and then replacing dummy guides from the microinjector
tract 30 minutes prior to drinking. Similarly, for studies involving systemic
administration of drug, mice were habituated to the injection procedure by
administering daily intraperitoneal (ip.) injections of vehicle for several days before
alcohol access and then at 30 minutes prior to drinking sessions. Mice were trained
to drink alcohol in their home cage in the limited access “Drinking-in-the-Dark”
(DID) procedure, as previously described (Anderson et al., 2018a). A single bottle
of alcohol (20% v/v) was presented 3 hours into the dark cycle in place of the water
bottle. Access to alcohol was for 2 hours on 3 consecutive days, and then extended
for 4 hours on the 4th day. Alcohol intake was determined for each 2-hour session
and then for the 0-2 and 2-4 hour time periods during the final (4th day) 4-hour
drinking session. An identical procedure was used for assessing sucrose (0.5%
w/v) consumption. All mice were given one 4-day cycle of binge drinking, 3 days
rest in the home cage, followed by a second 4-day binge cycle. For all experiments,
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drug challenges occurred during the second binge cycle, prior to the 4-hour access
(test) session. Average drinking across the first 3 days of the second binge cycle
were used to separate subjects evenly into drug treatment groups. Immediately
after the 4-hour test drinking session, blood samples were collected, plasma
extracted, and blood alcohol concentrations determined using an AM1 Alcohol
Analyzer (Analox Instruments, Stourbridge, UK). Separate, experimentally-naïve
groups of mice were used in each experiment to ensure that a history of prior
alcohol or sucrose consumption did not influence drinking or locomotor activity.
Locomotor Activity Test
Activity chambers (ENV-510; Med Associates) were used to assess
locomotor activity as previously described (May et al., 2015). Briefly, the open field
arenas measured 27.5 cm wide × 27.5 cm long × 20.5 cm deep. Mice were placed
into the locomotor activity apparatus 16-hours after microinjection and distance
traveled (cm) was measured in 1 min bins for 10 minutes. Additionally, cumulative
time spent in the center (10 cm) of the open field arenas was collected to assess
possible pharmacological effects on anxiety-like behavior.
Drugs
The KOR antagonist nor-Binaltorphimine dihydrochloride (nor-BNI; 2.5
µg/side, Tocris) and the KOR agonist U50,488 (0, 0.1, 0.2 µg/side) was dissolved
in 1xPBS for microinjection. The KOR agonist U50,488 (5 mg/kg; Tocris) was
dissolved in 0.9% saline. Doses of nor-BNI and U50,488 were based on previous
studies (Anderson et al., 2018a).
Microinjection Procedures
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Microinjections of nor-BNI were administered 16 hours before Day 4 of
drinking during the second binge cycle in a between-subjects design. Vehicle or
nor-BNI (2.5 µg/side) was delivered bilaterally into the BNST at 0.25 µL/min for 2min, followed by a 2-min diffusion period before microinjector removal (Anderson
et al., 2018a; Griffin et al., 2014; Haun et al., 2018). Obdurators were replaced and
mice returned to their home cage where they remained undisturbed until the
following day. Microinjections of U50,488 (0, 0.1, 0.2 µg/side) occurred 30 min prior
to drinking on Day 4 of the second, third, and fourth binge cycles in a
counterbalanced, within-subjects design. For systemic administration, saline or
U50,488 (5 mg/kg) was administered via intraperitoneal (ip) injection (10 ml/kg) 30min prior to the 4-hour test binge session.
Histology
At the conclusion of all experiments, mice were euthanized with urethane
and transcardially perfused with 10 mL saline followed by 10 mL of
paraformaldehyde (PFA; 4%). Brains were extracted, post fixed in 4% PFA for 24
hours and cryoprotected in sucrose (30% wt/vol) until sectioning. Tissue was sliced
in serial 40 µM sections and mounted on Permafrost slides. The tissue was then
dehydrated in alcohol and stained with Cresyl Violet for histological verification of
microinjector placement within the BNST, as previously described (Haun et al.,
2018). Only mice with verified bilateral placements in the BNST in reference to a
mouse stereotaxic atlas were included in the final analyses (Franklin and Paxinos,
2008).
Statistical Analysis
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The primary dependent variables were alcohol intake (g/kg), BEC (mg/dL),
sucrose intake (mL/kg), and distance traveled (cm). All data were analyzed by
ANOVA, with Time as a repeated factor as necessary. Significant factor
interactions were further evaluated using the Student-Newman–Keuls (SNK) for
post-hoc comparisons. Alpha was set to p< 0.05 for all analyses.
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RESULTS
Effect of KOR Antagonist Microinjection Into the BNST on Binge-Like
Alcohol Consumption.
Male (N= 17) and female (N= 17) mice were split evenly into drug treatment
groups based on alcohol intake averaged across the three preceding 2-hour
limited-access drinking sessions. During these three sessions, males consumed
an average of 2.01 ± 0.11 g/kg and females 3.01 ± 0.10 g/kg alcohol, consistent
with other reports indicating female mice consume more alcohol than males (Finn
et al., 2005; Rhodes et al., 2005; Sneddon et al., 2019).
Alcohol intake during the test drinking session for the vehicle and KOR
antagonist (nor-BNI) treatment groups are summarized in Figure 2.1. As shown in
Figure 2.1A, females consumed more alcohol than males during the 0-2 and 2-4
hour time periods following vehicle treatment. Further, nor-BNI strongly reduced
alcohol consumption in both male and female mice. Although ANOVA did not
indicate a significant 3-way interaction (Sex x Drug x Time; F= 0.43), there was a
significant Sex x Drug interaction [F(1,30)= 6.53, p< 0.025], as well as main effects
of Sex [F(1,30)= 19.06, p< 0.001] and Drug [F(1,30)= 67.50, p< 0.001].
Subsequent post-hoc analyses showed that nor-BNI significantly reduced alcohol
intake in both male in female mice during both time periods (* p< 0.001). Also,
vehicle-treated females consumed significantly more alcohol than vehicle-treated
males (^ p< 0.001). Lastly, both sexes generally consumed more alcohol during
the first 2-hour time period compared to the second 2-hour time period that was
supported by a main effect of Time [F(1,30)= 10.34, p< 0.01].
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Analysis of alcohol intake during the entire 4-hour test session showed that
intra-BNST injection of nor-BNI significantly reduced alcohol consumption (Figure
2.1B). This was supported by a significant Sex x Drug interaction [F(1,30)= 6.53,
p< 0.025], as well as main effects of Drug [F(1,30)= 67.50, p< 0.001] and Sex
[F(1,30)= 19.06, p< 0.001]. Post-hoc analyses showed that nor-BNI decreased
alcohol intake in both sexes compared to vehicle (* p< 0.001), and female mice
consumed significantly more alcohol than males following vehicle treatment (^ p<
0.001).
At the conclusion of the 4-hour test drinking session, blood samples were
collected and blood alcohol concentrations (BACs) were assessed. Consistent
with the alcohol intake data, BACs were significantly lower in both sexes after norBNI treatment and, under vehicle conditions, the higher alcohol intake in females
resulted in significantly higher BACs compared to males (Figure 2.1C). This was
supported by 2-way ANOVA that revealed a Sex x Drug interaction [F(1,30)= 5.54,
p< 0.025] as well as main effects of Drug [F(1,30)= 49.64, p< 0.001] and Sex
[F(1,30)= 7.15, p< 0.02]. Post hoc analyses revealed significantly reduced BACs
in male and female mice as a result of nor-BNI treatment compared to vehicle (*
p< 0.001) and higher average BACs in females compared to males receiving
vehicle (^ p< 0.001). Finally, a schematic representation of microinjector guide
placements within the BNST is represented in Figure 2.1D.
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Figure 2.1: KOR antagonist infusion into the BNST reduced binge-like alcohol
consumption. Male and female mice received a bilateral microinjection of vehicle
or the KOR antagonist, nor-BNI (2.5 g/side), 16 hours before a binge drinking
session. A) Alcohol intake (g/kg) during the consecutive 2-hour time periods (0-2
and 2-4 hour) in the 4-hour access session. Females consumed more alcohol than
males receiving vehicle across both timepoints (^ p< 0.001). Nor-BNI significantly
reduced alcohol intake in males and females (*ps<0.001) relative to vehicle but
drinking did not differ between sexes treated with nor-BNI at either time point. B)
Cumulative alcohol intake across the 4-hour session. When treated with vehicle,
females consumed more alcohol than males (^ p< 0.001). Nor-BNI reduced alcohol
intake in both males and females compared to their respective vehicle (* ps<
0.001). However, no difference was observed between males and females
receiving nor-BNI. C) Blood alcohol concentration (BAC; mg/dL) was assessed at
the end of the 4-hour session. Vehicle treated females had greater BACs than
males receiving vehicle (^ p< 0.001). BACs were significantly reduced in both male
and females compared to their respective vehicle groups (* ps< 0.001) but no
difference was observed between males and females treated with nor-BNI. D)
Representative microinjector tip placements within the BNST.
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Effect of KOR Antagonist Microinjection Into the BNST on Binge-Like
Sucrose Consumption.
Male (N= 16) and female (N= 16) mice were split into treatment groups
based on average intake across the preceding three days of 2-hour sucrose
drinking. Males consumed an average of 36.94 ± 1.97 mL/kg and females
consumed 47.85 ± 2.22 mL/kg during these three days prior to drug challenge.
During the test session, female mice generally consumed more sucrose than
males and nor-BNI treatment produced a modest reduction in intake in both sexes
(Figure 2.2A). ANOVA indicated main effects of Drug [F(1,28)= 9.29, * p< 0.005]
and Sex [F(1,28)= 10.47, ^ p< 0.01], but the Dug x Sex and Drug x Sex x Time
interaction terms did not achieve statistical significance (Fs< 2.2). Likewise,
analysis of sucrose intake during the entire 4-hour test session indicated that norBNI reduced sucrose consumption in both sexes and females generally consumed
more sucrose than males (Figure 2.2B). This was supported by significant main
effects of Drug [F(1,28)= 9.29, * p< 0.01] and Sex [F(1,28)= 10.47, ^ p< 0.01].
BNST microinjector placements for mice in this study are represented in Figure
2.2C.
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Figure 2.2: KOR antagonist infusion into the BNST reduced binge-like sucrose
consumption. A) Sucrose intake (mL/kg) during the consecutive 2-hour time
periods (0-2 and 2-4 hour) in the 4-hour access session. Females consumed more
sucrose than males (^ p< 0.01) and infusion of nor-BNI into the BNST resulted in
a general suppression of sucrose intake (* p= 0.005). B) Cumulative sucrose intake
across the 4-hour session. Sucrose intake was greater in females (^ p< 0.01) while
intake was lower in mice treated with nor-BNI compared to vehicle across sexes (*
p= 0.005). C) Representative microinjector tip placements within the BNST.
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Comparison of nor-BNI’s effects in the BNST on alcohol and sucrose
consumption.
Because direct administration of nor-BNI into the BNST decreased
consumption of both alcohol (Figure 2.1) and sucrose (Figure 2.2), the effect size
was compared by expressing data from these 2 experiments as the percent
change from vehicle (mL/kg). As can be seen in Figure 2.3, intra-BNST nor-BNI
injection reduced alcohol consumption to a greater extent than sucrose. This was
supported by ANOVA that indicated a significant Solution x Drug interaction
[F(1,58)= 8.99, p< 0.005] as well as a main effect of Drug [F(1,58)= 61.45, p<
0.001] and Solution [F(1,58)= 8.50, p< 0.005]. There was no main effect of Sex or
interactions with this variable. Post-hoc analyses showed that the percent
decrease in intake after nor-BNI was significantly greater for alcohol compared to
sucrose (# p< 0.001). This suggests that the overall suppressive effect of local
KOR antagonist treatment in the BNST is more pronounced for alcohol compared
to sucrose.
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Figure 2.3: Suppressed intake after KOR antagonist infusion into the BNST is
greater for alcohol compared to sucrose. A) Using data collected in Experiments
1 and 2, a percent change from vehicle calculation was made based on 4-hour
intake of alcohol or sucrose for each sex. Nor-BNI microinjection into the BNST
resulted in a significant decrease compared to vehicle for intake of alcohol and
sucrose (* ps< 0.001). However, the percent change from vehicle after nor-BNI
treatment was significantly greater in mice consuming alcohol compared to those
drinking sucrose (# ps< 0.001).
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Examination of Non-Specific Locomotor Effects of KOR Antagonist
Microinjection in the BNST.
A separate cohort of male (N= 17) and female (N= 16) mice were used to
determine if the decrease in alcohol and sucrose consumption following intraBNST nor-BNI microinjection resulted from non-specific sedative effects by
examining locomotor activity in an open-field arena. While females were generally
more active than males [F(1,29)= 31.40, p< 0.001], nor-BNI infused into the BNST
16 hours prior to testing did not affect distance traveled in either sex (Figure 2.4A).
This was supported by the fact that ANOVA did not reveal a main effect of Drug
(F= 0.03) or an interaction of Drug with Sex or Time variables. This suggests that
the suppressive effect of nor-BNI on drinking behavior is not likely related to a
general sedative-like effect. Further, analysis of time spent in the center of the
open field indicated no significant main effects of Sex (F= 0.53) or Drug (F= 0.02).
This suggests that KOR blockade within the BNST did not affect anxiety-like
behavior under these behavioral testing conditions (Figure 2.4B). Microinjector
placements within the BNST for this study are represented in Figure 2.4C.
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Figure 2.4: KOR antagonist infusion into the BNST does not affect locomotor
activity. A) Cumulative distance traveled (cm) after vehicle or nor-BNI
microinjection into the BNST 16 hours before open field testing. Females generally
traveled a greater distance than males (^ p< 0.001) but nor-BNI did not affect
locomotor activity. B) Representative microinjector tip placements in the BNST.
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Effect of KOR Agonist Microinjection Into the BNST on Binge-Like Alcohol
Consumption.
Male (N= 10) and female (N= 10) mice were split evenly into drug treatment
groups based on alcohol intake averaged across the three preceding 2-hour
limited-access drinking sessions. Male mice consumed an average of 2.12 +/- 0.2
g/kg and females 2.72 +/- 0.28 g/kg alcohol during these three days. Two female
mice were excluded from testing due to microinjector head-cap dislocation.
Alcohol intake during the test drinking sessions after microinjection of the
KOR agonist U50,488 (0, 0.1, 0.2 µg/side) is shown in Figure 2.5. Because neither
a main effect of Sex [F(1,32)= 0.39, p= 0.54) nor a factor interaction was observed
during the 4-hour binge drinking test sessions, data were averaged across males
and females. Microinjection of U50,488 resulted in an increase in alcohol intake
(Figure 2.5A). Repeated-measures ANOVA revealed a main effect of Drug
[F(2,64)= 3.61, p< 0.05) and a Drug x Time interaction neared significance
[F(2,64)= 2.48, p= 0.09). As can be seen, the increase in alcohol intake was likely
driven by drinking during the first 0-2 hr epoch of the test given the equivalent
levels of intake during the latter 2-4 hr timepoint. A 2-way ANOVA of the 0-2 hr
timepoint was conducted to further evaluate the dose dependency of U50,488.
Analysis revealed a main effect of Drug [F(2,32)= 7.57, p< 0.005] and post-hoc
analysis showed that alcohol intake was greater than vehicle for both the low dose
(0.01 µg/side; p< 0.05) and high dose (0.02 µg/side; p< 0.001) of U50,488.
Similarly, analysis of alcohol drinking during the entirety of the 4-hour drinking
session indicated that U50,488 resulted in a modest increase alcohol drinking
compared to vehicle supported by a near significant main effect of Drug [F(2,32)=
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3.18, p= 0.054] (Figure 2.5B). Microinjector placements within the BNST for this
study are represented in Figure 2.5C.

80

B.
4
3

Alcohol Intake (g/kg/4hr)

Alcohol Intake (g/kg/2hr)

A.
Vehicle
0.1ug
0.2ug
*

2
1
0

0-2hr

2-4hr

#

4
3
2

#

1
0

Vehicle

0.1ug

0.2ug

C.
+0.26

+0.14

+0.02

Figure 2.5: KOR agonist infusion into the BNST increased binge-like alcohol
consumption. Male and female mice received a bilateral microinjection of vehicle
or the KOR agonist, U50,488 (0, 0.1, 0.2 µg/side), 30-min before binge drinking
sessions in a within-subjects design. Data are averaged across males and females
due to a nonsignificant main effect of Sex. A) Alcohol intake (g/kg) during the
consecutive 2-hour time periods (0-2 and 2-4 hour) in the 4-hour access session.
BNST infusion of U50,488 increased alcohol intake compared to vehicle at the 02 hr timepoint (*ps< 0.05). B) Cumulative alcohol intake across the 4-hour session.
U50,488 microinjection into the BNST modestly increased alcohol intake
independent of dose supported by a near significant main effect of Drug (#p=
0.054). C) Representative microinjector tip placements within the BNST.
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Effect of KOR Agonist Microinjection Into the BNST on Binge-Like Sucrose
Consumption.
Male (N= 10) and female (N= 10) mice were split evenly into drug treatment
groups based on sucrose intake averaged across the three preceding 2-hour
limited-access drinking sessions. Male mice consumed an average of 24.4 +/- 2.5
mL/kg and females 33.8 +/- 6.0 mL/kg sucrose during these three days.
Sucrose intake during the test drinking sessions after microinjection of the
KOR agonist U50,488 (0, 0.1, 0.2 µg/side) is shown in Figure 2.6. Because neither
a main effect of Sex [F(1,38)= 2.90, p= 0.1) nor a factor interaction was observed
during the binge drinking test sessions, data were averaged across males and
females. Microinjection of U50,488 in the BNST did not affect sucrose intake
across the 0-2 hr and 2-4 hr timepoints in the binge drinking session [F(2,76)=
257.61, p= 0.26] (Figure 2.6A). Similarly, U50,488 had no effect on sucrose
drinking cumulatively during the 4 hr drinking session (Figure 2.6B). Microinjector
placements within the BNST for this study are represented in Figure 2.6C.
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Figure 2.6: KOR agonist infusion into the BNST did not affect binge-like sucrose
consumption. A) Sucrose intake (mL/kg) during the consecutive 2-hour time
periods (0-2 and 2-4 hour) in the 4-hour access session. Compared to Vehicle,
U50,488 did not influence sucrose drinking across the binge session. B)
Cumulative sucrose intake across the 4-hour session. No effect of U50,488 was
observed. C) Representative microinjector tip placements within the BNST.
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Microinjection Into the BNST 30-min Prior to Testing Negatively Affects
Behavior.
For studies in Figure 2.1 and Figure 2.2, vehicle or nor-BNI were
administered 16-hr prior to testing and drinking during the first 2 hours of the binge
session after vehicle treatment was similar to the average of intake over the 3 days
preceding testing. However, drinking appeared lower after vehicle microinjection
into the BNST 30-min prior to testing relative to drinking on the prior 3 days. To
further explore this disruption to drinking, data during the first 2 hours of drinking
from studies involving U50,488 microinjection into the BNST are shown in Figure
2.7A and include average intake across the three 2-hr limited access sessions
prior to the binge session. Alcohol intake was significantly impacted by
microinjection of vehicle into the BNST, supported by a main effect of
Microinjection [F(3,48)= 10.03, p< 0.001]. Further post hoc analysis showed that
alcohol drinking after vehicle or U50,488 (0.1 µg/side) was significantly less than
drinking after mock microinjection handling on Days 1-3 (ps< 0.05). No effect of
Sex was observed so data are presented as male and female group averages.
Similar to alcohol drinking, sucrose drinking is presented in Figure 2.7B that was
disrupted by microinjection into the BNST, evidenced by a main effect of
Microinjection [F(3,54)= 3.07, p= 0.03). Post hoc analysis revealed that sucrose
drinking decreased after microinjection of U50,488 (0, 0.1, 0.2 µg/side) compared
to handling on days 1-3. (ps< 0.05).
To determine if the microinjection procedure was resulting in sedation or
impaired locomotor activity, mice were then tested in an open field task after
receiving either Handling, or a microinjection of Vehicle or U50,488 (0.2 µg/side;
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Figure 2.7C). ANOVA revealed a main effect of Microinjection and further post hoc
analysis showed that cumulative locomotor activity for mice receiving a
microinjection into the BNST was significantly less that those handled under mock
microinjections conditions 30-min prior to testing.
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Figure 2.7: Microinjection into the BNST 30-min prior to testing disrupted drinking
and locomotor activity. A) Microinjection of Vehicle or 0.1 µg/side of U50,488 into
the BNST resulted in significantly lower drinking than the previous Day 1-3
involving handling. B) Similarly, sucrose intake was negatively affected by
microinjection of Vehicle, and both doses of U50,488 compared to the previous
three days of handling only. C) Compared to handling, mice receiving a
microinjection of Vehicle or U50,488 (0.2 µg/side) displayed significantly
decreased locomotor activity in an open field task.
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Effect of Systemic KOR Agonist Challenge on Binge-Like Alcohol
Consumption After Microinjection of a KOR Antagonist Into the BNST.
We previously showed that systemic administration of the KOR agonist,
U50,488, increased binge-like alcohol consumption in male mice (Anderson et al.,
2019). Experiment 5 was conducted to determine whether KOR within the BNST
contribute to U50,488’s ability to increase alcohol intake in male and female mice.
Male (N= 35) and female (N= 34) mice were separated into drug treatment
groups based on average intake across the three 2-hour drinking sessions
preceding testing on Day 4. During these sessions, males consumed an average
of 2.42 ± 0.08 g/kg and females consumed 2.93 ± 0.12g/kg alcohol. Initial analysis
indicated a trend but no significant main effect of Sex [F(1,60)= 3.20, p= 0.08].
Since Sex did not interact with the other factors, data for the 4-hour test binge
session were averaged across males and females. Consistent with our previous
report, systemic administration of U50,488 robustly increased binge-like alcohol
consumption (Anderson et al., 2018a). Further, microinjection of nor-BNI into the
BNST decreased alcohol intake and blocked the ability of U50,488 to increase
alcohol consumption in this binge-drinking model (Figure 2.8A). ANOVA indicated
a Systemic Treatment x Microinjection x Time interaction [F(1,60)= 24.52, p<
0.001] and subsequent post hoc analysis showed that U50,488 robustly increased
alcohol intake during the first 2 hours of the test binge session relative to vehicle
(* p< 0.001). In contrast, alcohol consumption was lower in mice treated with
U50,488 compared to vehicle (* p< 0.001) during the latter half (2-4 hour) of the
binge session, an effect likely due to a ceiling effect reached in the first 2 hours of
drinking. As observed in Experiment 1, nor-BNI microinjection into the BNST
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significantly decreased alcohol intake compared to vehicle during both time
periods of the binge session (* p< 0.001). Further, blocking KOR in the BNST via
direct injection of nor-BNI completely blocked increased drinking following
systemic administration of the KOR agonist U50,488 during the first 2 hours of the
session (+ p< 0.001).
Cumulative alcohol intake during the entire 4-hour test session is presented
in Figure 2.8B, also collapsed across Sex. Analysis revealed a significant
Systemic Treatment x Microinjection interaction [F(1,60)= 7.33, p= 0.009]. Post
hoc tests indicated that systemic administration of U50,488 increased alcohol
intake compared to vehicle (* p< 0.01), intra-BNST nor-BNI treatment alone
reduced alcohol intake (* p< 0.001), and blocking KOR in the BNST blocked the
ability of systemic U50,488 to elevate drinking (+ p< 0.001). Analysis of BACs
determined immediately following the test binge-drinking session indicated a
significant Systemic Treatment x Microinjection interaction [F(1,60)= 16.46, p<
0.001]. Resultant BACs mirrored cumulative drinking data in that BACs were
elevated in mice treated with U50,488, reduced in mice that received nor-BNI in
the BNST alone, and lower than U50,488 or vehicle levels in mice that received
both systemic U50,488 and intra-BNST injection of nor-BNI (ps< 0.001) (Figure
2.8C). Representative microinjector placements are depicted in Figure 2.8D.
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Figure 2.8: KOR antagonist infusion into the BNST blocked elevated alcohol
consumption after systemic administration of a KOR agonist. Nor-BNI was
microinjected into the BNST 16 hour prior to the 4-hour drinking session and the
KOR agonist, U50,488 (5 mg/kg; ip.) was administered 30 min prior to drinking.
Alcohol drinking data are collapsed across sex given a nonsignificant main effect
(p= 0.079). A) Systemic U50,488 treatment resulted in a significant increase in
alcohol intake during the first 2 hours of drinking compared to vehicle (*p<0.001).
However, a ceiling effect was likely reached given that intake was lower in the 2-4
hour period (* p< 0.001). Microinjection of nor-BNI into the BNST resulted in
significantly lower alcohol consumption compared to vehicle (* p< 0.001) and
U50,488 (+ p< 0.001) during the first 2 hours. In mice receiving nor-BNI infusion
into the BNST combined with systemic U50,488, alcohol intake was reduced
compared to vehicle (* p< 0.001) and U50,488 alone (+ p< 0.001) during the first
2 hours. Drinking was also lower in the drug combination group than vehicle during
the final 2 hours of testing (*p<0.001). B) A similar pattern of drinking was observed
for cumulative intake across the 4-hour session. U50,488 (ip.) resulted in a
significant increase in alcohol intake (* p< 0.01) while nor-BNI microinjection in the
BNST decreased intake compared to vehicle (*<0.001). Intake was significantly
less than both vehicle and U50,488 in mice receiving the combined U50,488 and
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nor-BNI (* p< 0.001; + p< 0.001). C) BAC was assessed at the end of the 4-hour
drinking session. Systemic U50,488 resulted in significantly greater BACs
compared to vehicle while mice treated with nor-BNI microinjection into the BNST
or combined nor-BNI and U50,488 (ip.) had lower BACs relative to vehicle (* ps<
0.001). Furthermore, mice receiving nor-BNI in the BNST or nor-BNI and U50,488
had lower BACs compared to U50,488 alone (+ps < 0.001). D) Representative
microinjector tip placements within the BNST.
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DISCUSSION
Results from these studies show that KORs in the BNST play a role in
regulating binge-like alcohol drinking in male and female mice. Direct
administration of the KOR antagonist nor-BNI into the BNST significantly reduced,
while microinjection of the KOR agonist U50,488 increased alcohol consumption
in the DID model. Further, intra-BNST nor-BNI injection completely blocked the
ability of systemically administered U50,488 to increase binge-like alcohol
consumption in the model. While nor-BNI injection into the BNST reduced sucrose
consumption, the magnitude nor-BNI’s effect on sucrose intake was smaller than
the suppression of alcohol intake. Infusion of U50,488 into the BNST had no effect
on sucrose drinking. Collectively, these data are consistent with our earlier report
showing that systemic administration of KOR a agonist or antagonist bidirectionally alter alcohol consumption in the DID model (Anderson et al., 2018a)
and extend those findings to show that KOR signaling in the BNST is significantly
involved in regulating binge-like alcohol consumption.
These findings agree with several reports suggesting that KOR antagonists
attenuate excessive alcohol consumption in several rodent models, and the effects
are mediated by action within the extended amygdala (Anderson et al., 2018b;
Crowley and Kash, 2015; Koob, 2013). For example, nor-BNI was shown to
decrease binge-like alcohol intake when administered systemically, as well as via
microinjection into the CeA, or as reported here, within the BNST (Anderson et al.,
2018a). The CeA is of particular relevance because it expresses dynorphinergic
(DYN+) neurons that send dense projections to the BNST (Ahrens et al., 2018; Al-
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Hasani et al., 2015; Mansour et al., 1994; Marchant et al., 2007; Normandeau et
al., 2018). Chemogenetic inhibition of DYN+ neurons in the CeA decreased binge
alcohol consumption and, thus, it is possible that reduced activity of KORs within
the BNST may mediate this effect (Anderson et al., 2018a). Since there is a high
degree of co-expression of DYN and other neuropeptides in the CeA (Kim et al.,
2017; McCullough et al., 2018; Pomrenze et al., 2019a), it is possible that targeted
chemogenetic inhibition of the CeA-BNST pathway may produce its effects by also
altering release of other peptides. For example, DYN is co-expressed with CRF
within the CeA and inactivation of the CeA-BNSTCrf pathway decreased
dependence-related drinking and anxiety-like behavior (de Guglielmo et al., 2019;
Marchant et al., 2007; Pomrenze et al., 2019b). Further, increased anxiety-like
behavior induced by CeA-BNST excitation is dependent upon KOR signaling within
the BNST, suggesting involvement of the CeA-BNSTDYN circuit (Ahrens et al.,
2018). It is likely that CeA-BNSTDYN projections are similarly recruited during binge
drinking and influence KOR actions in the BNST. Future studies will need to
selectively target the CeA-BNSTDYN pathway using the DID model to more directly
address this issue. Nevertheless, while it is difficult to rule out the involvement of
other neuropeptide systems, results from the present study support the notion that
KOR signaling in the BNST contributes to regulating alcohol drinking in the DID
binge model.
While KOR blockade within the BNST decreased alcohol consumption in a
robust manner (55% reduction), nor-BNI injection into the BNST also produced a
modest decrease (25% reduction) in sucrose consumption under the same binge-
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drinking conditions. Interestingly, systemic administration of nor-BNI did not affect
sucrose intake in the DID model, suggesting that KORs in the BNST may play a
more prominent role in general consummatory behavior (Anderson et al., 2018a).
The DYN/KOR system is known to influence feeding behavior, including
consumption of natural (palatable) rewards (Karkhanis et al., 2017; Nogueiras et
al., 2012). However, the mechanisms and site of action for these effects are not
entirely clear. For example, neither systemic nor intracerebroventricular (ICV)
administration of nor-BNI altered sucrose or saccharine intake (Lopez et al., 2011).
In another study, ICV infusion of nor-BNI reduced feeding behavior, but targeted
blockade of KORs in the BNST did not alter responding for palatable food pellets
(Le et al., 2018; Lopez et al., 2011). Thus, it is unclear to what extent
pharmacological antagonism of KORs produce general reductions in food intake.
Results from the present study suggest that alcohol intake is more sensitive to
KOR antagonism, but since only a single dose of nor-BNI was evaluated, future
studies are needed to determine whether an alcohol-selective effect reflects a shift
to the left in the dose-response function. Finally, since KOR antagonists do not
appear to influence water intake (Lindholm et al., 2001; Zhou and Kreek, 2019),
reduced binge-drinking in this study is not likely due to a general effect on fluid
consumption.
It is possible that nor-BNI influences the rewarding properties of alcohol and
sucrose that is reflected in reduced consumption of these two solutions. For
example, nor-BNI (ip.) administration prior to conditioning potentiated statedependent conditioned place preference (CPP) when mice were challenged with
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2 g/kg alcohol (Nguyen et al., 2012). Similarly, nor-BNI potentiated CPP
expression to a lower dose of alcohol (0.8 g/kg) only in mice with a history of forced
swim stress prior to conditioning (Sperling et al., 2010). However, nor-BNI does
not affect CPP expression during testing in the absence of alcohol under nonstressed conditions (Nguyen et al., 2012; Sperling et al., 2010). These studies
suggest recruitment of DYN/KOR under conditions involving a high dose of alcohol
or under stressful conditions that affect the reinforcing properties of alcohol. KOR
antagonists similarly have no effect on the expression of alcohol-induced
conditioned taste aversion (CTA) when given before conditioning or during testing
(Anderson et al., 2013; Roma et al., 2008). KOR specifically within the BNST have
received less attention in relation to CPP or CTA. Therefore, it is difficult to
determine whether nor-BNI infused into the BNST in the present studies is
affecting the reinforcing properties of alcohol.
Heightened anxiety is thought to promote excessive drinking and KOR
antagonists have been shown to exert anxiolytic effects (Koob, 2013; Van't Veer
and Carlezon, 2013). More specifically, systemic administration of nor-BNI
decreases anxiety-like behavior in open field (OF) and elevated plus-maze (EPM)
tests (Knoll et al., 2007; Wittmann et al., 2009). Given the expression of KOR within
the BNST, a structure known to be involved in anxiety (Kash et al., 2015), nor-BNI
administration in the BNST was expected to result in an anxiolytic phenotype in
the present studies. However, we observed no difference in the amount of time
spent in the center portion of the open field arena between vehicle and nor-BNI
treated mice. This is consistent with another report that showed a similar dose of
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nor-BNI (2 g/side) microinjected into the BNST of male mice had no effect on
center time in the OF nor in time spent in the open arm of an EPM (Ahrens et al.,
2018). However, nor-BNI administration into the BNST attenuates ultrasonic
vocalizations, physiological withdrawal scores, and alcohol intake in rats with a
history of alcohol dependence (Erikson et al., 2018). Different measures of anxiety
such as novelty suppressed feeding (Carr and Lucki, 2010), fear-potentiated startle
(Knoll et al., 2007), and forced swim stress (Mague et al., 2003) are also sensitive
to KOR antagonists. Thus, it is likely that KOR in the BNST mediate anxiety-like
behavior, but they may be selectively recruited under specific testing conditions
and/or the state of the subjects.
The present studies found, in agreement with others, that female mice
generally consume more alcohol than males, resulting in significantly greater BACs
(Finn et al., 2005; Rhodes et al., 2005; Sneddon et al., 2019). Females also
exhibited greater sucrose intake and higher levels of locomotor activity upon first
introduction to an open-field arena, consistent with other reports (Archer, 1975;
Crabbe et al., 1999; Kaur et al., 2012; Tucker et al., 2016). Interestingly, no studies
have directly explored sex differences in the effect of KOR antagonists on bingedrinking. We observed a proportionately larger suppression of alcohol intake
resulting from nor-BNI microinjection in the BNST for female mice compared to
males. This finding points to potential sex differences in the ability of KOR
antagonists to modulate alcohol intake and merits further exploration including
more thorough testing of nor-BNI dosing. While sex differences were observed in
alcohol consumption in Experiment 1, no significant differences were observed in
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Experiment 5. In this case, the observation of females consuming more alcohol
than males neared significance (p=0.08), with females consuming roughly 0.5 g/kg
more than males. Sex differences in alcohol intake are not consistently observed
in different models of excessive alcohol consumption and, in this case, may be due
to differences in experimental design between Experiment 1 and 5 (Hilderbrand
and Lasek, 2018). Mice in Experiment 1 received a single microinjection into the
BNST prior to drinking while mice in Experiment 5 received a microinjection
combined with an ip. injection 30-min prior to the test drinking session. The more
robust handling procedure may have resulted in slightly lower intake, obscuring
potential sex differences in alcohol intake.
In contrast to KOR antagonists, sex differences in response to KOR
agonists have been reported but vary by brain region. For example, male guinea
pigs exhibit greater U50,488-induced GTPS activity in the cortex, claustrum,
periaqueductal gray, and substantia nigra while females show greater GTPS
activity in the dentate gyrus and hypothalamus (Wang et al., 2011). Females are
also less sensitive than males to U50,488-induced responding for intracranial selfstimulation suggesting sex differences in the ability of KOR to mediate motivated
behaviors, such as binge-like alcohol consumption (Russell et al., 2014). The
BNST is a sexually dimorphic region of particular interest in relation to KOR
activation given that after U50,488 administration, expression of the immediate
early gene c-Fos is greater in females than males, and sex differences in KOR
mRNA expression have been reported (Conway et al., 2019; Russell et al., 2014).
In the context of binge drinking, however, our studies indicate no sex differences
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in the ability of U50,488 to enhance alcohol drinking to a high level, nor in the ability
of nor-BNI to counter U50,488’s effects within the BNST. The effect of KOR
agonists to increase intake appears to be selective to alcohol under binge
conditions given that the same dose of U50,488 (5 mg/kg; ip.) does not affect
sucrose intake (Anderson et al., 2018a). Others have similarly reported no change
in sucrose consumption after challenge with the KOR agonist, Mesyl Salvinorin B
(Zhou et al., 2017). To more selectively probe the role of KOR activation, U50,488
was microinjected into the BNST resulting in increased alcohol intake in both male
and female mice. These data build upon the previous findings of systemic
administration of U50,488 and pinpoint the BNST as a likely site mediating
increased alcohol intake. Interestingly, the increase in intake after U50,488
microinjection was not observed in a separate cohort of mice drinking sucrose
suggesting that KOR activation in the BNST selectively promotes alcohol drinking
and does not affect consummatory behavior involving a natural reward.
While the present studies indicate that KOR activity within the BNST
bidirectionally modulates alcohol drinking in the binge model, direct microinjection
into the BNST in close proximity to behavioral testing negatively affected
consumption of both alcohol and sucrose. This finding was supported by analyzing
drinking levels during the 3 days of mock microinjection handling compared to the
analogous first 2 hours of drinking during the 4-hour test session. The disruption
to drinking may be due to impaired locomotor activity given than mice receiving a
microinjection were less mobile in an open field task compared to mice being
handled prior to testing. However, microinjection of vehicle into the BNST 16-hours
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prior to testing did not affect alcohol or sucrose drinking given that drinking during
the first 2 hours of the 4-hour test day was comparable to drinking the prior 3 days
during handling. Previous studies have utilized the same procedure for
microinjections into the CeA, mPFC, or NAc prior to testing without any significant
disruptions to drinking (Anderson et al., 2018a; Griffin et al., 2014; Haun et al.,
2018). Therefore, it is difficult to determine the exact cause of the disruption to
behavior after microinjection into the BNST immediately preceding testing.
Microinjection into the BNST of rats within the context of alcohol drinking is more
common and negative effects on behavior are not commonly observed (Erikson et
al., 2018; Le et al., 2018). Of note in mice, microinjection of a neuropeptide-Y
receptor agonist into the BNST 2-hours prior to drinking in the DID model
decreased intake while drinking was relatively unaffected by vehicle (Pleil et al.,
2015). The microinjection procedure utilized by Pleil et al., 2015 involved a much
longer pretreatment time (2 hours) and a slower infusion rate of 0.100 uL/min. This
is an important consideration given that our studies involving 16-hour pretreatment
of vehicle did not influence drinking. A similar procedure with increased
pretreatment time and smaller injection volume will be of consideration for future
studies when possible. None the less, a clear effect of intra-BNST U50,488 to
enhance alcohol drinking was observed in the present studies supporting the
contribution of KOR within this structure to alcohol drinking.
Taken together, these findings point to a role for KOR within the BNST in
regulating excessive alcohol drinking. However, it remains unclear as to how
DYN/KOR activity influences drinking in the context of non-dependent binge-like
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alcohol consumption when the majority of studies suggest efficacy of KOR
antagonists only under conditions of alcohol dependence. Interestingly, many
neuropeptide systems associated with dependence-related drinking also affect
binge-like drinking in non-dependent subjects. For example, antagonists targeting
the CRF1 receptor (Funk et al., 2007), orexin1 receptor (Lopez et al., 2016b), or
KOR (Walker and Koob, 2008) all attenuate dependence-related drinking without
affecting more moderate levels of consumption in non-dependent animals. And
yet, these systems are also engaged in and promote binge-like drinking prior to
the development of dependence. Selective antagonists targeting the CRF1
receptor (Lowery-Gionta et al., 2012), orexin1 receptor (Olney et al., 2015), or KOR
(Anderson et al., 2018a) decrease binge-drinking, effectively normalizing intake to
a moderate level. Since all of these neuropeptide systems are responsive to stress,
they may become engaged under drinking-in-the-dark conditions that engenders
high levels of alcohol intake, that presents as a potent stressful event (Anderson
et al., 2018b; Koob, 2013; Rivier, 1996; Stephens and Wand, 2012). In the context
of binge drinking, the high level of alcohol intake achieved results in a rapid
elevation in BAC and may recruit the DYN/KOR system. For example, systemic
administration of alcohol at doses generating BACs only in excess of 80 mg/dL
results in increased extracellular DYN release within the nucleus accumbens
(Marinelli et al., 2006). This increase in DYN occurs during the acute effects of
alcohol intoxication suggesting a dynamic response of DYN to alcohol beyond the
contribution of DYN/KOR signaling to dysphoria experienced during withdrawal
(Chavkin and Koob, 2016). Therefore, KOR antagonists may modulate the stress
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response to alcohol or anxiety associated with binge drinking in non-dependent
mice resulting in a normalization of intake to more moderate levels. This is
supported by the fact that nor-BNI has no effect on moderate alcohol consumption
in non-dependent subjects when delivered by systemic injection (Walker et al.,
2011) or into extended amygdala structures (Erikson et al., 2018; Kissler et al.,
2014).
Thus, the DYN/KOR system, along with other stress-related peptides
contribute to excessive alcohol consumption, and are further recruited as bouts of
binge drinking and intoxication increase in frequency, leading to escalated and
uncontrolled drinking observed in dependence. This provides a potential
prophylactic window during binge drinking to selectively target these systems early
in the trajectory of the addiction cycle to normalize intake such that regular bouts
of binging become less frequent, thereby reducing the likelihood of escalation of
intake over time. In conclusion, the present series of studies demonstrate that
targeted KOR antagonist treatment within the BNST attenuates binge-like alcohol
consumption and normalizes KOR agonist-potentiated drinking in both male and
female mice. Future studies aimed at targeting the precise dynorphinergic circuity
within the extended amygdala that contributes to activity at KOR within the BNST
will shed further light on the role the DYN/KOR system plays in mediating
excessive binge-like alcohol drinking.
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CHAPTER 3: Increased Neuronal Activity Within the Central Amygdala is
Associated With Binge Drinking.
INTRODUCTION
In Chapter 2, we demonstrated that KOR activity within the BNST
modulates binge-like alcohol consumption in male and female mice. The precise
BNST afferent projection sites that contribute to binge drinking, however, are
poorly understood. The CeA is a likely candidate in that it is involved in various
alcohol-related behaviors and sends dense peptide-rich, projections to the BNST
(Ahrens et al., 2018; de Guglielmo et al., 2019; Koob, 2003, 2009; Li et al., 2012;
Waraczynski, 2006). Preclinical models have demonstrated a role for the CeA in
the motivational effects of alcohol and withdrawal-related sequalae that promote
excessive drinking (Gilpin et al., 2015; Koob, 2009; Sharko et al., 2016). Further,
a growing body of literature has focused on the CeA within the context of binge
drinking. For example, gene expression is up-regulated in the CeA of rats with a
history of binge-like drinking (McBride et al., 2010). The immediate early gene
(IEG), C-Fos, is often used as a proxy for neuronal activity and increased c-Fos
expression has been observed in the CeA after a bout of binge drinking (Burnham
and Thiele, 2017; McReynolds et al., 2018). In fact, there is a distinct population
of neurons within the CeA that is recruited prior to bouts of binge drinking that
promote excessive drinking behavior (George et al., 2012). Ensemble recruitment
in the CeA is also critical to network remodeling that contributes to excessive
drinking as a function of dependence (de Guglielmo et al., 2016; George et al.,
2012; Kimbrough et al., 2020). Of note, projections from the CeA to the BNST
mediate high levels of alcohol consumption in dependent rats and the CeA-BNST
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circuit is thought to be involved in the motivation to drink excessively during a binge
(de Guglielmo et al., 2019).
While the CeA is involved in alcohol consumption, it is also responsive to
the pharmacological effects of alcohol. For example, human imaging studies have
reported decreased activity within the amygdala and BNST after acute alcohol
challenge (Hur et al., 2018). The dampening of extended amygdala activity is
thought to account for, in part, the anxiolytic properties of alcohol (Koob, 2013). In
fact, emotionally charged cues typically evoke a strong BOLD response in the
amygdala, but this response is blunted when alcohol is on-board (Gilman et al.,
2008; Sripada et al., 2011). Preclinical studies measuring c-Fos activity in the CeA
after acute alcohol challenge also support the pharmacological action of alcohol
(Hitzemann and Hitzemann, 1997; Ryabinin et al., 1997). Relevant to binge
drinking, acute administration of alcohol in doses generating blood alcohol
concentrations (BACs) in excess of 80 mg/dL resulted in increased c-Fos
expression in the CeA (Hansson et al., 2008; Hitzemann and Hitzemann, 1997;
McBride, 2002). This effect was not observed with lower doses of alcohol that
result in lower BACs (Ryabinin et al., 1997). Similarly, moderate levels of alcohol
drinking do not alter c-Fos activity suggesting that the high BAC achieved during
a binge is sufficient to induce c-Fos expression within the CeA (Burnham and
Thiele, 2017; Hitzemann and Hitzemann, 1997; McBride, 2002). Little is known,
however, about activity within projections from the CeA to the BNST during binge
drinking and or in response to pharmacologically relevant BACs.
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The drinking-in-the-dark (DID) model has been widely used in the field and
proven to be effective in serving as a platform for pharmacological and circuit-level
interrogation of brain systems that drive binge drinking (Rhodes et al., 2005; Sprow
and Thiele, 2012; Thiele and Navarro, 2014). Few studies, however, have
examined c-Fos expression as a function of binge drinking in the DID paradigm.
The only study to date characterized c-Fos expression in C57BL/6J male mice
across multiple brain regions relative to water drinking controls, with tissue
collected 30 min after a 2 hour drinking session (Burnham and Thiele, 2017). This
study found that c-Fos expression was elevated within the CeA and BNST of binge
drinking male mice. It is unclear, however, if activity within the CeA and BNST are
related or at what time these populations are recruited during a 4 hour drinking
session. Therefore, the present study was designed to address this gap in the
literature by determining c-Fos activity within projections from the CeA to the BNST
during multiple timepoints of a binge-drinking session.

MATERIALS AND METHODS
Subjects
Male and female (N= 30/sex) C57BL/6J mice (Jackson Laboratories, Bar
Harbor, ME) at 10 weeks of age were singly housed and tested in a temperature
and humidity controlled AAALAC approved facility on a reverse 12-hr light/dark
cycle with food and water continuously available. For all experiments, mice were
treated in accordance with both the NIH Guide for the Care and Use of Laboratory
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Animals (National Research Council, 2011) and the Institutional Animal Care and
Use Committee at MUSC.
Surgical Procedures
Originally, this study was designed to determine activity within projections
from the CeA to BNST in the context of binge drinking. This, mice were
anaesthetized with isoflurane and 0.15 uL of red Retrobeads (Lumafluor) were
bilaterally infused into the BNST (AP: + 0.22, ML: +/- 0.75, DV: -4.6) using a 0.5
uL Hamilton Neuros syringe at a flow rate of 0.05 uL/min for 5 min. The syringe
was then left in place during a 10 min diffusion period and retracted over 5 min
(Haun et al., 2018). The volume of Retrobead infusion was based on a pilot study
but retrograde labeling in neurons within the CeA of experimental animals was not
consistently measurable. Therefore, co-labeling of c-Fos and Retrobeads within
CeA projections to the BNST was not quantified and is not described further.
Alcohol Binge Drinking Procedure
After surgery, all mice were given 2 weeks to recover prior to the start of
experiments and were trained to drink alcohol in their home cage in the limited
access “Drinking-in-the-Dark” (DID) procedure, as previously described (Anderson
et al., 2018a; Haun et al., 2020; Rhodes et al., 2005). A single bottle of alcohol
(20% v/v) was presented 3 hours into the dark cycle in place of the water bottle.
Access to alcohol was for 2 hours on 3 consecutive days and then extended to 4
hours on the 4th day. Alcohol intake was determined for each 2-hour session and
then for the 2- and 4-hour time periods during the final (4th day) drinking session.
All mice were given one 4-day cycle of binge drinking, 3 days rest in the home
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cage, followed by a second 4-day binge cycle. On the final 4-hour binge drinking
session, mice were perfused and blood samples collected at the 2-hour and 4-hour
timepoints (Figure 3.1). These time points were chosen because peak c-Fos
expression is detected 90 min after experimental manipulation, but activity can be
detected between 30 and 120 min post manipulation (Barros et al., 2015; Cullinan
et al., 1995; Hope et al., 1994; Kovacs, 1998). Therefore, tissue collected at the 2hour timepoint is reflective of neuronal activity occurring roughly 30 min into the
drinking session. Similarly, c-Fos expression for tissue collected at the 4-hour
timepoint coincides with activity 150 min into the binge session. Plasma was
extracted from blood samples and blood alcohol concentrations (BAC) determined
using an AM1 Alcohol Analyzer (Analox Instruments, Stourbridge, UK). Water
drinking control mice were housed under the same conditions as alcohol drinking
subjects and handled equally (weekly cage changes and body weight
assessments). These mice remained alcohol naïve for the duration of
experimentation and were sacrificed at the same 2- and 4-hr timepoints, were
perfused, and their tissue extracted in an identical manner to alcohol drinking test
subjects. However, BAC was not assessed in this group.
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A.
0hr

2hr

c-Fos
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c-Fos

Figure 3.1: Procedure overview. A) Mice consumed alcohol across a 4 hr limitedaccess drinking session. Tissue was collected at the 2 hr and 4 hr timepoints for
blood alcohol concentration (BAC) and c-Fos assessment. Tissue collected at the
2 hr timepoint indicates c-Fos expression after 30 min of drinking and the 4 hr
timepoint reflects activity after 150 min of drinking.
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Immunohistochemistry
Mice were euthanized with urethane and transcardially perfused with 10 mL
saline followed by 10 mL of paraformaldehyde (PFA; 4%). Brains were extracted,
post fixed in 4% PFA for 24 hours and cryoprotected in sucrose (30% wt/vol) until
sectioning. Tissue was sliced in serial 40 µM sections and processed for
immunohistochemical staining as previously described (Smith et al., 2019). Freefloating sections were rinsed (1-min washes, repeated 6 times) in 1x phosphate
buffered saline (PBS) then blocked in 0.3% H2O2 and 0.3% triton-X 100 (PBST)
for 1 hr. Tissue was then rinsed and incubated overnight in rabbit anti-c-Fos
primary antibody (1:8000; Synaptic Systems) in 5% normal goat serum and PBST
at room temperature. The following morning, tissue was rinsed and incubated for
1 hr in biotinylated goat anti-rabbit secondary antibody (1:1000; Jackson Immuno
Research). After washing, tissue was incubated for 1 hr in ABC (1:1000; Vector
Elite Kit, Vector Labs) and rinsed. Finally, immunolabeling was visualized after a
20 min incubation 3,3’ diaminobenzidine (DAB; 0.025%), nickel ammonium sulfate
(0.05%), and H202 (0.015%) in PBST for 20 min. The tissue was then rinsed and
free-floating sections were mounted onto Permafrost slides, and coverslipped with
Permount mounting medium.
Images were collected under 10X magnification on an EVOS-FL
microscope (AMF-4300, ThermoFisher) and c-Fos immunoreactivity was
assessed with ImageJ imaging software. A representative image of the CeA was
collected from the left and right hemisphere of two sections corresponding to AP:
-1.46 and AP: -1.58 (Franklin and Paxinos, 2008). ImageJ software was used to

107

generate a single standard region of interest (ROI) encompassing the CeA and cFos immunoreactive nuclei were counted. C-Fos counts were averaged across
hemisphere and serial sections to generate a single mean for each subject.
Statistical Analysis
The primary dependent variables were alcohol intake (g/kg), BAC (mg/dL),
and c-Fos+ nuclei. Alcohol intake (g/kg) and BAC (mg/dL) were analyzed by 2way ANOVA to assess main effects of Sex and Time (2 hr, 4 hr). Pearson’s
correlation was used to determine the relationship between alcohol intake and
BAC. Linear regression analysis was then used to determine the correlation
between alcohol intake and BAC, accounting for Sex and Time as betweensubjects factors. C-Fos data were analyzed by 3-way ANOVA with Sex, Solution
(Water, Alcohol), and Time as between-subjects factors. Pearson’s correlation was
used to determine the general relationship between alcohol intake (or BAC) and cFos expression in the CeA. Linear regression analysis was then used to determine
the combined effect of the predictors on alcohol intake (or BAC) and c-Fos
expression, accounting for Sex and Time as between-subjects factors. Significant
factor interactions were further evaluated using the Student-Newman–Keuls (SNK)
for post-hoc comparisons. Alpha was set to p< 0.05 for all analyses.
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RESULTS
Drinking-in-the-Dark Paradigm Engenders Excessive Drinking and Elevated
BAC.
Male (N= 20) and female (N= 20) mice trained in the drinking-in-the-dark
(DID) paradigm consumed alcohol during a final 4-hr binge drinking session and
tissue was collected for c-Fos analysis at the 2-hr and 4-hr timepoints (Figure 3.1).
Additional groups of alcohol naïve, water drinking male and female mice (N=
10/sex) were sacrificed at the same timepoints. Prior to analysis, three male and
three female mice were excluded due to technical errors.
Alcohol intake during the test drinking session for the 2-hr and 4-hr drinking
groups are summarized in Figure 3.2A. ANOVA revealed a main effect of Sex
[F(1,33)= 4.75, p< .05] and Time [F(1,33)= 76.08, p< .001] suggesting that females
generally consumed more alcohol than males, and intake was greater in mice
drinking for 4 hr compared to 2 hr regardless of sex. BAC was assessed
immediately after drinking for 2 hr and 4 hr (Figure 3.2B). As expected, BAC was
greater after 4 hr of drinking compared to 2 hr [F(1,33)= 13.4, p< .001), but no sex
differences were observed, despite females drinking more than males (def discuss
this in the discussion). Pearson’s correlation analysis showed a significant positive
relationship between alcohol intake and BAC under these binge drinking conditions
collapsing across Sex and Time [R2= .692, p< .001; Figure 3.2C]. . Multivariate
linear regression analysis further revealed that Sex and Time together explained
a significant amount variance in BAC relating to alcohol intake [F(3,33)= 22.51, p<
.001, R2= .69]. Linear regression analysis investigating the individual contributions
of these variables to BAC showed that alcohol intake [Beta= 1.16, t(33)= 5.80, p<
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.001] and Time [Beta= 0.41, t(33)= 2.12, p<.05], but not Sex [Beta= 0.05, t(33)=
0.41, p> 0.6] predicted BAC in response to alcohol drinking. Further analysis of 2hr and 4-hr epochs revealed a strong positive correlation between alcohol intake
and BAC at 2-hr [R2=.48, p<.005] and 4 hr [R2=.64, p<.001], collapsed across sex
(Figure 3.2D).

110

B.
10
8

400

#

2hr
4hr

6
4
2
0

Male

*

300
200
100
0

Female

C.

Male

Female

D.
10

Alcohol Intake (g/kg)

Alcohol Intake (g/kg)

2hr *
4hr

*
*

BAC (mg/dL)

Alcohol Intake (g/kg)

A.

*

8
6
4
2
0

0

100

200

300

400

10

2hr
4hr

8

*

6
4

*

2
0

0

100

200

300

400

BAC

BAC

Figure 3.2: Alcohol drinking in the DID paradigm resulted in high levels of intake
and elevated BAC. A) Cumulative alcohol intake across the final 2 and 4-hour
session. Alcohol intake was greater in mice drinking for 4 hr compared to 2 hr (*p<
.001) and females generally consumed more alcohol than males (# p< .05). B)
Blood alcohol concentration (BAC; mg/dL) was assessed at the end of the final 2
or 4-hour session. BACs were higher after 4 hr of drinking compared to 2 hr of
drinking in both males and females (*p< .001) C) Alcohol intake strongly predicts
BAC independent of time and sex (*p<.001). D) Alcohol intake and BAC were
significantly correlated after 2 hr and 4 hr of drinking (*ps< .005).
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Effect of Binge Drinking on C-Fos Expression Within the CeA.
Representative images of c-Fos immunoreactivity within the CeA of water
drinking alcohol-naïve control mice (CTL), and those consuming alcohol (EtOH)
for 2 or 4 hours is shown in Figure 3.3A. For CTL mice, data were analyzed from
a total of 10 males (2 hr: N= 5; 4 hr: N= 5) and 10 females (2 hr: N= 5; 4 hr: N= 5).
For alcohol drinking mice, data were analyzed for 17 males (2 hr: N= 10; 4 hr: N=
7) and 17 females (2 hr: N= 8; 4 hr: N= 9). Three-way ANOVA revealed a significant
main effect of Solution [F(1,46)= 121.97, p< 0.001] indicating that c-Fos expression
was elevated in mice consuming alcohol (Figure 3.3B). Furthermore, c-Fos
expression was overall greater in females supported by a main effect of Sex
[F(1,46)= 10.6, p< 0.005]. Finally, a main effect of Time [F(1,46)= 5.52, p< 0.025]
indicated greater c-Fos activity after 4 hours of drinking compared to 2 hours.
There was a significant factor interaction between Sex and Time [F(1,46)= 4.39,
p< 0.05) and post hoc analysis revealed that c-Fos expression in females
consuming alcohol was greater at 2 hr compared to males at 2 hr (p< 0.05), but
expression was equivalent at 4 hr across sex. For males, c-Fos activity was greater
after 2 and 4 hr of alcohol drinking compared to CTL at each timepoint (ps< 0.005).
C-Fos expression was also greater after 4 hr of alcohol drinking compared to 2 hr
(p< 0.001). No differences in c-Fos expression were observed between CTL mice
as a function of time in males (p= 0.56). For female mice, c-Fos expression was
elevated after 2 and 4 hr of alcohol drinking compared to CTL at each timepoint
(p< 0.001). However, there was no difference in expression in c-Fos levels of
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alcohol drinking mice after 2 and 4 hr (p= 0.67), nor in CTL mice at each timepoint
(p= 0.93).
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Figure 3.3: C-Fos expression in the CeA is elevated after binge-like alcohol
consumption. A.) Representative images of c-Fos immunoreactivity within the CeA
of water-drinking control mice (CTL) and alcohol-drinking mice (EtOH) after 2 or 4
hr of drinking. B) Mean c-Fos+ nuclei. C-Fos expression within the CeA was
increased in male and female mice relative to CTL at both 2 hr and 4 hr (*ps<
0.001). In males, c-Fos activity was greater after 4 hr of drinking compared to 2 hr
(#p< 0.001). C-Fos activity was also greater in female alcohol-drinking mice at 2
and 4 hr compared to male alcohol-drinking mice at 2 hr (#ps< 0.05). No
differences in c-Fos expression were observed in male or female CTL groups.
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Relationship Between Alcohol Intake and C-Fos Expression in the CeA.
Pearson’s correlation was used to determine if a relationship exists between
alcohol intake and CeA c-Fos expression (Figure 3.4A). Pearson’s correlation
revealved a strong possitive association between alcohol intake (g/kg) and c-Fos
expression [r= 0.46, p< 0.01]. Multivariate regression analysis was then conducted
to determine if Sex and Time together predicted CeA c-Fos expression in alcohol
drinking mice. It was found that Sex and Time explained a significant amount
variance in the levels of CeA c-Fos expression [F(3,33)= 6.30, p< 0.001, R2= 0.39].
However, analyzing these factors separately, Sex strongly predicted the CeA cFos response to alcohol drinking [Beta= 0.45, t(33)= 2.89, p< 0.01], and not Time
[Beta= 0.31, t(33)= 1.57, p> 0.2]. Given that sex predicted c-Fos expression, data
were analyzed separeately for males and females. Among male mice (Figure
3.4B), there was a strong positive correlation between alcohol intake and c-Fos
expression after 2 hr of drinking [R2= 0.641, p< 0.01] and not after 4 hr of drinking
in males (p> 0.4). There was no association between alcohol intake and c-Fos
expression in female mice at either the 2 or 4 hr timepoints (ps> 0.6; Figure 3.4C).
Because BACs above 80 mg/dL have a pharmacolocal effect on c-Fos
expression in the CeA (Hansson et al., 2008; Hitzemann and Hitzemann, 1997),
data were analyzed to determine the relationship between BAC and c-Fos activity
(Figure 3.4D). Pearson’s correlation revealed that BAC strongly predicted CeA cFos expression [r= 0.46, p< 0.01], independent of Sex and Time. Controlling for
Sex and Time, multivariate linear regression analysis revealed that Sex and Time
were associated with c-Fos expression and BAC [F(3,33)= 7.05, p< 0.001, R2=
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0.41], but Sex strongly predicted the c-Fos response to BAC [Beta= 0.42, t(33)=
2.91, p< 0.01]. Thus, separate regression analysis were conducted for males and
females. Similar to alcohol drinking, BAC strongly predicted c-Fos expression in
males at the 2 hr timepoint (R2= 0.47, p< 0.05) but not at 4 hr (p> 0.7) (Figure
3.4E). Finally, BAC did not predict c-Fos expression in female mice at either 2 hr
or 4 hr (ps> 0.2) (Figure 3.4F).
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Figure 3.4: Alcohol drinking and BAC correlate with c-Fos expression in the CeA.
A) Alcohol drinking strongly predicted c-Fos+ neurons within the CeA (p< 0.01). B)
The correlation between alcohol drinking and c-Fos expression was significant
after 2 hr of drinking in male mice (p< 0.01) but not at the 4 hr timepoint. C)
Although c-Fos expression was increased in the CeA of female mice consuming
alcohol, the level of intake did not predict with c-Fos expression. D) BAC strongly
predicted c-Fos expression in the CeA overall (p< 0.01). E) BAC was associated
with c-Fos expression in male mice at 2 hr (p< 0.05) but not at 4 hr. F) BAC did not
predict c-Fos levels in the CeA of female mice at either timepoint.
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DISCUSSION
The present study adds to the growing body of literature demonstrating that
alcohol drinking in the DID paradigm effectively models binge-like drinking
behavior in mice by reliably producing clinically relevant BACs. Further, these
findings extend previous work by assessing sex differences in CeA neuronal
activity during binge drinking. We found that females consumed significantly more
alcohol than males and that drinking in this paradigm produced BACs in excess of
80 mg/dL in both sexes, consistent with the literature (Finn et al., 2018; Rhodes et
al.,

2007;

Sneddon

et

al.,

2019).

Unfortunately,

sufficient

Retrobead

immunoreactivity was not detected within CeA projections to the BNST precluding
observations of circuit level activity. However, we found that c-Fos expression was
elevated within the CeA of both male and female mice relative to alcohol naïve
controls and that the amount of alcohol consumed and subsequent BAC predicted
the level of c-Fos expression. When accounting for sex, c-Fos activity was
generally greater in female mice but the correlation between alcohol intake and cFos expression was driven largely by males after 2 hours of drinking, suggesting
sex differences in CeA activity during binge drinking behavior in this model.
Activity of select populations within the CeA is associated reward saliency
that promotes appetitive behaviors, including alcohol consumption (Kim et al.,
2017; Koob, 2009; Koob and Volkow, 2016; Mahler and Berridge, 2009). For
example, the CeA is activated in response to the acquisition and maintenance of
consummatory behavior as well as emotionally salient stimuli like alcohol and
reward-related cues (Knapska et al., 2007). Optogenetic interrogation further
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revealed that neurons within the CeA promote positive reinforcement and that
activity of these neurons, assessed via calcium imaging, coincides with
consummatory behavior (Douglass et al., 2017). Likewise, reinstatement of leverpress behavior in the context of cue-induced reinstatement of alcohol seeking
predicts c-Fos expression in the CeA (Knapska et al., 2007; Radwanska et al.,
2008; Walker et al., 2017). In the context of voluntary consumption, increased cFos expression has been observed in the CeA of male mice in the DID paradigm
after 2 hours of drinking (Burnham and Thiele, 2017). Consistent with these
reports, our results indicate that c-Fos activity was elevated relative to water
drinking mice after 2 and 4 hours of alcohol drinking that supports involvement of
the CeA in binge drinking behavior. We also found that the amount of alcohol
consumed generally predicted c-Fos immunoreactivity within the CeA. Few
studies, however, have directly manipulated the CeA specifically in the context of
binge drinking to determine a causal role of this region in binge drinking behavior.
Pharmacological interrogation of CeA peptide systems has revealed that
microinjection of KOR or Crf1R antagonists attenuate binge drinking in male mice
(Anderson et al., 2018a; Lowery-Gionta et al., 2012). Direct manipulation of
neuronal activity within the CeA using chemogenetic inhibition of DYN-containing
neurons or selective knockdown of DYN/KOR also decreased binge drinking
(Anderson et al., 2018a; Bloodgood et al., 2020). Together, these findings
implicate the CeA as having a causal role in the expression of excessive bingelike alcohol consumption.
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While the CeA is involved in motivated behaviors, there is also sufficient
evidence demonstrating that this structure is sensitive to the pharmacological
effects of alcohol. For example, dose-response studies indicate that acute
systemic administration of a high dose of alcohol is sufficient to induce c-Fos
expression in the CeA (Hitzemann and Hitzemann, 1997). This elevation in CeA
activity is not observed with lower doses of alcohol that result in BACs below 80
mg/dL, suggesting that a threshold is needed for c-Fos induction (Chang et al.,
1995; Ryabinin et al., 1997; Ryabinin and Wang, 1998). Importantly, these studies
delivered alcohol independent of drinking behavior, suggesting that these
responses were purely due to the pharmacological effects of alcohol. The temporal
dynamics of the distribution of alcohol after oral self-administration follows a similar
pattern to systemic treatment, albeit strongly related to the intensity and duration
of drinking behavior (Griffin et al., 2009b; Robinson et al., 2000). For example,
alcohol can be detected in brain dialysate samples 30 min after bouts of drinking
(Griffin et al., 2009a; Griffin et al., 2007; Robinson et al., 2000). In the present
study, tissue was collected 2 hours after the onset of drinking, reflecting c-Fos
expression during the first 30 min of drinking session. This is a period when bout
frequency and duration are the highest during a 4 hour session, meaning that
BACs will rapidly rise thereafter from the large bolus of alcohol flooding the system
(Wilcox et al., 2014). Therefore, activity at the 2 hour timepoint reflects the initiation
of binge drinking behavior during the first 30 min of the session prior to the
circulation of alcohol throughout the brain at a relevant BAC. Because we observed
BACs in excess of 80 mg/dL after 2 and 4-hours of drinking, it is reasonable to
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suspect then that BACs remained elevated during the final 2 hours of drinking, and
that tissue collected during this time reflects a period of binge-level intoxication. CFos expression at this time was elevated in mice consuming alcohol indicative of
a pharmacological effect of alcohol. The temporal dynamics of c-Fos induction limit
interpretation of our results thus it is unclear if c-Fos activity at the 4 hour timepoint
reflects activity related to alcohol drinking or a pharmacological effect of alcohol.
Future studies can disentangle the drinking behavior and effect of alcohol by
utilizing genetically encoded calcium indicators to assess activity within the CeA
with high temporal specificity during a binge drinking session.
Studies of sex differences in alcohol intake across various limited-access
drinking paradigms generally show that female mice consume more alcohol than
males (Almeida et al., 1998; Crabbe et al., 2009; Jury et al., 2017). We and others
have observed this phenotypic difference specially in the context of binge drinking
in the DID paradigm (Crabbe et al., 2009; Finn et al., 2018; Haun et al., 2020;
Sneddon et al., 2019). Here, we replicate this finding and show that females
consumed more alcohol than males. The difference in intake was marginal in that
subsequent BACs after 2 or 4-hours of drinking were not different in males and
females. Studies of the neurobiological mechanisms underlying sex differences in
binge-like alcohol consumption, however, remain limited. Here, we show that cFos activity was elevated in mice drinking alcohol and also greater overall in the
CeA of female mice. The general elevated c-Fos levels in females may be
reflective of greater consummatory behavior under DID conditions. For example,
we and other have shown that females readily consume more sucrose than males
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in the DID model (Crabbe et al., 1999; Haun et al., 2020; Kaur et al., 2012). The
idea that the appetitive, consummatory behavior involved in binge drinking is
associated with activity in the CeA is supported by our finding that alcohol intake
predicted levels of c-Fos expression. However, this effect was largely driven by
male mice and thus, the association between binge drinking and activity of the CeA
in females remains unclear.
The CeA sends dense projections to the BNST and this pathway is thought
to contribute to various alcohol-related behaviors (de Guglielmo et al., 2019; Li et
al., 2012; Pomrenze et al., 2019a). For example, acute alcohol treatment results
in disinhibition of CeA projections to the BNST and it is hypothesized that activation
of the CeA-BNST circuit promotes alcohol drinking (Herman et al., 2013). To date,
one study has directly manipulated this circuit in the context of alcohol drinking that
demonstrated that optogenetic silencing of CeA-BNSTCrf neurons attenuates
excessive drinking as a function of alcohol dependence (de Guglielmo et al., 2019).
Of note, both Crf- and SST-containing neurons within the CeA-BNST circuit
promote anxiety-like behavior, the latter of which is mediated by KOR in the BNST
(Ahrens et al., 2018; Pomrenze et al., 2019b). Within the context of binge drinking,
antagonists targeting the Crf1 receptor and KOR attenuate binge drinking (Haun
et al., 2020; Lowery-Gionta et al., 2012). Therefore, it is likely that activity of Crfand DYN-containing neurons within the CeA-BNST circuit contribute to binge
drinking. A major aim of the present study was to determine c-Fos activity within
the CeA-BNST circuit during binge-like alcohol consumption. The present findings
were limited by inconsistent labeling of the CeA-BNST circuit but do support a
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general role for the CeA in binge drinking behavior. Because KOR within the BNST
modulate binge drinking behavior (Haun et al., 2020), it is reasonable to suspect
involvement of DYN-containing neurons within the CeA-BNST circuit given that the
CeA is activated during periods of binge drinking and that dynorphinergic neurons
within the CeA promote binge drinking behavior (Anderson et al., 2018a;
Bloodgood et al., 2020). Thus, these data support the further exploration of DYNcontaining neurons within the CeA-BNST circuit in the context of binge drinking.
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CHAPTER 4: Chemogenetic Inhibition of the CeA-BNSTDYN Circuit
Attenuates Binge-Like Alcohol Consumption.
INTRODUCTION
We have previously shown that KOR within the BNST contribute to bingelike alcohol consumption and it is hypothesized that dynorphinergic projections
from the CeA to the BNST mediate this effect. Neuroimaging of the CeA or BNST
in subjects with AUD or those with a history of binge drinking is limited, but there
is evidence to suggest that these structures are involved in affective disorders that
have a high co-occurrence with AUD. For example, high resting state connectivity
has been observed between the CeA and BNST and synchronized activity is
associated with the behavioral response to emotionally salient negative stimuli
(Pedersen et al., 2019; Pedersen et al., 2020). Functional activity within these
regions is also associated with anxiety in non-human primates (Fox et al., 2018;
Oler et al., 2012; Torrisi et al., 2015). Activity within the extended amygdala is
thought to promote maladaptive behaviors that alleviate stress and anxiety, such
as alcohol consumption (Koob, 2003; Koob and Volkow, 2016). For example,
amygdala activity during withdrawal is positively associated with AUDIT score and
is a strong predictor of AUD (Fede et al., 2019; Hu et al., 2018; Peters et al., 2017).
Conversely, acute alcohol dampens amygdala and BNST reactivity in response to
stressors including emotionally charged images in humans (Gilman et al., 2008;
Hur et al., 2018; Sripada et al., 2011). Increased activity within the extended
amygdala observed during withdrawal reflects a shift in allosteric load that is
thought to contribute to relapse, and the subsequent binge consumption of alcohol
transiently quells withdrawal-related sequalae (Koob, 2013; Koob and Le Moal,
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2008). The DYN/KOR system contributes to stress and anxiety experienced during
withdrawal that drives excessive drinking (Koob, 2003; Koob and Le Moal, 2008).
For example, a polymorphism in the genes coding for DYN and KOR, Pdyn and
Oprk1 respectively, have been reported in patients with AUD and are associated
with increased anxiety, impulsivity, and drinking severity (Edenberg et al., 2008;
Park et al., 2020; Votinov et al., 2014; Xuei et al., 2006; Xuei et al., 2007). Current
human imaging techniques, however, are limited by resolution of subcortical
structures making observation of DYN/KOR activity specifically within the CeA and
BNST of humans difficult at this time.
Studies involving various preclinical models of AUD have demonstrated a
similar recruitment of the DYN/KOR system in the promotion excessive drinking
and relapse-like behavior. For example, Pdyn/DYN expression is elevated within
the extended amygdala in rats with a history of alcohol dependence achieved
through chronic intermittent ethanol (CIE) exposure (Erikson et al., 2018; Kissler
et al., 2014). High levels of alcohol intake achieved after CIE can be attenuated by
systemic delivery of a KOR antagonist supporting a more causal role for KOR in
excessive drinking (Walker and Koob, 2008; Walker et al., 2011). Further probing
of the extended amygdala revealed that site-specific delivery of a KOR antagonist
into the CeA, BNST, or NAc similarly decreased dependent-like alcohol
consumption (Erikson et al., 2018; Kissler et al., 2014; Nealey et al., 2011). It is
likely that circuity promoting high levels of alcohol intake in models of dependence
may also contribute to binge-drinking as this pattern of drinking is positively
correlated with the emergence of dependence across species (Addolorato et al.,
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2018; Baker et al., 2017; Kroenke et al., 2014). In fact, recent studies support a
more general role for KOR in excessive drinking beyond the context of
dependence. For example, systemic delivery of a KOR antagonist attenuates
binge-like alcohol drinking in mice (Anderson et al., 2018a; Haun et al., 2020).
Direct delivery of a KOR antagonist into the CeA or BNST decreased binge-like
drinking, similar to the effect observed in subjects with a history of dependence
(Anderson et al., 2018a; Erikson et al., 2018; Haun et al., 2020; Kissler et al.,
2014). Finally, systemic KOR agonist treatment increased binge drinking, an effect
that is blocked by KOR antagonist delivery into the BNST suggesting that KOR in
the BNST are actively engaged to promote alcohol drinking behavior (Haun et al.,
2020). However, the endogenous circuity that provides dynorphinergic input to the
BNST involved in drinking behavior is unclear.
The CeA sends dense projections to the BNST and the CeA-BNST circuit
contributes to various alcohol-related behaviors, such as anxiety and fear (Asok et
al., 2018; Gilpin et al., 2014; Le et al., 2018; Roberto et al., 2012). A dense
population of neurons within the lateral subdivision of the CeA expresses DYN,
among other neuropeptides, and sends direct projections to the BNST (CeABNSTDYN) (Ahrens et al., 2018; Li et al., 2012; Marchant et al., 2007). No studies
to date have directly investigated a functional role of CeA-BNSTDYN circuitry,
however, chemogenetic inhibition of DYN-containing neurons within the CeA
(CeADYN) reduced binge-like alcohol consumption (Anderson et al., 2018). This
study provided the first evidence of DYN-containing neurons within the CeA
contributing to binge drinking. Further studies revealed that genetic deletion of
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DYN from the CeA attenuated binge-like alcohol consumption, directly pointing to
DYN as a driver of excessive drinking (Bloodgood et al., 2020). Therefore,
chemogenetic inhibition and deletion of DYN from CeADYN point to this population
as a key hub for binge drinking, but the downstream site of these projections has
yet to be determined. Manipulation of other CeA-BNST projections provide
valuable insight given the high levels of peptide co-expression within the CeA. For
example, DYN is largely co-expressed with CRF in the CeA and optogenetic
silencing of the CeA-BNSTCrf circuit attenuated dependence-related drinking and
decreases fear and anxiety-like behavior in rats (Asok et al., 2018; de Guglielmo
et al., 2019; Pomrenze et al., 2019b). Somatostatin (SST) colocalizes with DYN to
a large extent within the CeA and activation of CeA-BNSTSST projections increased
anxiety like behavior in mice, an effect that is dependent on KOR in the BNST
providing evidence for functional CeA-BNSTDYN circuitry (Ahrens et al., 2018).
Because the CeA-BNSTDYN pathway has not been directly manipulated in the
context of binge drinking, the present studies were designed to use a
chemogenetic approach to inhibit CeA-BNSTDYN in the context of binge drinking in
male and female mice.
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MATERIALS AND METHODS
Subjects
Male and female Pdyn-IRES-Cre mice ranging from 10-12 weeks old were
from an in-house colony as previously described (Anderson et al., 2018a; Krashes
et al., 2014). All animals were singly housed and tested in a temperature and
humidity controlled AAALAC approved facility on a reverse 12-hr light/dark cycle
with food and water continuously available. For all experiments, mice were treated
in accordance with both the NIH Guide for the Care and Use of Laboratory Animals
(National Research Council, 2011) and the Institutional Animal Care and Use
Committee at MUSC.
Surgical Procedures
Mice were anaesthetized with isoflurane and 0.25 uL of AAVrg-hSyn-DIOhM4Di-mCherry or AAVrg-eF1a-eGFP was bilaterally infused into the BNST (AP:
+ 0.22, ML: +/- 0.75, DV: -4.6) using a 0.5 uL Hamilton Neuros syringe at a flow
rate of 0.05 uL/min for 5 min. The syringe was then left in place during a 10 min
diffusion period and retracted over 5 min as previously described (Haun et al.,
2018). Bilateral guide cannula (Plastics One, Inc.) were then positioned above the
CeA (AP: -1.2, ML: +/- 3.0, DV: -3.6) and secured to the skull with a light-cured
resin system (Haun et al., 2018). Once inserted, microinjector tips extended 1 mm
beyond the guide to target the CeA for microinjection. After surgery, all mice were
given 4 weeks to recover for adequate viral expression prior to the start of
experiments.
Alcohol Binge Drinking Procedure
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Mice were trained to drink alcohol in their home cage in the limited access
“Drinking-in-the-Dark” (DID) procedure, as previously described (Anderson et al.,
2018a; Haun et al., 2020). Prior to drinking, mice were habituated to the
microinjection procedure by removing and then replacing dummy guides from the
microinjector tract 30 minutes prior to drinking. A single bottle of alcohol (20% v/v)
was then presented 3 hours into the dark cycle in place of the water bottle. Access
to alcohol was for 2 hours on 3 consecutive days, and then extended for 4 hours
on the 4th day. Alcohol intake was determined for each 2-hour session and then
for the 0-2 and 2-4 hour time periods during the final (4th day) 4-hour drinking
session. An identical procedure was used for assessing sucrose (0.5% w/v)
consumption. All mice were given one 4-day baseline cycle of binge drinking
followed by 3 days rest in the home cage. This 4-day binge drinking cycle followed
by 3 days of rest was repeated for 2 more cycles involving experimental testing.
For all experiments, microinjection challenge occurred 30-min before the 4-hour
binge session during the second and third binge cycle. Average drinking across
the first 3 days of the second binge cycle were used to separate subjects evenly
into drug treatment groups in a balanced within-subjects design. Immediately after
the 4-hour test drinking session, blood samples were collected, plasma extracted,
and blood alcohol concentrations determined using an AM1 Alcohol Analyzer
(Analox Instruments, Stourbridge, UK).
After the three 4-day binge cycles of alcohol drinking, mice were given 4weeks rest with food and water provided ad-libitum prior to sucrose drinking.
Sucrose (0.5% v/v) drinking was carried out in an identical fashion to alcohol
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drinking. This included one 4-day baseline week of sucrose binge drinking followed
by 3 days of rest. This 4-day binge cycle was repeated for 2 more test weeks with
microinjections occurring 30-min prior to testing on day 4 of the cycle.
Microinjection Procedures
The DREADD agonist clozapine-N-oxide (CNO; 1 mM/side, Tocris) was
dissolved in 1xPBS for microinjection. This dose was chosen given strong Giinduced neuronal quiescence in various brain regions and documented usage for
circuit level manipulation in the DID model (Mahler and Aston-Jones, 2018; Mahler
et al., 2014; Rinker et al., 2017). Microinjections were administered 30-min before
Day 4 of drinking during the second and third binge cycle in a within-subjects
design. Vehicle or CNO (1 mM/side) was delivered bilaterally into the CeA at a flow
rate of 0.25 µL/min for 2-min, followed by a 2-min diffusion period before
microinjector removal (Anderson et al., 2018a; Griffin et al., 2014; Haun et al.,
2018). Obdurators were replaced and mice returned to their home cage where they
remained undisturbed until testing.
Histology
At the conclusion of all experiments, mice were euthanized with urethane
and transcardially perfused with 10 mL saline followed by 10 mL of
paraformaldehyde (PFA; 4%). Brains were extracted, post fixed in 4% PFA for 24
hours and cryoprotected in sucrose (30% wt/vol) until sectioning. Tissue was sliced
in serial 40 µM sections and processed for verification of viral expression as
previously described (Anderson et al., 2018a). Briefly, tissue was washed in
1xPBS and incubated in rat anti-mCherry (1:1000; Invitrogen) overnight at room
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temperature. The following day, tissue was washed and incubated in AlexaFluor
goat anti-rat 555 (1:1000; ThermoFisher) for 2 hr. Tissue was then mounted on
permafrost slides with Prolong Diamond with Dapi for imaging. Tissue from mice
receiving AAVrg-eF1a-DIO-eGFP was perfused, sectioned, washed, and mounted
onto slides for imaging. IHC was not necessary given the strong endogenous
eGFP signal. Images were collected under 4x, 10x, and 20x magnification on an
EVOS-FL microscope (AMF-4300, ThermoFisher). Only mice with viral expression
and bilateral guide placements in the CeA in reference to a mouse stereotaxic atlas
were included in the final analyses (Franklin and Paxinos, 2008).
Statistical Analysis
The primary dependent variables were alcohol intake (g/kg), blood alcohol
concentration (BAC; mg/dL), and sucrose intake (mL/kg). All data were analyzed
by ANOVA, with Sex and Virus (hM4Di; eGPF) as between-subjects factors and
Drug (Vehicle; CNO) and Time (0-2; 2-4 hr) as a repeated factors as necessary.
Significant factor interactions were further evaluated using the Student-Newman–
Keuls (SNK) for post-hoc comparisons. Alpha was set to p< 0.05 for all analyses.
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RESULTS
Dynorphin-Containing Neurons in the CeA Project to the BNST.
We have previously demonstrated that both CeADYN neurons and KOR
within the BNST contribute to excessive alcohol drinking in the DID model
(Anderson et al., 2018a; Haun et al., 2020). Therefore, direct connectivity between
CeA-BNSTDYN circuitry may mediate binge-like alcohol consumption. To directly
test this, Pdyn-IRES-Cre mice were used to selectively target the CeA-BNSTDYN
circuit for chemogenetic silencing during binge drinking sessions. Commonly used
viral strategies for circuit level chemogenetic manipulation utilize an anterogradeexpressing viral vector that allows for receptor expression in the downstream
terminal

fields

where

CNO

is

directly

applied

for

selective

circuit

activation/inhibition (Armbruster et al., 2007; Lee et al., 2014; Mahler et al., 2014;
Roth, 2016; Urban and Roth, 2015). However, an alternative approach was
necessary to target CeADYN projections terminating in the BNST given the
disruption to behavior previously observed when microinjecting vehicle into the
BNST 30-min prior to drinking (Figure 2.7). Therefore, the AAVrg serotype was
utilized that allows for efficient retrograde expression restricted to a select cell
population when utilizing a Cre-driver line (Tervo et al., 2016). A double-floxed Gicoupled DREADD (or a control vector) under the AAVrg serotype was applied to
the BNST and CNO was targeted directly into the CeA to selectively influence
hM4Di receptors on cell bodies in CeA-BNSTDYN circuit for chemogenetic
inhibition.
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Mice received bilateral infusions (0.25 uL/side) of AAVrg-hSyn-DIO-hM4DimCherry (hM4Di) or AAVrg-eF1a-DIO-eGFP (eGFP) into the BNST and guide
cannulae were positioned above the CeA to selectively target cell bodies in CeABNSTDYN circuit with vehicle or CNO (Figure 4.1A). Cre-dependent expression of
hM4Di selectively within CeADYN of Pdyn-IRES-Cre mice has been previously
validated (Anderson et al., 2018a). Functionality has also been confirmed by
electrophysical testing that showed that bath application of CNO resulted in
significant hyperpolarization indicative of hM4Di-mediated inhibition (Anderson et
al., 2018a).
Expression of the mCherry (or eGFP) fluorescent tag was observed in
terminals within the dorsal and ventral subdivisions of the BNST (Figure 4.1B).
Expression of mCherry (or eGFP) was observed within the central lateral amygdala
(CeL) consistent with viral tracing studies demonstrating that neuronal populations
expressing DYN in the CeL send dense projections to the BNST (Figure 4.1C)
(Ahrens et al., 2018; Li et al., 2012). Microinjector tip placements within the CeA
are represented with black circles. Additional images showing bilateral DYN+
terminal expression in the BNST and expression in upstream DYN+ populations
including the CeA, BMA, and PVN are shown in Supplemental Figure 1A.
Representative images of AAVrg-eF1a-DIO-eGFP expression in the CeA is shown
in Supplemental Figure 1B.
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Figure 4.1: Viral strategy for targeting CeA-BNSTDYN circuit. A) Sagittal section
depicting AAVrg-hSyn-DIO-hM4Di-mCherry or AAVrg-eF1a-DIO-eGFP infusion
into the BNST of Pdyn-IRES-Cre and guide cannula positioning above the CeA.
B) Stereotaxic delivery of AAVrg-hSyn-DIO-hM4Di-mCherry into the BNST
resulted in expression of mCherry within DYN+ afferent terminals. Red= mCherry;
Blue= Dapi C) AAVrg uptake by Cre+ DYN-containing terminals in the BNST
results in expression within cell bodies within the CeA. Black circles represent
microinjector tip placements within the CeA targeting CeA-BNSTDYN neurons.
Red= mCherry; Blue= Dapi.
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Effect of CeA-BNSTDYN Inhibition on Binge-Like Alcohol Consumption.
Male and female mice expressing AAVrg-hSyn-DIO-hM4Di-mCherry
(hM4Di) or AAVrg-eF1a-DIO-eGFP (eGFP) were split into treatment groups based
on average intake across the preceding three days of 2-hour alcohol drinking.
Drinking data from 17 males (hM4Di= 9; eGFP= 8) and 16 females (hM4Di= 9;
eGFP= 7) were included in the final analysis after viral expression and
microinjector guide placement were confirmed. No differences in alcohol
consumption were observed during 4-hour testing based on Sex [F(1,29)= 3.21,
p= 0.08] with males consuming an average of 2.19 ± 0.12 g/kg and females 2.50
± 0.12 g/kg. Therefore, drinking data were collapsed across Sex for further
analysis.
During the test session, silencing of the CeA-BNSTDYN circuit resulted in
decreased alcohol consumption across both 0-2 and 2-4 hour timepoints (Figure
4.2A). 4-way ANOVA (Sex x Virus x Time with Drug as a repeated factor) revealed
a main effect of Drug [F(1,58)= 5.26, p< 0.05] and a Drug x Virus interaction
[F(1,58)= 10.99, p< 0.01). There were no significant main effects of Sex, Virus, or
Time (Fs< 2.49). Post hoc analysis indicated significantly lower alcohol
consumption during the 0-2 and 2-4 hour timepoints in mice expressing hM4Di
within the CeA-BNSTDYN circuit after CNO microinjection compared to vehicle (ps<
0.01). Furthermore, intake in the hM4Di group after CNO challenge was lower than
both vehicle and CNO treatment in mice expressing the eGFP control virus at both
timepoints (ps< 0.01). Drinking after CNO challenge in mice expressing eGFP was
no different than mice receiving vehicle.
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Likewise, analysis of alcohol intake during the entire 4-hour test session
indicated that CNO reduced alcohol consumption compared to vehicle after
silencing of the CeA-BNSTDYN circuit (Figure 4.2B). This was supported by a
significant main effect of Drug [F(1,29)= 6.60, p< 0.05] and Drug x Virus interaction
[F(1,29)= 13.79, p< 0.001). Post hoc analysis further supported overall decreased
alcohol intake in mice expressing hM4Di after CNO compared to vehicle (p< 0.001)
and compared to eGFP-expressing mice receiving vehicle (p< 0.01) or CNO (p<
0.005). Compared to vehicle, no effect of CNO was observed in eGFP-expressing
mice. Lastly, resultant BACs were significantly lower after silencing of the CeABNSTDYN circuit (Figure 4.2C). ANOVA revealed a main effect of Drug [F(1,31)=
6.86, p< 0.01] and Drug x Virus interaction [F(1,31)= 12.99, p< 0.001). Further post
hoc analysis determined that, compared to vehicle, hM4Di-expressing mice
receiving CNO had significantly lower BACs (p< 0.005). This BAC was also lower
than eGFP-expressing mice treated with vehicle or CNO (ps< 0.05).
For reference, alcohol drinking data from mice excluded from the above
analysis due to lack of viral expression within the CeA is shown in Supplemental
Figure 2A. 4-way ANOVA (Sex x Virus x Time with Drug as a repeated factor)
revealed no significant main effects nor factor interactions across the 0-2 and 2-4
hour timepoints (Fs< 1.73). Similarly, analysis of alcohol intake during the entire 4hour test session was similar across groups receiving vehicle microinjection,
compared to control (Fs< 0.15).
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Figure 4.2: Chemogenetic inhibition of CeA-BNSTDYN reduces binge-like alcohol
consumption. A) Alcohol intake (g/kg) during the consecutive 2-hour time periods
(0-2 and 2-4 hour) in the 4-hour access session. Microinjection of CNO to silence
the CeA-BNSTDYN circuit in hM4Di-expressing mice resulted in a significant
decrease in alcohol intake across both time points compared to vehicle (VEH; *ps
<0.005) and compared to eGFP-expressing mice receiving VEH or CNO (#ps<
0.005). No differences in drinking were observed after CNO microinjection in eGFP
expressing mice. B) Cumulative alcohol intake across the 4-hour session.
Cumulative alcohol intake across the entire 4-hour session was lower in hM4Diexpressing mice after CNO compared to VEH (*p <0.005) and compared to eGFPexpressing mice receiving VEH or CNO (#ps< 0.005). C) Blood alcohol
concentration (BAC) after binge drinking. CeA-BNSTDYN silencing with CNO
resulted in significantly lower BACs in hM4Di-expressing mice compared to VEH
(*p< 0.005). BACs were significantly lower than eGFP-expressing mice receiving
VEH and CNO (#p< 0.005). No differences in BAC were observed compared to
VEH after CNO microinjection in eGFP-expressing mice.
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Effect of CeA-BNSTDYN inhibition on binge-like sucrose consumption.
While silencing of CeADYN does not affect binge-like sucrose drinking,
targeted blockade of KOR within the BNST modestly reduced sucrose drinking in
the DID model (Anderson et al., 2018a; Haun et al., 2020). To determine the effect
of chemogenetic CeA-BNSTDYN inhibition on sucrose intake,

drinking was

assessed in 17 males (hM4Di= 9; eGFP= 8) and 16 females (hM4Di= 9; eGFP= 7)
after a 4-week cessation from alcohol drinking. Males consumed an average of
32.47 ± 4.82 mL/kg and females 44.10 ± 2.88 mL/kg during 4-hour drinking and a
main effect Sex neared significance [F(1,29)= 3.155, p= 0.09]. Thus, drinking data
were collapsed across Sex for further analysis.
Silencing of the CeA-BNSTDYN circuit had no effect on sucrose intake during
the 0-2 and 2-4 hour portions of the test session (Figure 4.3A). 4-way ANOVA
(Sex x Virus x Time with Drug as a repeated factor) indicated no significant main
effect of Drug [F(1,58)= 0.124, p= 0.73] suggesting that CNO had no effect on
sucrose intake in both hM4Di and eGFP-expressing mice. A main effect of Time
[F(1,58)= 4.26, p< 0.05] and Time x Sex intereaction [F(1,58)= 31.84; p< 0.001)
were observed and further post hoc analysis indicated that females consumed
more sucrose during the 2-4 hour epoch compared to males (p< 0.01). Cumulative
drinking across the entire 4 hour session was not affected by microinjection of
vehicle or CNO into the CeA of both hM4Di- and eGFP-expressing mice (Figure
4.3B). While a main effect of Sex neared significance [F(1,29)= 3.16, p= 0.09], no
effect of Virus or factor interaction was observed (Fs< 0.90).
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Figure 4.3: Inhibition of
does not affect binge-like sucrose
consumption. A) Sucrose intake (mL/kg) during the consecutive 2-hour time
periods (0-2 and 2-4 hour) in the 4-hour access session. Microinjection of CNO
into the CeA to silence the CeA-BNSTDYN circuit in hM4Di-expressing mice did not
affect sucrose consumption across the binge session. CNO had no effect in eGFPexpressing controls. B) Similarly, cumulative sucrose intake across the 4-hour
session was not affected by CNO in both hM4Di and eGFP-expressing groups.
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DISCUSSION
The extended amygdala has long been implicated in excessive alcohol
drinking and we have previously demonstrated recruitment of neurons within the
CeA during periods of binge drinking. Furthermore, recent studies have supported
a role for CeADYN and implicated KOR within the CeA and BNST specifically in the
context of binge-like drinking behavior (Anderson et al., 2018a; Bloodgood et al.,
2020; Haun et al., 2020). Given the strong connectivity between the CeA and
BNST, it was hypothesized that dynorphinergic projections from the CeA to the
BNST (CeA-BNSTDYN) contribute to binge drinking. Here we report that inhibition
of the CeA-BNSTDYN circuit using a novel chemogenetic strategy significantly
attenuated binge-like alcohol consumption in male and female mice. This effect
was not observed in mice harboring a control vector nor in those that received viral
surgery but failed to exhibit hM4Di expression within the CeA-BNSTDYN circuit.
Furthermore, the reduction in drinking behavior was specific to alcohol because
CeA-BNSTDYN inhibition had no effect on sucrose drinking under similar conditions.
Taken together, these data suggest that the CeA-BNSTDYN circuit promotes
excessive alcohol consumption within the DID model of binge drinking.
To the best of our knowledge, this is first use of an AAVrg strategy involving
the

microinjection of CNO in a target neuronal population for circuit level

manipulation. This strategy was implemented as an alternative to direct CNO
application at CeADYN terminal fields in the BNST because vehicle microinjection
into the BNST disrupted both drinking behavior and locomotor activity in previous
experiments. The limited use of this AAVrg strategy is likely due to the potential for
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activation of collateralized axonal inputs at the site of CNO administration. For
example, Cre-dependent AAVrg infusion in the BNST resulted in expression within
multiple DYN-expressing BNST afferent sites, including the CeA, BMA, and PVN
(Appendix Figure 1A). The BMA sends peptide-rich projections to both the CeA
and BNST and there is evidence of collateralization between these regions
(Bienkowski and Rinaman, 2013; Poulin et al., 2006). Because KOR antagonist
delivery into the CeA decreased binge drinking behavior, it is possible that
collateral BMADYN projections terminating in the BNST and CeA could be affected
by CNO microinjection and influence drinking (Anderson et al., 2018a). While we
acknowledge this as a possibility, it is unlikely because dual retrograde tracing
studies show minimal collateralization (~6%) within CeA- and BNST-projecting
neurons of the BMA (Bienkowski and Rinaman, 2013). Similarly, the BNST is also
rich in DYN-containing neurons and projections from the BNST to the CeA have
been described (Crowley et al., 2016; Gungor et al., 2015; Kash et al., 2015).
However, we only observed terminal expression in the BNST after Cre-dependent
viral infusion suggesting that the virus was not expressed locally within soma in
the BNST. Thus, under the current experimental conditions, it is possible but
unlikely that the effects observed were due to collateral activation of DYNexpressing terminals within the CeA. An optogenetic approach for CeA-BNSTDYN
terminal inhibition is a viable option for future studies in that this strategy has been
effectively utilized in mice to target the CeA-BNST circuit with cell type specificity
(Ahrens et al., 2018; Li et al., 2012).
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While these data demonstrate a causal role for the CeA-BNSTDYN circuit in
binge-like alcohol consumption, further studies will be of importance to clarify the
exact role of DYN within this pathway. Combined chemogenetic hM3Dq-mediated
activation and pharmacological blockade of target receptors in the downstream
terminal field is a common strategy to determine the contribution of a select peptide
in a circuit. For example, microinjection of a CRF1 receptor antagonist into the
BNST blocked the expression anxiety-like behavior after activation of the CeABNSTCrf pathway (Pomrenze et al., 2019b). Similarly, optogenetic activation of
CeA-BNSTSST is sufficient to induce an anxiogenic phenotype and expression of
anxiety-like behavior is blocked by nor-BNI administration in the BNST (Ahrens et
al., 2018). The use of the AAVrg serotype in the present study involved
microinjection of CNO into the CeA to target cell bodies within the CeA-BNSTDYN
pathway. Therefore, pharmacological challenge within the BNST after circuit level
manipulation was not feasible under these methodological constraints. Therefore,
the exact role of DYN within the CeA-BNST circuit is unclear under these
experimental conditions because DYN-containing neurons within the CeA also
express GABA, CRF, NTS, and SST, among other neuropeptides (Ahrens et al.,
2018; Marchant et al., 2007; Pomrenze et al., 2019a; Sanford et al., 2017;
Torruella-Suarez et al., 2020). To address these concerns, we propose an
intersectional viral approach for future studies to selectively knock down DYN
expression within the CeA-BNST pathway. More specifically, this approach
involves the use of 2 viral vectors. The first, AAVrg-Cre, can be infused in the BNST
such that the transgene Cre would be expressed in BNST afferents, including
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neurons within the CeA that terminate in the BNST. Secondly, a double-floxed
Pdyn-shRNA infused into the CeA would then target neurons within the CeA-BNST
circuit for pathway selective DYN-knockdown. While the present study
demonstrated a role for bulk CeA-BNSTDYN circuit activity in binge drinking
behavior, implementation of the strategy described above will better isolate the
contribution of DYN, and DYN alone, within the circuit to drinking.
In contrast with our previous studies, no differences in alcohol intake were
observed between male and female mice consuming alcohol in the DID model.
Females generally consume more alcohol than males across various limited
access drinking procedures, but this effect is not consistently observed (Finn et al.,
2005; Hilderbrand and Lasek, 2018; Sneddon et al., 2019). It is likely that different
experimental handling procedures across our studies accounts for this variation.
In the present study, mice received a microinjection 30-min prior to a binge drinking
session that involved robust handling in close temporal proximity to drinking
behavior. Similarly, we did not observe sex differences in alcohol intake when drug
was administered into the BNST 30-min prior to drinking (Figure 2.5). In contrast,
females consumed more alcohol than males when microinjections occurred 16-hr
prior to drinking or when mice did not receive handling prior to drinking (Figure
2.1; Figure 3.2). Thus, the robust handling involved in the microinjection procedure
in close proximity to drinking may have resulted in slightly lower alcohol intake,
masking potential sex differences. Different experimental handling procures in
future studies for CeA-BNSTDYN manipulation may uncover differential reactivity to
circuit level manipulation. It is also important to note that sex differences in c-Fos
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immunoreactivity within the BNST after U50,488 administration and in KOR mRNA
expression have been reported suggesting that CeA-BNSTDYN activation may
reveal sex differences in drinking behavior (Conway et al., 2019; Russell et al.,
2014). In the context of binge drinking, however, our studies indicate no sex
differences in the ability of U50,488 to enhance alcohol drinking to a high level, nor
in the ability of nor-BNI to counter U50,488’s effects within the BNST. Furthermore,
inhibition of the CeA-BNSTDYN circuit did not differentially affect alcohol
consumption in male and female mice but we cannot rule out the possibility of sex
differences given our experimental design.
An important finding of the present study was alcohol, but not sucrose
drinking was attenuated by CeA-BNSTDYN inhibition suggesting pathway specific
recruitment involved in motivated behavior exclusive to alcohol. This is in general
agreement with our studies showing that systemic administration a KOR
antagonist decreased binge-like alcohol consumption but did not affect sucrose
intake (Anderson et al., 2018a). Interestingly, site-specific KOR blockade in the
BNST decreased alcohol drinking but modestly reduced sucrose consumption.
These data seem to suggest that KOR in the BNST play a role in general
consummatory behaviors but selective inhibition of the CeA-BNSTDYN circuit did
not influence sucrose consumption. This is a potentially important finding because
the CeA is associated with reward saliency, involved in the maintenance of
consummatory behavior, and it would be feasible for projections to the BNST to
be involved in a motivated behavior such as sucrose drinking (Douglass et al.,
2017; Kim et al., 2017; Knapska et al., 2006; Mahler and Berridge, 2009). The
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DYN/KOR system is also known to influence feeding behavior, including
consumption of natural rewards like sucrose (Karkhanis et al., 2017; Nogueiras et
al., 2012). Manipulation of CeADYN in the context of sucrose drinking or general
consummatory behavior has not been directly tested, but manipulation of other
populations within the CeA that colocalize with DYN, such as nociceptin and
neurotensin, provide valuable insight into the role of select CeA projections
(Hardaway et al., 2019; Normandeau et al., 2018; Serafin et al., 2019). For
example, chemogenetic inhibition of nociceptin-containing neurons in the CeA
decreased sucrose intake supporting a role for peptidergic neurons within the CeA
in natural reward behavior (Hardaway et al., 2019). However, ablation of
neurotensin-expressing neurons in the CeA decreased alcohol intake but not
sucrose consumption, consistent with our findings with CeA-BNSTDYN inhibition
(Torruella-Suarez et al., 2020). Thus, KOR activity influenced by CeA-BNSTDYN
projections may act on discreet populations of neurons within the BNST that are
involved in alcohol drinking behavior opposed to circuitry involved in the general
consumption of palatable rewards.
It is important to note that DYN has both anterograde and retrograde
release properties (Gupta and Gintzler, 2003; Lindholm et al., 2007; Margolis et
al., 2003). The present chemogenetic strategy for circuit level inhibition involved
CNO delivery to cell bodies within the CeA. Thus, local KOR activity in the CeA
could have been affected because retrograde release of DYN has been described
in the extended amygdala (Crowley et al., 2016; Gilpin et al., 2014; Kang-Park et
al., 2013; Lindholm et al., 2007). Because microinjection of a KOR antagonist or
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genetic KOR deletion within the CeA decreased binge-like alcohol consumption,
we cannot rule out the possibility that the effect on drinking observed in the present
study was due to decreased retrograde or terminal release of DYN within the CeA
after CeA-BNSTDYN inhibition (Anderson et al., 2018a; Bloodgood et al., 2020).
This does not negate involvement of the circuit itself, but does raise the question
as to the site of DYN-mediated effects on drinking behavior. In support of local
KOR engagement in the CeA, GABAA receptors are expressed on presynaptic
terminals and microinjection of a GABAA antagonist into the CeA decreases
drinking in non-dependent rats suggesting a similar presynaptic mechanism as
KOR (Hyytia and Koob, 1995). In fact, KOR antagonist application to the CeA
increased local inhibition via increased presynaptic release of GABA and this
mechanism is sensitive to the effects of alcohol (Gilpin et al., 2014; Kang-Park et
al., 2013). However, an inherent discrepancy exists in that KOR antagonists
increase GABA release but GABA activity is also enhanced within the CeA of
alcohol-dependent rats and mice that contributes to excessive drinking (Kang-Park
et al., 2013; Gilpin et al., 2014). Therefore, it is counterintuitive that KORantagonist treatment dually increases presynaptic GABA release and also
decreases alcohol intake since increased GABA is associated with increased
drinking. It is important to note that study of alcohol’s effects on CeA functionality,
be it chronic or acute, has primarily focused on the medial subdivision (CeM) of
the CeA, which is the main source of behavioral output in the amygdala.
Interestingly, KOR-expressing neurons within the CeA are primarily found within
the lateral subdivision (CeL) and neurons within the CeL impinge directly on output
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neurons within the CeM and functionally gate behavioral output through a
monosynaptic GABAergic connection (Bloodgood et al., 2020; Herman et al.,
2013). Therefore, KOR antagonists may facilitate GABA release onto CeM output
neurons resulting in decreased drinking behavior (Kang-Park et al., 2013).
Similarly, within the CeL, DYN or KOR agonist activity at presynaptic GABAergic
terminals would have the net effect of CeL disinhibition that may influence the
activity of other peptide rich populations within the CeL that drive drinking behavior
(De Guglielmo et al., 2019). More specifically, CRF-expressing neurons in the CeL
promote excessive drinking in the context of alcohol dependence and there is
extensive literature supporting interactions between the DYN and CRF systems
(Bruchas et al., 2010; de Guglielmo et al., 2019; Pomrenze et al., 2019a).
Therefore, KOR antagonists may drive increased GABA release onto CeLCrf
neurons and thereby decrease alcohol intake, a possibility that has not been tested
to the best of our knowledge. We suspect that CeA-BNSTDYN inhibition may
influence local release of DYN in the CeA and attenuate drinking similar to the
effect of intra-CeA nor-BNI through the scenario outlined above. Further study of
the topography of KOR expression within the microcircuitry of the CeL and CeM
may be the key to unlocking the discrepancy between KOR-mediated regulation
of GABAergic activity and the effects of alcohol on GABA release in the CeA.
Concerning KOR activity in the BNST, a series of elegant studies from the
Kash lab supports a role for presynaptic KOR modulation of GABA release similar
to that described above within the CeA. More specifically, bath application of the
KOR agonist, U69593, or DYN results in decreased presynaptic release of GABA
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within the BNST (Li et al., 2012). Because the BNST is rich in KOR-expressing
nuclei, it is possible that KOR modulation of GABA release is derived from local
interneurons or from presynaptic terminals of BNST afferents. Sorting of neuronal
populations based on cellular properties revealed that the effect of U69593 on
BNST activity was specific to KOR-expressing afferents because activity in
interneurons was not affected. Therefore, we posit that the decrease in drinking
behavior observed after CeA-BNSTDYN inhibition or nor-BNI microinjection into the
BNST is due to enhanced presynaptic GABA release. Interestingly, KOR-mediated
suppression of GABAergic release in the BNST has been observed in BNSTprojecting neurons of the CeA (Li et al., 2012). This suggests the existence of two
parallel circuits within CeA-BNST circuitry because there is minimal co-expression
of DYN and KOR within the CeA (Bloodgood et al., 2020). The functional role of
these dissociable CeA-BNSTDYN and CeA-BNSTKOR pathways has not been
explored. In support of this hypothesis, there is evidence for recruitment of
presynaptic KOR on discrete populations within the BNST based on the source of
input. For example, activation of glutamatergic BNST-projecting neurons of the
BLA promotes the expression of an anxiolytic phenotype (Crowley et al., 2016).
However, activation of DYN-containing neurons within the BNST attenuates
glutamate release from the BLA and not from the PFC, suggesting pathway
specific KOR modulation of neurotransmitter release relevant to anxiety and
drinking behavior (Crowley et al., 2016). Furthermore, glutamatergic projections
from the mPFC that terminate in the BNST promote activity of local DYNcontaining neurons that drive anxiety-like behavior and excessive drinking (Hwa et
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al., 2019). This suggests that activity of DYN/KOR within the BNST can be derived
from different sources of input that act on discrete circuity. However, in-vivo
evidence of endogenous DYN release within the BNST has been limited to
stimulated release of local DYN-containing neurons (Crowley et al., 2016).
Retrograde release of DYN has been observed in the NAc, CeA, and BNST and
action at presynaptic KOR in these regions decreases GABA release (Crowley et
al., 2016; Gilpin et al., 2014; Lindholm et al., 2007). There is also evidence for
anterograde release of DYN directly onto presynaptic terminals or dendrites/cell
bodies expressing KOR (Gupta and Gintzler, 2003; Margolis et al., 2003).
Therefore, it is possible that CeA-BNSTDYN directly influences activity of CeABNSTKOR through an axoaxonic interaction. Future studies utilizing genetically
encoded peptide sensors will allow for the detection of DYN/KOR activity within
these select circuits.
Within the BNST, projections to downstream structures involved in alcohol
drinking, such as the VTA, are likely affected as a result of KOR
activation/inactivation or CeA-BNSTDYN inhibition. For example, the BNST sends
long-range GABAergic and glutamatergic projections to the VTA, placing this
pathway in direct relevance to addiction circuitry (Kudo et al., 2012; Dedic et al.,
2018; Jennings et al., 2013). In fact, this pathway is involved in excessive drinking
because chemogenetic inhibition of CRF-expressing neurons in the BNST-VTA
circuit decreased alcohol intake in the DID model (Companion and Thiele, 2018;
Rinker et al., 2017). Therefore, it is possible that endogenous activity of CeABNSTDYN results in KOR-mediated inhibition of GABAergic presynaptic terminals
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in the BNST that disinhibit the BNST-VTACrf circuit thereby promote alcohol
drinking behavior. Likewise, inhibition of CeA-BNSTDYN would restore inhibition
over BNST-VTACrf and attenuate binge drinking. This model, however, does not
account for the inhibitory influence of GABA release from CeA-BNSTDYN in the
BNST. However, GABAergic activity could have an inhibitory effect on local
interneurons and influence activity of output populations such as BNST-VTACrf.
There is evidence in support for local microcircuit activity in the BNST and these
discrete populations are dysregulated by a history of alcohol dependence (Pati et
al., 2020). More specifically, excitability is increased in local CRF-expressing
neurons within the BNST during withdrawal from chronic alcohol and this is thought
to affect activity in non-CRF neurons that project to the VTA or LH. Furthermore,
these findings suggest that local BNST circuits are sensitive to alcohol and
contribute to decreased activity in otherwise anxiolytic circuitry, thereby facilitating
the expression of negative affective behaviors that promote excessive drinking.
Because alcohol use disorder is conceptualized as stress surfeit disorder, it is
possible that early binge drinking sensitizes these stress-related circuits and
facilitates an escalation of intake over time (Koob, 2013). Therefore, future studies
will be of importance to determine the precise circuitry and directionality of DYN
release within the extended amygdala that contributes to excessive alcohol
drinking behavior.
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CHAPTER 5: Conclusion and Final Thoughts
DYN/KOR and Binge Drinking
The goal of this dissertation was to use a multifaceted approach involving
pharmacology, histological assessment of neuronal activity, and chemogenetic
tools to interrogate the dynorphin/kappa opioid (DYN/KOR) neuropeptide system
within extended amygdala circuity as it relates to excessive binge-like alcohol
consumption. Here, we have shown that activity of KOR within the bed nucleus of
the

stria terminalis (BNST) bidirectionally modulates binge-like

alcohol

consumption in the drinking-in-the-dark (DID) model. More specifically,
microinjection of a KOR antagonist into the BNST decreased excessive drinking
and blocked the ability of systemic KOR activation to enhance alcohol intake.
Furthermore, microinjection of a KOR agonist selectively into the BNST increased
alcohol consumption and together, these data demonstrate that KOR activity within
the BNST is both necessary and sufficient to promote binge drinking behavior.
Because the central amygdala (CeA) sends dynorphinergic projections to the
BNST and the CeA-BNST circuit has been implicated in excessive drinking
behavior, a study was conducted to assess neuronal activity within this pathway
during a binge drinking session. This study revealed that c-Fos immunoreactivity,
serving as a proxy for neuronal activity, was increased within the CeA of mice
consuming alcohol compared to those drinking water. The level of alcohol
consumption was positively correlated with c-Fos expression in the CeA, an effect
that was largely driven by male mice. While determination of activity within CeA
projections to the BNST was not quantified due to methodological constraints, a
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more rigorous study was conducted to determine a causal role for the CeA-BNST
pathway in binge drinking behavior. More specifically, we demonstrated that
chemogenetic inhibition of the CeA-BNSTDYN circuit decreased binge-like alcohol
consumption, an effect that was selective to alcohol because sucrose drinking was
not affected. Taken together, these data support the overarching hypothesis that
DYN/KOR activity within the extended amygdala contributes to excessive drinking
and that the effect observed after CeA-BNSTDYN inhibition is likely mediated by
KOR in the BNST.
While this dissertation work outlines the role KOR in the BNST and
implicates the CeA-BNSTDYN circuit in mediating binge drinking, the exact role of
DYN within endogenous CeA-BNST circuitry still remains unclear. DYN-containing
neurons within the CeA are GABAergic and also co-express a number of peptides
involved in drinking behavior, such as CRF, NTS, and SST. Chemogenetic
strategies confer cell-type and pathway specificity, but influence bulk
neurotransmitter and peptide release within the targeted population. Thus, it is
possible that the release of GABA or a neuropeptide such as CRF was affected by
CeA-BNSTDYN inhibition and may influence drinking behavior. To address this
concern, future studies will employ pathway-specific shRNA-mediated knockdown
of DYN within CeA-BNST projections. This approach will deplete DYN expression
within the circuit but leave other systems intact. Utilization of this strategy will build
upon the present findings and more clearly define the role of DYN within CeABNST circuitry.
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One important limitation of this dissertation work is that microinjection into
the BNST in close proximity to behavioral testing resulted in a disruption to drinking
behavior. This methodological constraint limits interpretation of potential sex
differences in response to U50,488 microinjection into the BNST on alcohol
drinking. However, U50,488 did elevate alcohol consumption as hypothesized
albeit a modest increase. This limitation also directed the use of a retroviral
strategy to target the CeA-BNSTDYN circuit for chemogenetic studies. The most
commonly used chemogenetic strategy to target select circuitry involves the use
of an anterograde vector harboring a DREADD and CNO delivery into the
downstream terminal field. In the present studies, a retro-viral approach was used
that involved microinjection of CNO into the CeA. While this strategy allowed for
effect circuit-level inhibition,
Finally, studies aimed at determining neuronal activity within the CeA-BNST
circuit during binge drinking were inconclusive due to poor expression of the retrotracer in the CeA. Within the CeA, c-Fos expression was elevated in mice
consuming alcohol relative to water drinking control

and supports a general

involvement of this region in binge drinking. However, the temporal dynamics of cFos induction limit interpretation of our results. Future studies utilizing genetically
encoded calcium indicators will build upon the present findings by measuring
neuronal activity within DYN-containing neurons with high temporal specificity. For
example, targeted viral expression using a Cre-dependent genetically-encoded
fluorescent calcium biosensor in PDYN-IRES-Cre mice will allow for selective
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measurement of real-time activity within the CeA-BNSTDYN pathway that can be
time-locked to licks at an alcohol bottle.

Clinical Perspectives
AUD arises from the diverse and complex interaction between genetic,
epigenetic, and environmental factors that influence the neurobiological basis of
behavior (Koob and Volkow, 2010, 2016). The DYN/KOR systems accounts for but
one of the plethora of variables that contribute to AUD and targeting this system
alone is unlikely to restore proper functioning in all systems that together contribute
to excessive drinking, negative affect, and craving that embody AUD. Thus, KOR
antagonists are not a likely “all-inclusive” cure for AUD, but may be better suited
as an adjunct therapy to treat persistent negative affect, promote stress resilience,
and thereby reduce the drive to drink excessively.
The widely accepted theoretical framework of the addiction cycle involves
chronic binge drinking that precipitates the emergence of withdrawal syndrome
and persistent negative affect that, in turn, drive craving, relapse, and further binge
drinking. Indeed, KOR antagonists attenuate excessive alcohol drinking,
withdrawal-related anxiety, and negative affective behaviors in preclinical models
of alcohol dependence through action within the extended amygdala. The present
dissertation builds upon these findings and indicates that KORs within the
extended amygdala also modulate excessive binge-like alcohol consumption prior
to the development of alcohol dependence. Together, these findings suggest that
the DYN/KOR system is a shared neurobiological mechanism involved in initial
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binge drinking and excessive drinking in the context of dependence. It is likely that
the emergence of withdrawal syndrome and negative affect, which are absent in
initial sporadic episodes of binge drinking, promote increased frequency and
intensity of subsequent drinking through an increase in function of the DYN/KOR
system.
Increased dynorphinergic tone is hypothesized to promote excessive
drinking and a PDYN SNP is associated with drinking severity in patients with AUD
(Preuss et al., 2013; Williams et al., 2007; Xuei et al., 2006). Furthermore, a SNP
in the gene coding for KOR, Oprk1, is positively associated with diagnoses of AUD
as well as severity of alcohol drinking, withdrawal symptomology, impulsivity, and
craving (Park et al., 2020). However, further imaging studies are needed to
determine exactly how SNPs in PDYN and Oprk1 affect expression and signaling
of DYN/KOR throughout the brain, and specifically within the extended amygdala.
It also remains to be seen how KOR antagonists may influence dysregulated limbic
network activity as a function of AUD. None the less, KOR antagonists may serve
as a viable option to treat patients with a genetic vulnerability to AUD.
Clinical trials involving selective KOR antagonists are currently underway
although initial trials raised concern over drug safety. The long-lasting receptor
inactivating antagonist, JDTic, has entered into Phase 2 clinical trials but have yield
mixed success for the treatment of drug abuse, anxiety disorders, and treatment
resistant depression. More specifically, studies were aborted due to off-target
cardiovascular effects in a subset of patients. More conventional antagonists that
compete at the receptor, unlike JDTic that inactivates c-Jun Kinase signaling,
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serve as a viable alternative because they are well tolerated and have shown
promise in clinical trials for the treatment of anxiety and depression (Schattauer et
al., 2017; Lowe et al., 2014). For example, Opra Kappa (formerly LY2456302 or
CERC-501) is a conventional KOR antagonist that has recently completed clinical
trials in persons with cocaine dependence, nicotine use disorder, and in healthy
controls (Jones et al., 2020; Reed et al., 2017). While the drug failed to attenuate
craving or measures of depression, the KOR antagonist was well tolerated and
holds promise for further studies.
Lastly, de Laat and colleges provide compelling evidence in support of KOR
pharmacotherapies by demonstrating that the non-selective opioid antagonist
naltrexone reduces alcohol intake and attenuates craving in patients diagnosed
with AUD through activity at KOR (de Laat et al., 2018). In fact, an ongoing clinical
trial is utilizing combined naltrexone and buprenorphine to treat subjects with AUD
and comorbid PTSD. While buprenorphine is a KOR antagonist and partial MOR
agonist, combined treatment with naltrexone allows for MOR blockade and more
selective KOR antagonist activity. Combined pharmacotherapies offer a viable
alternative to costly drug development while achieving KOR selectivity.

Final Thoughts
Presently, a comprehensive understanding of the neurobiological
underpinnings of AUD is far from complete and, although great advances have
been made in the last decade, the translation of preclinical findings into new
therapeutic interventions that attenuate excessive alcohol consumption remain
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limited. Thus, there is a pressing need for the development of novel compounds to
treat individuals suffering from an AUD and alleviate the enormous health and
financial burden caused by excessive drinking. There is currently ample evidence
indicating that neuropeptide systems contribute to excessive alcohol drinking and
AUD. This dissertation adds to the growing body of preclinical literature supporting
a role for the DYN/KOR system in excessive alcohol consumption and supports
further study of this system as a promising druggable target for the treatment of
AUD.
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SUPPLEMENTAL FIGURES

A.

BNST: Bregma 0.14

CeA: Bregma -1.34

PVN: Bregma -0.94

BMA: Bregma -1.06

B.

Supplemental Figure 1: Pattern of cre-dependent AAVrg expression after
infusion into the BNST of Pdyn-IRES-Cre mice. A) Expression of mCherry was
enhanced by colorimetric staining with DAB to better visualize terminal expression
in the BNST relative to landmarks that can be difficult to see with fluorescent
staining. Bilateral terminal expression can be seen within the BNST at the site of
viral infusion. Expression can be seen in DYN-containing neurons within the CeA,
BMA, and PVN. B) Infusion of the control vector, AAVrg-eF1a-DIO-eGFP, resulted
in eGFP expression within the CeA.
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Supplemental Figure 2: Alcohol drinking in mice that received surgery to target
the CeA-BNSTDYN circuit but lacked viral expression. A) Alcohol drinking across
the 0-2 and 2-4 hr timepoints was similar after VEH or CNO microinjection into the
CeA. B) Similarly, cumulative alcohol intake at 4 hours was similar after VEH or
CNO treatment suggesting that hM4Di expression within the CeA-BNSTDYN circuit
is necessary for CNO to affect drinking behavior.
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